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ABSTRACT
Endothelin (ET)-1 is a 21-amino acid peptide which has been the subject of intense 
interest since its discovery in 1988. It has a number of properties which may be 
important in physiology and pathophysiology, including potential relevance to airway 
diseases. A putative role for ET-1 in asthma has been proposed, and we sought to 
examine this further, as well as to extend our investigations to other respiratory 
diseases, including chronic obstructive pulmonary disease and cystic fibrosis. The 
technique of sputum induction has been developed recently as a non-invasive method of 
obtaining airway secretions for analysis, and we have applied this to the investigation 
of the role of ET-1 in diseases involving the airway. We have demonstrated for the first 
time that ET-1 is a highly potent bronchoconstrictor with a prolonged duration of action 
when administered by aerosol in asthma, and that asthmatics exhibit bronchial 
hyperreactivity to ET-1 compared with non-asthmatic subjects, but we found no 
evidence of an acute inflammatory airway response at 30 minutes or 4 hours following 
ET-1-induced bronchoconstriction in asthma, assessed by analysis of cell counts and 
soluble mediators in induced sputum. The bronchoconstrictor activity of ET-1 was not 
potentiated by an infusion of angiotensin II in stable asthmatics, despite animal 
evidence of potentiation, although the possibility of such interaction remains in acute 
severe asthma, where plasma angiotensin II levels are elevated. We did not find 
increased levels of ET-1 in induced sputum in mild asthmatics compared with non­
asthmatic subjects, nor was there a fall in sputum ET-1 comparing samples obtained 
during acute severe asthma with those obtained in convalescence, although sputum and 
saliva levels of ET-1 are greater than plasma ET-1, suggesting local production within 
the respiratory tract. Examination of sputum ET-1 following allergen challenge in 
asthma showed a trend towards an increase in sputum ET-1 after allergen challenge, 
with a relationship between the increase in sputum ET-1 and the extent of sputum 
eosinophilia, suggesting a relationship between asthmatic airway inflammation and ET- 
1 release. Sputum ET-1 is increased in smokers without lung disease, and in subjects
u
with chronic obstructive pulmonary disease (COPD), with a trend towards a fall in 
sputum ET-1 comparing acute exacerbation with convalescence. Finally, we have 
demonstrated a marked increase in sputum ET-1 in patients with cystic fibrosis 
compared with healthy subjects. We conclude from this series of studies that there is 
continuing evidence for a role for ET-1 in a number of diseases affecting the airway, 
and speculate that drugs which oppose the action of ET-1 may have a role in the 
treatment of these conditions.
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CHAPTER 1
INTRODUCTION
INTRODUCTION
1.1 - ENDOTHELINS
1 .1 .1  HISTORICAL BACKGROUND AND CLASSIFICATION
Endothelin (ET) was first isolated from porcine aortic endothelial cells by Yanagisawa 
and co-workers (1) in 1987, based on a report of a previously unidentified 
vasoconstrictor factor present in a conditioned medium of cultured bovine endothelial 
cells, published 2 years earlier by Hickey eta l (2). In 1980, Furchgott eta l (3) had 
demonstrated the presence of an endothelial-derived, locally acting, non-prostaglandin 
relaxing factor (later identified as nitric oxide), and the discovery of this and other 
relaxant factors, prompted a search for counterbalancing constrictor substances. Hickey 
demonstrated that one of these substances produces vasoconstriction lasting for more 
than 60 minutes, in contrast to the brief actions of other substances produced by the 
endothelium, and within a remarkably short time period in 1987, Yanagisawa and 
colleagues had purified and sequenced the propeptide (preproendothelin) and cloned and 
pharmacologically profiled the 21 amino-acid peptide which was later designated 
endothelin-1. Analysis of human genome sequences subsequently revealed the presence 
of three distinct genes for ET, which encode the three distinct isopeptides, designated 
ET-1, ET-2 and ET-3 (4), comprising the human endothelin family. ET-1 was found to 
be the most potent vasoconstrictor peptide known, and since it is the major 
endogenously produced endothelin, ET-1 has been the focus of the majority of the 
research work in human systems, with less being known about physiological and 
pathophysiological roles for ET-2 and ET-3. At an early stage of research, 
autoradiographic studies demonstrated the presence of ET-1 binding sites not only in the 
cardiovascular system, but also in a range of other organs, including lung, adrenal 
gland, kidney, brain, intestine and others (5), suggesting a wide variety of function in 
different organ systems. Assay systems to measure ET-1 in plasma were developed
soon after its identification, and it became apparent that circulating ET-1 in healthy adults 
is present at very low levels (6), which were not sufficient to elicit constriction of 
vascular smooth muscle. Like prostacyclin and nitric oxide, ET-1 appears not to be 
stored in granules in cells (7), but produced by rapid induction of ET-1 messenger RNA 
(mRNA), with synthesis and secretion of ET-1 within minutes in response to certain 
stimuli (8). In addition, despite its prolonged duration of action in a number of tissues, 
ET-1 has a short plasma half life, and is extensively cleared by the lungs during first 
passage (9). Studies using vascular endothelial cell culture reveal that 75% of ET-1 
secretion from endothelial cells is towards the vascular smooth muscle side of the cell, 
and away from the vascular lumen (10), and similar studies using tracheal epithelial cells 
suggest that the proportion secreted basally may be greater than 90% (11). These data 
suggest that ET-1 acts not primarily as a circulating hormone, but rather in a paiacrine 
fashion, although plasma levels may rise with disease activity in some conditions, 
including chronic heart failure (12), renal failure (13), and acute severe asthma (14).
1 .1 .2  E N D O T H E L IN -1 - B IO SY N T H E SIS, R EC EPTO R S AND  
CLEARANCE
Structure and Biosynthesis
Each endothelin is a product of a separate gene which codes for a large precursor protein 
mRNA, with the gene for ET-1 being on chromosome 6 (15). The preproendothelin-1 
gene is 203 amino-acids long, and is processed to the 39 amino-acid prohormone big 
endothelin-1 (big-ET-1) which is secreted and circulates in plasma (fig 1.1) (16). Big- 
ET-1 is pharmacologically much less active than ET-1, and is cleaved between positions 
21 and 22 by endothelin converting enzymes (ECEs), (a group of metalloproteinases), 
resulting in the generation of ET-1, the more active 21 amino-acid peptide (17). ET-1 
differs from ET-2 and ET-3 by 2 and 6 amino acids respectively (fig 1.2), and 
although the synthesis of ET-2 and ET-3 are less well characterised, ET-1 synthesis is 
taken as a likely template for the processes involved. Endothelial cell production of 
preproET-1 is known to be affected by a number of factors, including haemodynamic 
shear stress, hypoxia, transforming growth factor-13 (TGF-13), tumour necrosis factor-a 
(TNF-a), thrombin, erythropoetin, bradykinin, angiotensin II, vasopressin and phorbol 
ester (which stimulates protein kinase C) (18). Endothelins exhibit close structural 
homology to a group of cardiotoxic peptides (sarafotoxins) isolated from the venom of 
the burrowing asp Atractaspis engaddensis, which similarly have 21 amino-acids, and 
have complete identity with endothelins at nine of these residues, including four crucial 
cysteine residues which form intrachain disulphide bonds (19). These compounds have 
been of considerable value in the study of the function of endothelins, and the structural 
homology, along with that of endothelins in other mammalian species, is taken to 
suggest a degree of genomic conservation consistent with an essential role for 
endothelins in the host (20). The disulphide bonds present in the ET molecule appear to 
be important for high-affinity binding to one class of ET-receptors (ETa), but less so for 
the other main class of receptor (ETb) (5),
Preproendothelin-1
(203 amino acids)
I ENDOPEPTIDASE
Cleavage site
Big Endothelin-1 (39 amino acids)
cQOOOOOOOOOOOOOd^
ENDOTHELIN CONVERTING 
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O O O O O O c
Endothelin-1 (21 amino acids)
Figure 1.1
Biosynthetic pathway for endothelin-1 (adapted from Yanagisawa 1988)
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Figure 1.2
The structure of endothelin-1, endothelin-2 and the snake venom sarafotoxin S6c 
(an endothelin B receptor agonist). Differences in amino acid structure between 
the peptides are marked by shaded amino acid residues.
Receptors
Once the three isoforms of ET had been cloned and characterised, it became apparent 
that there were saturable, high-affinity membrane binding sites for these peptides, which 
were characterised initially on the basis of rank order of potencies of either binding or 
function. ET-1 was found to be significantly more potent than ET-3 in stimulating 
contraction of vascular smooth muscle in isolated tissues, and increasing blood pressure 
in vivo (4, 21), while ET-1 and ET-3 produce comparable transient vasodilation 
responses in vitro and in vivo (22), suggesting the presence of two receptors, which 
were designated ETa and ETb receptors (23). The discovery of specific ET receptor 
antagonists allowed the identification of receptor subtypes (sarafotoxins containing Glu^ 
for example, are potent, highly selective ETb antagonists (24)), and DNA cloning 
identified the two different types of receptors, one with isotype selectivity ET-1 > ET-2 
>ET-3 (25), and another with binding specificity ET-1 = ET-2 = ET-3 (26), which to 
conform with previous pharmacological characterisation were called ETa and ETb, 
respectively. The existence of a third receptor subtype (ETc receptor) which selectively 
responds to ET-3 has been demonstrated in Xenopus laevis dermal melanophore (27), 
but to date there is no evidence of mammalian ET receptor with ET-3 specificity, nor has 
genomic analysis by Southern blotting of human DNA revealed any other genes closely 
related to the human ETA and ETB receptor genes (28). It is possible that the amphibian 
receptor is simply a species variant of the ETb receptor, or that if such a receptor exists 
in human cells, it has a markedly different structure to that of the other receptors. There 
is tentative evidence for the existence of a subtype of the ETb receptor in human 
bronchus (29), based on functional and binding characteristics, but no direct 
confirmation of its presence or structure at present.
7Clearance from  plasma
ET-1 is rapidly cleared from plasma, with the lung being responsible for about 50% of 
the clearance in man (30), and the estimated plasma half-life of ET-1 is around 3.5 
minutes (31). Animal studies suggest that clearance is mainly achieved through specific 
binding in the pulmonary vasculature (32), which can be inhibited by the prior 
administration of an ETs-selective antagonist (33), suggesting that the ETb receptor may 
act as a "clearance receptor", which may be important in removing ET-1 from the 
circulation. The contribution of specific receptors to clearance of ET-1 in man has not 
been clearly defined. In addition, a number of enzymes capable of degrading ET-1 have 
been described, including deamidases, neutral endopeptidases, and other peptidases 
(18). Degradation of i^^I-labelled ET-1 has been demonstrated by activity of 
metalloproteinases and serine proteinases in rat lung and kidney extract, with 
metalloproteinases being more important in pulmonary than renal degradation (34). It 
appears therefore, that ET-1 is removed from the circulation by binding to its receptors, 
internalisation and uncoupling, followed by enzymatic degradation, resulting in low 
levels of free and intact ET-1 in serum, as is confirmed by plasma measurements. It is 
worth noting however, that the prolonged duration of vasoconstrictor activity of ET-1 
following I.V. administration is not adequately explained on the basis of its 
pharmacokinetic properties. ET-1 binding to its receptor results in rapid internalisation 
and inactivation of the receptor-1 igand complex, but this appears to be followed by 
externalisation of new or recycled receptors (35), suggesting that maintenance of 
contraction may be dependent on ET-1 binding to a supply of unoccupied newly 
externalised receptors.
81 .1 .3  PHYSIOLOGICAL PROPERTIES OF ET-1
The presence of binding sites for ET-1 has been demonstrated in a wide variety of body 
tissues, including vasculature, respiratory system, neuroendocrine system, central 
nervous system, gastrointestinal tract and the reproductive and fetoplacental system, 
with evidence for local synthesis and activity in each case. This brief summary of the 
physiological properties of ET-1 concentrates on cardiovascular and pulmonary activity, 
along with the role of ET-1 as a mitogen and co-mitogen in respiratory tract cells with 
mention of other systems where direct effect on these systems is suggested. The specific 
properties of ET-1 which could relate to asthma are discussed in greater detail in section 
1. 2 .
Cardiovascular system
As mentioned above, ET-1 causes prolonged contraction of vascular smooth muscle 
after initial transient vasodilation, and it is a potent pressor agent, producing a prolonged 
rise in blood pressure in animals (1) and man (31) following I.V. administration. Local 
administration produces slow onset, prolonged local arterial constriction in the human 
forearm model (36), with similar effects on venous tone (13). Animal studies suggest 
that the pressor response is due to an increase in total peripheral resistance (37), with 
others reporting additional chronotropic (38) and inotropic (39) activity. Although 
pressor activity appears to be mainly mediated by ETa receptors on vascular smooth 
muscle cells (25), the activation of ETb receptors probably also contributes to 
vasoconstriction (40). Under physiological conditions endogenous production of ET-1 
contributes to the maintenance of vascular tone (41), and this activity appears to be 
balanced by the release of nitric oxide (NO) and other vasoactive agents (42) produced, 
like ET-1, by vascular endothelial cells. ET-1 is a potent coronary vasoconstrictor, with 
a putative role in myocardial infarction/ischaemia (43), and ET-1 also produces 
vasoconstriction in a wide range of vascular beds and organ systems. Renal vascular 
resistance rises with ET-1 infusion, with a decrease in renal plasma flow and glomerular
9filtration rate (44), and hepatic vasoconstriction also occurs (45). Interest in the 
cardiovascular activity of endothelins has grown exponentially, with thousands of 
publications, and phase 1 and phase 2 trials of endothelin antagonists in man. The 
detailed role of ET-1 in the cardiovascular system is beyond the scope of this thesis, 
although specific aspects will be referred to as appropriate in other sections.
Respiratory system
The first evidence of a non-vascular site of synthesis of ET in the lung was 
demonstrated by in situ hybridisation techniques, which demonstrated the presence of 
large quantities of ET mRNA in rat fetal lung bronchioles (46). Airway epithelial cells 
(47), endothelial cells, macrophages (48) and neuroendocrine cells (49) can all 
synthesise endothelins, and airway epithelial ET-1 synthesis is increased by thrombin
(50) and various cytokines, including interleukin (IL)-8, TNF-a and TGF-B, with big- 
ET-1 synthesis increased by IL-1, IL-2, IL-6 and insulin-like growth factor (IGF)-1
(51). Autoradiographic and binding studies have revealed high-affinity binding sites in 
human lung, localised largely to airway and vascular smooth muscle (52, 53), and 
parasympathetic ganglia (54), but also present in other tissues, including peripheral 
airways (55), airway epithelia (56) and alveolar septa (54). In addition to its 
vasoconstrictor activity, ET-1 is one of the most potent bronchoconstrictors yet isolated 
(57), with all three endothelins producing slowly developing and long-lasting 
contractions in human isolated bronchi (58). The mechanism by which ET-1 produces 
bronchoconstriction is not clear, and while in animal bronchi this effect is at least 
partially mediated by cyclo-oxygenase metabolites (59), this does not appear to be the 
case in human bronchial preparations where contractions to ET-1 are unaltered by 
indomethacin, and in contrast to many other bronchoconstrictor substances do not 
require activation of protein kinase C to produce a mechanical response (60).
A study by Pons et al (61) comparing the bronchopulmonary effects of ET-1 
administered intra-arterially and by aerosol in the guinea-pig isolated lung found that
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although both routes of administration produced bronchoconstriction, by contrast with 
intra-arterial ET-1, aerosol administration did not produce a rise in pulmonary perfusion 
pressure, and the effects were not mediated by arachidonic acid metabolites. In human 
isolated bronchus, contraction appears to be mediated by the mobilisation of intracellular 
calcium, rather than the influx of extracellular calcium (58, 62). The bronchoconstrictor 
activity of all three endothelins is significantly augmented by the removal of the 
bronchial epithelium (63), suggesting that the epithelium has a function in regulating the 
contractile activity of endothelins, possibly by the release of an epithelial-derived 
relaxant factor (64), such as nitric oxide (NO). There is evidence of a negative feedback 
loop in human bronchial rings, where ET-1 activation of ETa receptors leads to 
epithelial release of NO, modulating the contractile response to ET-1 (65). Animal 
studies have also examined the effects of ET-1 administration in vivo on airway function 
with intravenous (66) and aerosol administration (67) producing dose-dependent 
bronchoconstriction in guinea-pigs without evidence of inflammatory reactions or 
epithelial damage (57), and confirmed the findings in the isolated guinea-pig lung (61) 
that aerosol administration of ET-1 produced bronchoconstriction without a rise in mean 
arterial blood pressure (67). The use of receptor antagonists suggests that in contrast to 
the vascular system (including the pulmonary vascular system (68)) where the ETa 
receptor is the principal receptor mediating vasoconstriction (25), bronchoconstriction of 
human airways in vitro by ET-1 is mediated primarily by the ETb receptor (68), while 
other actions such as proliferation of airway smooth muscle are ETA-dependent (69).
The potential contribution of ET-1 to airway diseases has been addressed in section 1.3 
for asthma, and data relating to chronic obstructive pulmonary disease and cystic 
fibrosis is presented in the relevant chapters, since there is very little other work on the 
potential role of ET-1 in these conditions.
11
Mitogenic activity
ET-1 is known to possess mitogenic activity for a number of cell types, both alone and 
as a co-mitogen. It stimulates growth of vascular (70) and bronchial (71) smooth muscle 
cells along with bronchial epithelial cells (72) and a fibroblast cell line (73). An in vivo 
study of an 18 day continuous intravenous infusion of ET-1 in guinea-pigs resulted in 
thickening of the airway smooth muscle, with a doubling in proliferating cell nuclear 
antigen in the ET-1 treated group compared to controls (74). ET-3 failed to induce 
proliferation in either airway smooth muscle (75) or airway epithelial cells, suggesting 
that the mitogenic activity of ET-1 may be mediated via the ETa receptor, a theory 
supported by the fact that this activity was inhibited by BQ-123, a selective ETa 
antagonist, in a dose-dependent manner (72). Although the mitogenic potency of ET-1 
alone is low compared to other mitogens, it can significantly potentiate the proliferative 
activity of other mitogens (76), with co-mitogenicity in airway smooth muscle having 
been demonstrated with platelet-derived growth factor (PDGF)-BB (75, 77), PDGF-AB 
(78), and epidermal growth factor (EGF) (69). Stimulation of fibroblast growth by ET-1 
is potentiated by transforming growth factor (TGF)-B, EGF, insulin and PDGF (79). 
Some of these growth factors may also increase the gene expression and production of 
ET-1 (including TGF-B, EGF, insulin and PDGF (76)), and ET-1 can induce the 
expression of TGF-B and PDGF-A chain (80) in vascular smooth muscle cells, mitogen 
activated protein (MAP) kinases and DNA synthesis in tracheal smooth muscle cells 
(81), and fibronectin (Fn) - which has potent fibroblast chemotactic activity - in 
bronchial epithelial cells (82). Mitogen-activated protein (MAP)-kinases are believed to 
regulate a number of early events in mitogenesis, and are essential for fibroblast 
proliferation (83). Although the role of ET-1 in pathophysiological processes involving 
cellular proliferation remains to be clarified, it appears to have a role in a number of 
mitogenic processes, and it is postulated that in airway diseases this may contribute to 
the development of structural changes in the airway with resultant airflow obstruction.
12
1.2 - POTENTIAL ROLE OF ET-1 IN ASTHMA
The question of whether ET-1 contributes to the pathogenesis of asthma may be 
addressed by examining a number of other questions in turn. The potential role of ET-1 
in the pathogenesis of cystic fibrosis and COPD will be discussed in the relevant 
chapters.
• 1.2.1 Do the actions of ET-1 resemble clinical features of asthma?
• 1.2.2 Is there evidence of increased synthesis and release of ET-1 in 
asthma?
• 1.2.3 Are ET receptor numbers, localisation and subtypes altered in 
asthma?
• 1.2.4 Does blocking the actions of ET-1 improve asthma?
13
1 .2 .1  - DO THE ACTIONS OF ET-1 RESEM BLE CLINICAL
FEATURES OF ASTHMA?
ET-1 has a number of biological activities which may mimic features of asthma (figure 
1 . 2 . 1)
Actions of ET-1 which may contribute to asthma
• Bronchoconstriction
• Bronchial hyperreactivity
• Pro-inflammatory activity
• Airway remodelling
• Neuromodulation
• Mucous secretion
• Airway penneability
14
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Potential actions of endothelin-1 in the airways
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B ronchoconstric tion
Our own group and others have demonstrated that ET-1 produces prolonged and potent 
contraction of tracheal and bronchial smooth muscle in vitro in the human (58, 60, 84), 
and in several animal species (53, 85) and in animal studies administration of ET-1 by 
aerosol produces a similar effect in vivo (67). Prior to the data contained in this thesis 
there were no reports of the direct administration of ET-1 to human airways in vivo. 
There is debate about the mechanism of action of ET-1 in the airways, with animal 
studies suggesting that contractile activity is at least in part mediated by arachidonic acid 
metabolites (in particular thromboxanes (86)), leukotrienes and histamine (87), but this 
has not been confirmed by studies using human bronchi (60), where ET-1 appears to act 
directly on smooth muscle, without the involvement of acetylcholine, leukotrienes, 
histamine or platelet activating factor (88). While evidence suggests that 
bronchoconstriction is primarily mediated by the ET g receptor in the human airway, in 
contrast to vasoconstriction, which is primarily ETa receptor-mediated, in both the 
bronchi (89) and the vascular system (90) blockade of both receptors is required to 
abolish contraction. Epithelial disruption is a feature of the inflammation associated with 
asthma (91), and it has been demonstrated that epithelial removal significantly enhances 
the contractile activity of ET-1 in the human isolated bronchus (63), raising the 
possibility that epithelial disruption contributes to contractile activity of ET-1 in asthma. 
Apart from direct action on bronchial smooth muscle, ET-1 is known to have other 
effects which could lead to muscular or non-muscular bronchial narrowing. ET-1 acts 
on glandular ET receptors in human nasal mucosa, inducing lactoferrin and mucous 
glycoprotein release (92), induces cytokine production (GM-CSF, IL-6 and IL-8) in 
human bronchial epithelial cell culture (93), and potently stimulates release of TNF-a, 
IE-18, and IL-6 from monocytes and monocyte-derived macrophages (94), all of which 
could contribute to airway obstruction.
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B ronchia l hyperreactivity
ET-1-induced bronchoconstriction in guinea-pigs is not associated with the development 
of bronchial hyperresponsiveness (95), and contrary to expectations, airway 
hyperreactivity to methacholine was markedly enhanced, rather than attenuated, in 
heterozygous ET-1+/- knockout mice (96). An additional effect of ET-1 knockout on 
nitric oxide synthesis was postulated, and it is difficult to be sure if this finding 
represents an incidental characteristic of ET-1 knockout mice or a true association 
between decreased ET-1 production and bronchial hyperresponsiveness. Subjects with 
increased bronchial reactivity to inhaled distilled water (and methacholine) have 
increased immunostaining for ET-1 on bronchial biopsy (97), but the contribution of 
airway ET-1 to bronchial hyperresponsiveness in asthma is not clear.
Airway rem odelling
A  proportion of asthmatics will develop a degree of irreversible airflow obstruction, 
thought to be due to in part to structural changes in the airway, with accumulation of 
collagen, fibronectin and specialised cells known as myofibroblasts beneath the 
bronchial epithelium (see section 1.3.1), There is some evidence that ET-1 may 
contribute to this process in that bronchial epithelial cells cultured from atopic asthmatic 
subjects and exposed to allergen induce differentiation of airway fibroblasts into 
myofibroblasts, and this process appears to be associated with an increase in ET-1 
production (98). ET-1 has mitogenic properties, with animal studies indicating a role in 
the proliferation of cultured airway smooth muscle cells (71) and airway epithelial cells 
(72). Acting alone however, ET-1 has only modest mitogenic activity (99), but it is able 
to significantly potentiate the mitogenic activity of other growth factors (69), and it 
induces the expression of pro-fibrotic factors including tumor necrosis factor (TNF)-a
(100) and fibronectin (82). These effects are predominantly mediated by the ETa 
receptor (69). ET-1 also attenuates apoptosis in cultured human smooth muscle cells
(101), which could contribute to abnormal cell growth. The potential role of ET-1 in 
contributing to airway remodelling remains to be explored.
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Pro-inflam m atory activity
In vitro data shows that ET-1 promotes the inflammatory activity of neutrophils (20) and 
macrophages (102), and increases the expression of adhesion molecules on endothelial 
cells. Additionally, ET antagonists have been shown to inhibit airway inflammation in 
animal studies (103, 104) in response to a number of stimuli. The production from 
mononuclear cells from asthmatics of the proinflammatory cytokines TNF-a (100) and 
IL-18 (105) are increased by ET-1 in vitro, but there is very little in vivo or human data. 
ET-1 causes mast cell activation in the presence of IL-4 (106), and stimulates the release 
of IL-6 from human monocytes (107). There is animal evidence of a greater role for the 
ETa receptor than the ETb receptor in mediating proinflammatory activity in the lung 
(108, 109) and that ET receptor blockade can attenuate airway inflammation induced by 
antigen (103) and other stimuli ( 110).
N e iiro m o diila tio n
ETb receptors have been identified in pulmonary parasympathetic ganglia and 
submucosal nerve plexuses (111), and binding for radiolabelled ET-1 is present in 
parasympathetic ganglia and paravascular nerves in animals, while in humans, ETa 
receptors are present in nerves associated with small bronchi (112). In functional 
studies, prejunctional ETb receptor activation has been shown to potentiate cholinergic 
nerve-mediated contraction in human bronchial preparations (113), suggesting that ET-1 
might exert a neurally mediated bronchoconstrictor effect, in addition to smooth muscle 
contraction.
M ucus secretion
As mentioned above, ET-1 immunoreactivity can be localised to mucus glands in the 
airway, and ET-1 is known to increase mucus secretion in human nasal cells in vitro 
(92) and in vivo, with more symptoms and secretions in subjects with allergic rhinitis 
(114), but no increase in histamine production. In the sheep, ET-1 inhibits tracheal 
mucus velocity (a marker of mucociliary clearance) (115), which could contribute to
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bronchial obstruction. There is evidence that the increase in mucus glycoprotein 
secretion in response to ET-1 is inhibited in the presence of epithelial cells, suggesting 
that epithelial cells may release an inhibitory factor (116). The impact of ET-1 on mucus 
production in asthma has not been examined.
Airway perm eability
Airway wall edema is a feature of asthma, along with airway inflammation and 
microvascular leakage. Intravenous administration of ET-1 in the rat induces 
extravasation of plasma proteins in the bronchi (117), a process which may be a result 
of the ability of ET-1 (and ET-3) to increase the formation of interendothelial gaps
(118).
It is clear that endothelins (and ET-1 in particular) have a number of actions which could 
contribute to clinical features of asthma, and this has stimulated interest in its potential 
contribution to the disease, leading to studies assessing the relationship between the 
production and release of ET-1 in asthma.
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1.2.2 - IS THERE EVIDENCE OF INCREASED SYNTHESIS AND 
RELEASE OF ET-1 IN ASTHMA?
Acute severe asthma
Modest increases in plasma levels of ET-1 have been observed in acute severe asthma 
(119, 120), with a relationship between plasma levels and severity of airflow 
obstruction, and a reduction in plasma ET-1 in response to treatment (120). While this is 
suggestive of a role for ET-1 in acute severe asthma, there is only one case report of 
increased levels of ET-1 in BAL from a patient with status asthmaticus (121). Since ET- 
1 in the airways is thought to primarily to act locally in an autocrine or paracrine fashion, 
information on airway levels of ET-1 may be of greater importance than plasma levels in 
assessing its contribution to the pathophysiology of acute severe asthma.
Chronic Asthm a
Several studies have now demonstrated increased production and release of ET-1 in 
stable asthma. Staining for immunoreactive ET-1 in bronchial biopsies is increased in 
asthma (122), and this increase is abolished in subjects receiving inhaled corticosteroids 
(123). ET-1 in BAL is increased in steroid-naive asthmatics compared to controls (124), 
and in symptomatic but not asymptomatic asthmatics, although exposure of cells from 
asymptomatic asthmatics to inflammatory mediators in vitro resulted in an increase in 
ET-1 production (125). Similarly, cells from asthmatics expressing the low affinity 
receptor for IgE respond to IgE by increasing ET-1 production (126), suggesting that 
atopy may contribute to ET-1 production. Others have demonstrated that in isolated 
epithelial cells from asthmatic patients there is increased expression of the precursor of 
ET-1, preproendothelin, and increased ET release (47). Despite the observation in one 
study of a relationship between BAL ET-1 and % predicted FEY i ( 124), the relationship 
between detection of ET-1 and severity of airway obstruction is not consistent (122), 
and in the case of nocturnal asthma, the opposite relationship has been described (127).
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The influence of asthma therapy on ET-1 release does however suggest a link between 
severity of asthma and ET-1 activity.
In fluence o f  asthma therapy
The ability of corticosteroids (inhaled or oral) to decrease the synthesis of ET-1 is 
thought to result at least in part from a reduction in ET-1 mRNA production by epithelial 
cells (128), although their influence on the expression of proinflammatory cytokines 
may also influence ET-1 production. ET-1 is released from a variety of cells in response 
to proinflammatory cytokines, including IL -la , IL-lp, TNF-a (129), IL-8 and TGF-p 
(51) whose expression may be reduced by corticosteroids. The p2 agonist 
bronchodilator salbutamol does not alter ET-1 expression (125), and in atopic asthmatic 
children, specific allergen immunotherapy did not significantly reduce plasma ET-1, but 
did reduce ET-1 production from stimulated blood mononuclear cells (14). While 
steroids are known to reduce expression of proinflammatory cytokines and 
inflammatory cell recruitment, reduction in ET-1 production may be another mechanism 
by which steroids influence symptoms in asthma.
Bronchial challenge testing
Studies in sensitised animals suggest a role for ET-1 in response to allergen in the 
airway, where immediate allergic responses (characterised by bronchoconstriction) can 
be modified by antagonism of the ETb receptor (109), while late allergic responses 
(characterised by airway inflammation) are inhibited by ETa or combined ETaÆTb 
receptor antagonists (103, 110). In rats there is a relationship between changes in ET-1 
in BAL in response to allergen and the increases in BAL total cell count, eosinophils and 
neutrophils (110). The influence of allergen challenge in asthmatics on ET-1 production 
is not so clear. Using a bronchoscopic technique of segmental allergen challenge, 
Redington et at (130) unexpectedly found lower levels of ET-1 in allergen challenged 
bronchial segments compared with saline challenged segments in steroid-naive 
asthmatics, 10 minutes after the introduction of allergen, while a Japanese study
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(English abstract) found the opposite effect in both early and late allergic responses 
measuring ET-1 in induced sputum after allergen challenge (131). The reasons for this 
difference are not known, although differences in timing of sample and method of 
sampling may be important. As mentioned above however, a reduction in BAL ET-1 has 
been observed during symptoms in nocturnal asthma (127), and studies examining ET-1 
mRNA expression may help to clarify this area. Other forms of bronchial challenge have 
also been examined, with increased immunostaining for ET-1 demonstrated in biopsies 
from subjects who were sensitive to the bronchoconstrictor effects of hypertonic saline 
(97).
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1.2.3 - ARE ENDOTHELIN RECEPTOR NUMBERS, LOCALISATION 
AND SUBTYPES ALTERED IN ASTHMA?
While the ETa and ETb receptor types are recognised in many species (with clear 
evidence for another receptor subtype only in non-mammalian species (132)), there is 
considerable species variation in the relative proportions of the 2 receptors in the lung, 
with human studies indicating that the ETb receptor constitutes around 70% of total 
number in peripheral lung (112), and between 60 and 90% of the total number in the 
airway smooth muscle (84, 89). Receptors are also found in other sites including 
submucosal glands, nerve ganglia and plexuses, and blood vessels. While the ETb 
receptor appears to be primarily responsible for mediating bronchoconstriction in the 
human lung (84), there is also evidence of bronchoconstrictor activity in the presence of 
ETb blockade, and blockade of both receptors is required to antagonise the 
bronchoconstrictor activity of ET-1 in human bronchi (89). Studies in asthmatic human 
lung show no alteration of receptor subtypes, and no increase in ET receptors in 
asthmatic airways (84) or peripheral lung (112), with a slight decrease in sensitivity to 
bronchoconstriction by the ETb agonist sarafotoxin S6c (84) in asthmatic lung. Despite 
this, increased production of ET-1 in the presence of normal receptor numbers is likely 
to result in ET-1 induced bronchoconstriction in asthma.
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1.2.4 - DOES BLOCKING THE ACTIONS OF ET-1 IM PROVE  
ASTHMA?
Antagonism of the activity of ET-1 can be produced in a number of ways. Specific 
antagonists of ETa and ETb receptors exist, along with combined ETa/ETb receptor 
antagonists. In addition, it is possible to inhibit the activity of endothelin-converting 
enzymes (ECE's), and since other metalloproteases can cleave ET precursors, dual ECE 
and neutral endopeptidase inhibitors are also being developed. Animal and human in 
vitro studies suggest that ET receptor antagonists can attenuate both direct (89, 133) and 
neurally mediated (113) ET-1-induced bronchoconstriction, reduce allergen-induced 
(103, 109) and experimental (110) airway inflammation, and oppose co-stimulation by 
ET-1 of human airway smooth muscle proliferation (69), and although less information 
is available about ECE inhibitors, early evidence suggests they can reduce ET-1 release 
from tracheal epithelial cells (134, 135). Many of these studies and others testify to the 
ability of these compounds to modify actions of ET-1 which might contribute to asthma, 
but as yet no studies have been published examining their effect in asthmatic subjects. 
Immediate effects on bronchoconstriction and inflammatory responses are of interest, 
and longer term effects on airway remodelling in chronic asthma may have even greater 
potential. These studies may answer important questions, not only about the 
contribution of ET-1 to the pathophysiology of the disease, but more importantly about 
the potential therapeutic benefits of ET-1 antagonism in asthma.
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1.2.5 SUMMARY
There is evidence that ET-1 has a number of properties which could contribute to 
asthma, with particular interest in its bronchoconstrictor, (co)-mitogenic and pro- 
inflammatory activities. ET-1 is present in BAL from asthmatics at concentrations 
greater than those found in non-asthmatic subjects, and conventional anti-asthma therapy 
such as inhaled glucocorticoids can reduce ET-1 levels in BAL. There is very little data 
on the effects of ET-1 in vivo in asthmatics, and data is presented in subsequent chapters 
to try to address some of the questions associated with this area. There is as yet no data 
on the effect of endothelin antagonists in asthmatic subjects, and we have been unable to 
obtain trial drugs for this purpose, despite approaches being made to a number of 
companies.
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1.3 AIRW AY DISEASES AND THE ASSESSM ENT OF AIRWAY  
INFLAMMATION
Airway diseases, predominantly asthma and chronic obstructive pulmonary disease 
(COPD) are among the world's most prevalent diseases. The prevalence of asthma has 
been increasing in a number of countries in the world, and it affects as many as 5% of 
the population in some western countries, with a higher incidence in children. Similarly, 
COPD is a common cause of morbidity and mortality, and COPD is now among the 
most common causes of death in the world, largely as a consequence of the prevalence 
of cigarette smoking. Both asthma and COPD are identified by the presence of 
characteristic symptoms and functional abnormalities, with airflow obstruction being the 
essential hallmark of both diseases. In asthma, airflow obstruction is characterestically 
reversible, while in COPD irreversible airflow obstruction is the norm when assessed 
over time, although some patients with chronic asthma who do not smoke may develop 
irreversible airflow obstruction. In both diseases lung inflammation is found, which is 
likely to be the underlying cause of the functional abnormalities observed.
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1.3.1 ASTHMA
Although an exact definition of asthma is elusive, asthma is characterised by airflow 
obstruction which is variable over time, generally reversible to bronchodilator drugs, 
and which is associated with bronchial hyperresponsiveness to a number of 
bronchoconstrictor substances, such as histamine, cold air or cholinergic agonists (e.g. 
methacholine). With the exception of occupational asthma, the risk factors for adult and 
childhood asthma are broadly similar, and although there is a genetic link with the 
presence of parental asthma or atopy as the strongest determinants, genetic factors do 
not explain the majority of the heritability of asthma (136), and in general the heritability 
of surrogates for asthma such as atopy and IgE is greater than that observed for asthma 
itself. Reports of ethnic factors demonstrate a variable effect, but no substantive 
differences in asthma prevalence were demonstrated in a study of 3 ethnic populations 
within the UK (137). Other factors including in utero and neonatal factors may influence 
the likelihood of developing asthma, and environmental factors including exposure to 
cigarette smoke during childhood (138), personal smoking and dietary factors may play 
a role.
Airway inflam m ation in asthma
The central role of airway inflammation in the pathophysiology of asthma has been 
increasingly recognised, and bronchial biopsy studies have shown an increase in 
eosinophils, T lymphocytes and mast cells in the large airways of patients with asthma, 
with more recent information also suggesting the presence of inflammation in the small 
airways (139) and in the lung parenchyma (140). Studies have demonstrated airway 
inflammation in asthma even in subjects with newly diagnosed asthma (91) and in those 
with only intermittent symptoms (141), although to a lesser extent than those with 
persistent or more severe disease.
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Cells involved in airway inflam m ation in asthma
E o sin o p h ils  - Immunohistochemical staining of bronchial biopsies identifies increased 
numbers of eosinophils in asthma (142), which is also observed in bronchoalveolar 
lavage (143) and induced sputum (144), and electron microscopic features along with 
markers of eosinophil activation would suggest that these eosinophils are in an activated 
state. The actual role of the eosinophil in asthma remains to be fully explained, since 
there is no specific method to counteract the recruitment and activation of eosinophils in 
the human, but the consistent association between relative eosinophilia and asthma 
strongly supports a pathophysiological role for the cell. Correlations have been reported 
between the severity of asthma assessed by clinical scoring and BAL eosinophils, with a 
stronger correlation for alveolar than bronchial eosinophils (145), and similar 
relationships have been reported between BAL eosinophilia and lung function 
parameters in asthma (146). Increases in eosinophil numbers following challenge with 
allergen have been demonstrated in BAL (147) and induced sputum (148), and a 
decrease in eosinophil numbers is generally seen in response to inhaled or oral 
corticosteroids (149, 150), although exacerbation of asthma is not invariably associated 
with eosinophilic inflammation (151), and some subjects have persistent airway 
eosinophilia despite regular treatment with inhaled corticosteroids (152). Although 
eosinophilic airway inflammation is characteristic in asthma, it is not specific to asthma, 
since airway eosinophilia has been reported in a number of conditions including COPD 
(153), Churg-Strauss syndrome, polyarteritis nodosa and interstitial lung diseases.
T -lym p h o cy tes
The T lymphocyte is the most abundant nonconstituent cell in the airway epithelium (91) 
and there is evidence of increased T lymphocyte activation in asthma (154) which 
correlates with disease severity (155), even if studies have not consistently shown 
increased numbers of T cells in the asthmatic airway, with some finding no difference in 
T cell numbers or CD4+/CD8+ ratios in asthmatics compared with normals (142, 154), 
while others including electron microscopy have reported an increase (91). It has been
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increasingly recognised that the T lymphocyte may have a central role in orchestrating 
the inflammatory process in asthma through the local generation and release of cytokines 
such as interleukins (IL)-3, IL-4, IL-5 and granulocyte macrophage stimulating factor 
(GMCSF), in a manner analogous to that of the murine Th2 subpopulation of CD4+ T 
cells. In situ hybridisation studies on BAL cells from asthmatics have demonstrated 
increased mRNA expression for the above cytokines along with IL-2, but not for 
interferon gamma (IFN-y), consistent with the presence of an activated Thz-like 
population in asthma (156).
M ast cells
Mast cells comprise a very small proportion of the cells in BAL or sputum, although 
increased numbers have been recovered in asthmatics compared with non-asthmatics, 
with greater spontaneous and stimulated histamine release in asthma. In contrast to the 
small percentage in BAL, tissue mast cells are abundant and are activated (157). Mast 
cells have the capability to secrete cytokines, and several which are relevent to asthma 
have been identified stored within airway mast cells in a preformed state, including IL-4, 
IL-5, IL-6 and tumour necrosis factor (TNF)-ot (158).
M acrophages
Bronchial macrophages are hypodense in asthma (159), and have increased spontaneous 
release of IL-1 (160), and although the majority of studies using BAL or induced 
sputum do not suggest increased numbers of macrophages or other mononuclear 
phagocytes in asthma compared with control subjects, there are increased numbers in the 
submucosa. T cell regulatory activity is an important part of macrophage function, and 
there is increasing evidence that the mononuclear phagocyte system plays a central role 
in the regulation of local T cells, through the release of soluble mediators such as 
cytokines, arachidonic acid metabolites and reactive oxygen species, and also through 
antigen processing and presentation (161).
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Airway epithelial cells
In addition to their protective and structural function, bronchial epithelial cells have 
important metabolic funtion, being able to generate ET-1 as discussed in preceding 
sections, along with lipid mediators such as prostaglandins, and cytokines including IL- 
6, IL-8 and GMCSF on stimulation (162), as well as the inducible form of nitric oxide 
synthase (163).
Inflam m atory mediators in asthma
A  variety of mediators have been implicated in asthma, but since each mediator may 
have a number of effects on different cells, and may interact with other mediators in 
different ways, the role of individual mediators may be hard to assess. Mediators such 
as cysteinyl leukotrienes and other arachidonic acid metabolites, histamine, cytokines, 
adhesion molecules, growth factors, monoxides, oxidants and peptides may all 
contribute to the initiation and maintenance of asthmatic airway inflammation, and 
interest has focussed on those mediators which can be modified by treatment, in 
particular corticosteroids, and more recently the leukotriene antagonists, since there are 
relatively few specific antagonists of proposed asthmatic inflammatory mediators.
Structural changes in asthma
It is recognised that some patients with asthma have persistent impairment of lung 
function, without reversibility, either in terms of spontaneous variability or reversiblity 
to bronchodilators, and there is evidence of an increased rate of decline in FEVi in 
asthma, even in the absence of a smoking history (164). Relative thickening of the 
airway wall was reported in some very early studies in fatal asthma, and subsequent 
studies using bronchial biopsy techniques have confirmed the presence of thickening, 
particularly in the subepithelial layer of the bronchial wall (165). The use of electron 
microscopy has indicated that the lamina reticularis is greatly increased in depth, and 
immunohistochemical analysis suggests that this thickened layer is largely composed of 
collagen types III, V and to a lesser extent I and fibronectin (166). A specialised
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network of fibroblastic cells possessing contractile apparatus have been identified, and 
have been termed "myofibroblasts", which are present in normal subjects, but increased 
in asthma, and it has been shown that the number of these cells correlates with the 
degree of collagen thickness, suggesting that these cells are responsible for the 
deposition of collagen (167). More recent data derived from high resolution computed 
tomography (HRCT) of the lungs suggests the presence of bronchial wall thickening in 
asthmatics of varying severity (168), and even in a study which did not confirm this 
finding, there was a relationship between bronchial wall thickness and airway reactivity 
(169), suggesting that airway remodelling has direct functional consequences in 
asthma. The clinical relevance of airway remodelling is further highlighted by the fact 
structural changes can occur early in the course of the disease as illustrated by their 
presence in young children (170), and there is evidence that the potential to reverse 
airflow obstruction and measures of bronchial responsiveness is impaired in patients in 
whom cessation of therapy with inhaled corticosteroids was delayed (171). Further 
work is needed to examine the effect of corticosteroids on structural changes in the 
airway, since only some studies have demonstrated reversal of airway collagen 
deposition (172) or remodelling (173), while others have not shown a similar effect 
(149, 174).
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1.3.2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Like asthma, it has been difficult to provide an exact definition of COPD, although 
essential components are the presence of airflow limitation, and the fact that this 
limitation is not variable over short periods of time, with most attempts at definition 
specifying no significant variability in airflow limitation over a period of several months 
(175). Differentiation between severe chronic asthma and COPD on the basis of lung 
function tests can be difficult however, since asthmatics may exhibit irreversible airflow 
obstruction, while patients with COPD may have some reversibility to bronchodilator 
therapy, and in symptomatic terms, the presence or absence of cough and sputum, 
nocturnal or diurnal wheeze, partial response to bronchodilators or a family history of 
chest disease are unhelpful in differentiating chronic asthma and COPD (176). Both 
asthma and COPD are associated with airway and lung parenchymal inflammation, with 
consequent structural changes, although there are some differences in the nature and site 
of this inflammation and its consequent structural alterations which may be helpful in 
distinguishing the conditions, which may of course co-exist. The single most important 
cause of COPD is cigarette smoking, which dominates over all other aetiological factors, 
and which has a dose response relationship to the risk of developing COPD (177), and 
the best guide to prognosis is the rate of decline of the FEVi over time (175), which is 
accelerated in smokers who are susceptible to the development of COPD. Two major 
interactive hypotheses exist for the development of the tissue damage which is seen in 
COPD, namely a protease-antiprotease imbalance, and an oxidant-antioxidant imbalance. 
Cigarette smoke disturbs the normal balance between these processes, and results in 
unchecked protease and oxidant activity, which in turn leads to tissue damage by a 
variety of mechanisms.
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Airway inflam m ation in COPD
Studies using a range of techniques have shown infiltration of the bronchi and 
bronchioles by inflammatory cells. In bronchial biopsies, T lymphocytes, in particular 
CD8+ cells are predominant (in contrast to the CD4+ cells found in asthma), and the 
CD8+ cell numbers show a significant relationship with decline in lung function (178). 
In contrast, BAL and induced sputum are characterised by increased numbers of 
neutrophils (179, 180), which are not reflected in the subepithelial area in bronchial 
biopsies, but increased numbers are found in bronchial glands (181) and in the 
epithelium (182). Eosinophils are present, particularly in exacerbations, but they do not 
appear to be activated and do not degranulate ( 153), and may not be active participants in 
the airway inflammation in COPD.
Inflam m atory markers in COPD
Pro-inflammatory cytokines have been measured in bronchial secretions in COPD, and 
markers such as IL-8 and TNF-a (180) may have a role in neutrophil recruitment and 
activity. Similarly, increased levels of adhesion molecules which may be involved in 
neutrophil adherence and migration have been demonstrated in the circulation and BAL 
(183), and many studies have examined for evidence of protease and oxidant acitivity, 
which can influence inflammatory as well as structural processes in the lung.
Structural changes in COPD
In COPD structural alterations of the epithelium include atrophy, squamous metaplasia 
and qualitative and quantitative abnormalities of ciliated cells, and mucous galnd 
hyperplasia and enlargement are hallmarks of chronic bronchitis (184). Peribronchiolar 
and peribronchial fibrosis may occur, and abnormalities commonly extend to the lung 
parenchyma, where there may be disruption of the normal alveolar architecture, resulting 
in emphysema.
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1.3.3 THE ASSESSMENT OF AIRWAY INFLAMMATION
As discussed above, airway inflammation is fundamental to a number of airway diseases 
including asthma, and recurrent exacerbations of symptoms are generally associated 
with exacerbation of airway inflammation. Clinical assessment of these conditions still 
relies principally on clinical findings and lung function, but there is increasing interest in 
more direct assessment of airway inflammation in the hope that this will clarify the 
impact of the type and severity of airway inflammation on disease outcome and 
treatment. This section will focus on asthma, but similar principles are applicable to the 
assessment of other airway diseases including COPD, although with different results in 
terms of the nature an extent of the inflammation. Assessment of airway inflammation is 
possible in fatal asthma at post mortem, and in less severe disease by bronchoscopic 
techniques, sampling of peripheral blood (and in some cases urinary markers) and more 
recently through the use of induced sputum and analysis of exhaled air.
M ethods o f  assessm ent o f  airway in flam m ation  o ther than  induced  
spu tum
Post mortem studies
Early studies assessing airway inflammation in asthma and COPD were based on post­
mortem findings, and while fatal cases clearly represent an important subgroup of very 
severe disease, their relevance to mild cases and the evolution of the disease processes is 
not clear. Post-mortem studies have however contributed to the understanding of the 
pathophysiology of asthma, and demonstration of significant tissue eosinophilia, 
disruption of the bronchial epithelial cell layer and mucous plugging are hallmarks of 
severe asthma (185), although there is evidence of heterogeneity of cellular infiltration 
even in fatal asthma (186). Thankfully, asthma is only rarely a fatal condition, and 
therefore post mortem studies will rarely be able to provide important pathophysiological 
information about more mild asthma, and certainly cannot provide information on the
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time-course of changes in airway inflammation in response to airway challenge or 
treatment.
Bronchoscopic studies
The use of fibreoptic bronchoscopy, which can be carried out safely subject to certain 
guidelines (187, 188), allows sampling of airway cells and mediators by 
bronchoalveolar lavage (BAL) along with histological studies using biopsy and 
bronchial brushing, and in addition controlled provocation of inflammation may be 
carried out using allergen challenge.
Bronchoalveolar lavage - While the technique of BAL has been widely used in the 
study of asthma and other airway diseases, there are limitations to its use, in particular 
the dilutional effect of BAL, with estimates suggesting that 2% of the BAL sample 
originates in the airway, with the remainder being return of the lavage fluid. Studies 
using BAL have confirmed the presence of eosinophilia with activation and 
degranulation of the eosinophils, and have shown associations between eosinophil 
numbers and eosinophil granule protein concentration and markers of disease severity 
such as symptom scores and measures of lung function (145, 146) and bronchial 
hyperreactivity (143). T cell numbers are relatively low in BAL, so a number of 
techniques have been used to try to increase the information obtained, including the 
detection of activation markers such as CD25 which suggests activation of CD4+ cells in 
atopic asthma (154) and both CD4+ and CD8+ cells in intrinsic asthma (155). BAL 
studies have also examined the effect of allergen challenge on airway cells and 
mediators, either using inhaled allergen, or using a segmental allergen challenge which 
involves treating one bronchial segment with allergen, and another with a sham 
challenge as a control (189).
B ronchia l brushing  - Bronchial brushing is a particularly effective way to study 
bronchial epithelial cells, and some studies have reported its use in asthma (190). It is a
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complementary method which may be used along with BAL and biopsy in the study of 
airway inflammation.
B ronchia l biopsy - Although some of the work done to establish the inflammatory 
basis of asthma was done using the rigid bronchoscope (e.g. (191, 192)), the advent of 
the flexible bronchoscope has allowed much wider use of bronchial biopsy samples in 
the study of asthma and other airway diseases. It has become apparent that some of the 
changes observed in fatal asthma accord with those observed in much more mild 
asthma, with evidence that airway inflammation characterised by eosinophilia and 
infiltration by activated T lymphocytes is present even in newly diagnosed asthma (91), 
but also evidence, even in mild asthma, that there is thickening of tissues adjacent to the 
epithelial basement membrane, with deposition of fibroblasts and myofibroblasts (166, 
167). Bronchial biopsy samples taken before and after treatment demonstrate the 
efficacy of inhaled corticosteroids in reducing inflammation ( 193), although the effect on 
subepithelial fibrosis is less clear. The ability to assess morphology is a significant 
advantage of biopsy studies, and biopsies are generally taken as the standard against 
which other methods of sampling are judged, although there are obvious disadvantages 
relating to the invasive nature of the procedure.
Peripheral markers o f  inflam m ation
Peripheral markers of airway inflammation such as inflammatory cell counts in 
peripheral blood or plasma (or urine) levels of inflammatory mediators have been 
assessed as surrogate markers of airway inflammation. In general, the markers chosen 
relate to cells which are pertinent to airway inflammation and may be directly released by 
these cells.
E o sin o p h ils  - Until relatively recently, interest has centred on the eosinophil and its 
principal cationic proteins, in particular eosinophilic cationic protein (ECP), secreted 
during activation of eosinophils. Peripheral eosinophilia may be present in asthma 
(194), and reduce in response to inhaled steroid therapy (195), but peripheral 
eosinophilia is not specific to asthma. Similarly ECP may be of value in assessing
36
airway inflammation in asthma (196), and is elevated after allergen (197) and exercise
(198) challenge in adult asthmatics, but elevation is not invariable, there is a wide scatter 
of results in most studies and the measurement of ECP is subject to a number of 
confounding factors, including the release by eosinophils of ECP after blood has been 
sampled. Elevated serum ECP may also be found in patients with atopic dermatitis
(199), which may limit its utility in patients with co-existent disease.
T  cells and cytokines - Peripheral blood T cell activation correlates with the severity 
of asthma (200), and circulating CD4+ T cell activity is reduced by glucocorticoid 
therapy (201). Numerous reports have been published of levels of circulating T-cell 
cytokines in asthma, with studies reporting levels of IL-5, IL-4, GM-CSF being of 
obvious relevance to the known pathogenesis of asthma. There are however limitations 
to interpretation of these findings, in that relatively little is known however about the 
factors which might influence the passage of these cytokines into the circulation, and the 
local and systemic degradation and clearance of cytokines secreted in the bronchial 
mucosa, either in health or disease. In addition since cytokines are primarily local 
messengers, it would seem important to know the relationship between local production 
and functionally relevant circulating levels of cytokine, but such data is not yet known, 
and conversely it is recognised that a cytokine may have an important local role without 
being detectable in significant quantities in the circulation.
M ast cells and neutrophils  - Although histamine levels may rise during early 
allergic reactions and during exercise, levels may be modified by the numbers of 
circulating basophils (202), and mast cell tryptase is not a useful marker for asthma. 
Circulating neutrophils are primed or activated in asthma, with evidence of increased 
chemotactic activity in response to a number of stimuli (203, 204), and in acute severe 
asthma (205). These markers are not however routinely used in the clinical or 
experimental assessment of airway inflammation.
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Other markers in peripheral blood
Adhesion molecules, eicosanoids (also in urine) and reactive oxygen species have been 
studied, with evidence of some relevance to asthma, but further work is needed to 
clarify their relationship to airway inflammation and their utility as markers for clinical 
monitoring in asthma.
Exhaled air
There has been substantial interest in the measurement of markers of inflammation in 
exhaled air, with the prospect that this could provide a completely non-invasive method 
of assessing airway inflammation. Exhaled nitric oxide (NO) is increased in asthma 
(206, 207), probably due to upregulation of inducible nitric oxide synthase (iNOS), and 
levels of exhaled NO are related to bronchial hyperresponsiveness (208), asthma 
exacerbation (209) and airway inflammation following allergen challenge (210). Exhaled 
NO is reduced by treatment with inhaled steroids (211), but not by p-agonist 
bronchodilators, suggesting that exhaled NO may be a marker of airway inflammation. 
Similarly, levels of another monoxide, carbon monoxide (CO) have been shown to be 
elevated in asthma, with a reduction following treatment with corticosteroids (212), and 
further work has shown an association with increased expression of the stress protein 
heme oxygenase-1 which catabolises heme to bilirubin, free iron and CO (213). It is 
possible to measure other potential markers of inflammation in exhaled air, and this is an 
aetive area of research, but further work is need to assess the utility of these markers in 
the assessment of asthma.
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1.3.4 INDUCED SPUTUM
The analysis of sputum in lung diseases is not a new phenomenon, but although a 
proportion of asthmatics may be able to produce spontaneous sputum samples on 
request, the cell counts and viability of cells in such samples is often too low for 
analysis, and there is greater contamination of samples with squamous epithelial cells 
(214). This limits the utility of spontaneous sputum samples in asthma (and even more 
so in healthy subjects) and has led to interest in sputum induction as a non-invasive 
method of assessing airway inflammation. The technique of sputum induction using 
hypertonic saline administered by aerosol was first reported in 1958 with the aim of 
obtaining sputum for cytology in suspected lung cancer (215), but it has only recently 
been extended to include the assessment of airway inflammation. The mechanism by 
which hypertonic saline induces sputum is not known although proposals include 
osmotic effects (216), an increase in mucociliary clearance (217) and stimulation of 
glandular secretions.
M ethodo logy
The methodology and validity of sputum induction as a technique has been a topic of 
particular interest, with studies reporting the use of a number of techniques. Sputum 
induction has been shown to be safe in asthmatics of varying severity (218), including 
severe asthma (219), if necessary with variations in strength of hypertonic saline and 
time of inhalation, and the technique is now accepted as being valid, reproducible (220- 
222) and responsive. There are subtle differences in the method of inducing sputum 
between groups, some using increasing concentrations of hypertonic saline (generally 3,
4 and 5%) with others, including our own group, using a fixed concentration of saline 
(3%), and there are also minor differences in the time periods over which sputum is 
induced. Choice of technique does not seem to significanity alter the differential cell 
count in the sputum obtained (223). Sputum induction is superior to the collection of 
spontaneous sputum in its greater applicability, greater cell viability and sputum yield in
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both asthma (214) and COPD (224). There has been lively debate about the best method 
of processing of samples, either by analysis of the whole sputum sample or by 
analysing only the viscid portion of the sputum, which is taken to reduce salivary 
contamination. We have adopted the latter technique, and our findings for salivary levels 
of ET-1 presented in chapter 6 indicate that salivary contamination may have 
consequences other than simply dilution of the sample and an increase in squamous 
epithelial cells. Studies have compared the methods, and current evidence suggests that 
although sputum selection may provide more viable cells, including eosinophils, and 
increased concentrations of mediators (225), both methods allow differentiation between 
health and disease (226). The general consensus is that although there are differences 
between the two techniques and the results are not therefore interchangeable, the utility 
of the sputum induction when performed in a standardised way, with appropriate 
monitoring and safety precautions is not influenced by the choice of processing method 
(223). Standardisation and consistency in method of sputum induction and processing 
of samples would allow direct comparison of results from different groups, but despite 
calls for such standardisation (227) no agreement has yet been reached.
Conformity with other measures o f  airway inflamm ation
The composition of induced sputum in asthmatics has been assessed in comparison with 
other direct measures of airway inflammation, such as bronchial wash (BW), 
bronchoalveolar lavage (BAL) and bronchial biopsies, and also in comparison with 
some non-invasive markers of airway inflammation. Current evidence suggests that 
sputum contains higher absolute numbers of eosinophils and neutrophils, but fewer 
lymphocytes and macrophages than BW or BAL (228-231). There is agreement that 
eosinophil proportions are similar comparing induced sputum with BW, but not all 
studies have reported a significant relationship with BAL eosinophils (228, 229, 231). 
The relationship between cell numbers and proportions comparing induced sputum with 
bronchial biopsies is less clear (228, 232). Comparison of induced sputum composition 
with non-invasive markers of airway inflammation would suggest that sputum
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eosinophilia is a better marker of asthma than peripheral blood eosinophil counts (233) 
or ECP levels (234), while there is a relationship between sputum eosinophilia and 
exhaled NO in asthma (208).
Responsiveness to in tervention
Experience to date would suggest that induced sputum is able to reflect changes in the 
degree of airway inflammation in asthma in response to a variety of factors. Exposure to 
allergen (148, 235) has shown increases in eosinophils and metachromatic cells in 
sputum, and conversely, responsiveness of induced sputum parameters to treatment has 
been demonstrated in asthma over a range of severity (236-238), including 
responsiveness to relatively subtle changes in treatment regimens (237, 239).
1.3.5 GENERAL COM M ENTS ON M ETHODS OF A SSESSING  
AIRWAY INFLAMMATION
Airway inflam m ation and airway function
There is a tendency to assume that the assessment of airway inflammation in asthma 
offers direct information about symptoms, prognosis and response to treatment, and 
vice versa, but in fact the relationship of airway inflammation to airway function and its 
clinical patterns is not yet clear (240, 241). Current treatment strategies in asthma are 
directed towards the control of symptoms of the disease and lung function (242), partly 
on the assumption that these are correlates of airway inflammation, but there is evidence 
that patients who appear to be clinically controlled may still have airway 
hyperresponsiveness (AHR) and persistent airway inflammation (243 , 244). 
Relationships have been described between airway inflammatory cells and AHR 
assessed by methacholine, and it has been suggested that assessment of AHR should be 
a component of clinical evaluation in asthma (152), although it is important to note that 
airway inflammation is not the only contributor to AHR (245), and that some studies 
have demonstrated a dissociation between AHR and airway inflammation in asthma 
(246, 247). If it is true that airway inflammation contributes to airway remodelling, then 
it may be necessary to incorporate some measure of airway inflammation into treatment 
protocols, either directly, or via some surrogate marker, for example AHR or non- 
invasive markers such as exhaled gases. There is evidence that AHR may act as a 
marker of the risk of exacerbation in asthma (248), and that treatment aimed at 
controlling AHR rather than symptoms alone can reduce the exacerbation rate, with 
associated reduction in inflammatory cells in bronchial biopsies (249). Interestingly, the 
same study demonstrated a greater reduction in the reticular layer thickness beneath the 
epithelium in bronchial biopsy specimens comparing the group whose treatment was 
aimed at controlling AHR with the group whose treatment was aimed at controlling 
symptoms (249), supporting a presumed association between AHR, airway 
inflammation and airway remodelling. Overall, a link between symptoms, AHR, airway
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inflammation and response to therapy seems intuitive, but regardless of the method of 
assessing airway inflammation, it should be recognised that each of these "measures" of 
asthma may reflect subtly different components of the disease, giving complementary 
rather than identical information about disease activity and prognosis.
Bronchoscopic m ethods
Although generally safe and well tolerated, bronchoscopy is invasive and carries some 
degree of risk, which although small, may limit the utility of the technique in clinical 
management. The degree of risk which is acceptable will vary according to the patient 
group under investigation, such that a degree of risk which might be tolerable in lung 
cancer could be intolerable in a disease such as asthma which has a very low death rate, 
and similarly intolerable in healthy or patient group volunteers. In general, ethical 
permission can be obtained for bronchoscopic studies in patients with mild asthma, and 
for a small number of healthy volunteers, and while some studies have involved 
repeated samples, the nature of the procedure would make time-course studies difficult, 
and the expense and need for specialised equipment would prevent bronchoscopy being 
used for larger studies of airway inflammation. Bronchoscopic studies are however 
likely to remain the "gold standard" against which other methods of assessing airway 
inflammation are measured.
Induced  sputum
There has been some concern that sputum induction itself may act as an inflammatory 
stimulus, and studies have shown that in normal volunteers, a rise in sputum neutrophils 
is seen on repeat sputum induction at 8 hours after the first induction, which was 
sustained at 24 hours (250), with similar results in asthmatics who had repeat sputum 
induction at 24 hours (251). While this may be a limitation of the technique of sputum 
induction, there are important technical considerations which remain to be fully 
explored, such as the effect of the nebuliser output and type of nebuliser and the 
concentration of saline used, as studies differ in these respects, and although these data
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should not affect results of a single sputum induction, there may be an effect on serial 
samples.
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1.4 HYPOTHESES AND AIMS OF THESIS
The background to this thesis is found in the work published from our group reporting 
the in vitro activity of ET-1 in bronchial tissue. Our group and others had demonstrated 
that ET-1 has potent bronchoconstrictor activity in animal (85) and human (60) tissue in 
vitro, and demonstrated differences between the mechanism of bronchoconstriction of 
ET-1 inhuman compared with bovine tissue (60), and responses to bronchodilators of 
tissue pre-contracted by ET-1 (252). From this we hypothesised that ET-1 could have a 
role in bronchoconstriction in asthma, and were supported in this hypothesis by the 
published literature identifying increased immunostaining for ET-1 in asthmatic airways 
(122), and a relationship between BAL ET-1 and airflow obstruction in asthma (124). 
As part of a study from our group examining a role for angiotensin II in acute severe 
asthma, plasma ET-1 concentrations were measured, and were found to be elevated
(119), providing further support for a role in acute severe asthma. The other component 
behind this work was an evolving interest in the use of the non-invasive technique of 
sputum induction in the assessment of asthma, and the desire to apply it in the 
measurement of novel mediators as well as in quantification of cellular inflammation in 
asthma.
Initial aims were therefore based along two lines of enquiry, the first being to confirm in 
vivo the bronchoconstrictor activity and potency of ET-1, and the second to examine the 
use of sputum induction to assess airway concentrations of ET-1. These two themes 
form the basis for the main subdivisions of the thesis, with the bronchoconstrictor 
activity of ET-1 being the focus of chapters 3, 4 and 5, while the use of sputum 
induction to obtain fluid for the measurement of ET-1 underlies the work presented in 
chapters 6 to 9. The initial hypothesis was based around asthma, but as outlined above, 
several of the properties of ET-1 could relate to other diseases affecting the airways, and 
we extended the hypothesis therefore to include cigarette smoking and COPD, and on
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the basis of some speculative pilot work, also measured sputum ET-1 in cystic fibrosis 
(CP).
The results of these investigations should increase our understanding of the potential 
role of ET-1 in the pathophysiology of asthma, and provide the basis for further 
investigation of a previously unsuspected role in COPD and CF.
CHAPTER 2
GENERAL METHODS AND MEASUREMENTS
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GENERAL METHODS AND MEASUREMENTS
2.1 SUBJECTS
Mild asthmatic subjects were recruited from the outpatient asthma and general 
respiratory clinics of the West Glasgow Hospitals University NHS Trust (Gartnavel 
General Hospital and the Western Infirmary, Glasgow) and patients presenting with 
acute severe asthma or COPD were recruited via the respiratory wards at Gartnavel 
General Hospital and the Acute Receiving Unit at the Western Infirmary, Glasgow, with 
the permission of the admitting consultant. Patients with cystic fibrosis were recruited 
from the West of Scotland Adult Cystic Fibrosis Unit, which is based at our institution. 
Healthy volunteers were recruited mainly from medical, nursing and ancillary staff in 
these hospitals. None of the asthmatic subjects were cigarette smokers. Further 
demographic data for each subject group is presented and discussed in the appropriate 
chapter.
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2.2 LUNG FUNCTION AND BRONCHIAL CHALLENGE TESTS 
Sp irom etry
Spirometry was performed using a Vitaiograph Compact electronic pneumotachograph 
spirometer (Vitaiograph, Buckingham, UK). The spirometer was calibrated regularly 
using a fixed volume syringe, and regular maintenance checks were performed. Subjects 
were requested to inhale to full inspiration and then exhale forcibly to full expiration, 
and the best of three readings was taken for each measurement. The commonest 
measurement used to assess airflow obstruction in the forced expiratory volume in 1 
second (FEVi), and values used are the best of three readings in each case. In most 
cases, FEVi is expressed as a percentage of age and height predicted values (253), with 
values below 70% in general indicating airflow obstruction. Many mild asthmatics 
however will have normal or near normal FEVi values, and in the confirmation of 
asthma in particular, greater reliance was placed on bronchial provocation testing than on 
FEV1 values per se.
Peak Expiratory Flow
Peak expiratory flow rates (PEER) were used to assess severity in the patients with 
acute asthma or COPD at the time of admission. Where used, PEFR are expressed as 
litres/minute, and the value stated is the best of three readings.
Constant volume body plethysm ography
For the study described in chapter 3 measurements were made using a constant volume 
body plethysmograph (Erich Jaeger GmbH, Wuerzburg, Germany; "Masterlab v4.2"), 
with assessment of specific airways conductance (SGaw). SGaw is calculated using the 
software provided with the body plethysmograph, and in challenge testing, a fall of 35% 
in SGaw was used for analysis. Further details of the procedure employed in the study 
are given in chapter 3.
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B ronchial provocation tests
Bronchial hyperresponsiveness is an increased tendency to respond to a variety of 
stimuli by bronchoconstri ction, and is characters tic of but not exclusive to asthma. 
Asthmatics will in general respond to a bronchoconstrictor stimulus at a lower dose than 
non-asthmatics, and this characteristic can be used to support a clinical diagnosis of 
asthma. Since bronchial responsiveness is influenced by inhaled bronchodilator therapy 
and there is some diurnal variation, tests were performed at similar times of day, and 
subjects were asked to withhold short-acting B2 agonists (e.g. salbutamol/terbutaline) 
for 8 hours prior to testing, and long-acting B2 agonists for 24 hours. Slow release 
theophylline preparations were withheld for 48 hours if applicable, and inhaled 
corticosteroids were unchanged. (Although inhaled corticosteroids may alter bronchial 
hyperreactivity compaied with values when not taking inhaled steroid, this effect is not 
an acute effect, and bronchial provocation tests performed while on a stable dose of 
inhaled steroid are comparable.) The technique of bronchial challenge testing has been 
described for histamine by Cockcroft et al (254), and is applicable to other 
bronchoconstrictor substances. In summary, a substance is administered by nébulisation 
in incremental doses (usually doubling doses) with measurement of lung function (e.g. 
spirometry or body plethysmography) at each dose. This allows a dose-response curve 
to be established, and a threshold response can be identified to allow quantification of 
the response, expressed as the provoking concentration (PC) of the bronehoconstrictor 
substance required to produce a given change in lung function, and calculated by linear 
interpolation. For example, asthmatics tend to have increased sensitivity to histamine, 
with a provoking concentration required to produce a 20% fall in FEV \ (PC20FEV1) of 
< 8mg/ml.
For the purposes of the studies described, bronchial hyperresponsiveness to 
methacholine (an acetylcholine analogue) was used as confirmation of asthma, and as an 
entry requirement for all studies, with a value for PC20FEV1 to methacholine of < 8 
mg/ml. For screening purposes and for most of the studies, methacholine was
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administered using a timed inhalation at each dose from the same Wright's nebuliser. 
The nebuliser contained 3ml of nebulisate and was driven by a continuous airflow of 9 
1/min from a compressed air source of 501bs/in (345 kPa), calibrated to deliver an output 
of 0.13 ml/min. Where greater accuracy of dosing was required, for example for 
administration of allergen (Chapter 7) or endothelin-1 (Chapters 3,4 and 5), the 
substance was administered using an air-driven dosimeter ('Nebicheck' PK Morgan 
Ltd, Gillingham, U.K.), calibrated to deliver 0.006ml/breath, and dose was incremented 
by increasing the number of breaths at each dosage interval. In each case, baseline FEV i 
was measured, and the first inhalation was of phosphate buffered saline, followed by 
spirometry at 30, 90 and 180 seconds, with the lowest post saline value taken as the 
baseline from which subsequent falls were measured. At 5 minute intervals, subjects 
received inhalations of doubling concentrations of methacholine (dose range 0.0625 to 8 
mg/ml), and FEVi was repeated at 30, 90 and 180 seconds. Inhalations were continued 
until the FEVi fell by more than 20%, and the PC20FEV1 was then calculated by linear 
interpolation. At the end of each methacholine challenge, subjects received inhaled 
bronchodilator (from metered dose inhaler or nebuliser) to reverse the 
bronchoconstriction.
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2.3 SPUTUM INDUCTION AND PROCESSING OF SAMPLES 
Sputum  induction procedure
For the studies where induced sputum samples were obtained, sputum induction was 
performed using a modification of the method described by Pin etal.{lA4) Briefly, after 
salbutamol 200 meg was administered by metered-dose inhaler with large volume 
spacer, sputum induction was started using hypertonic (3%) saline administered via an 
ultrasonic nebuliser (Schuco International Ltd, London, U.K. or Medix Sonix 2000) 
over a period of 20 minutes. The subjects were encouraged to expectorate at any time 
throughout the procedure, and in addition inhalation was stopped every 5 minutes to 
allow expectoration, and to allow spirometry to be carried out. Prior to expectoration 
subjects were asked to rinse their mouth with water and to blow their nose to try to 
minimise contamination of sputum samples with saliva and nasal secretions. The sample 
was collected in a sterile container and was transferred to the laboratory on iee as soon 
as possible, and in all cases in less than 2 hours. If FEVi fell by more than 20%, the 
procedure was discontinued.
Processing o f  sputum  samples
Samples were processed without the laboratory staff being aware of the clinical 
information relating to the individual subject, and the procedure followed was similar to 
that described by Popov et at ( 2 5 5 ) .  This procedure is diagramatically represented in 
figure 2.3.1. Saliva samples (where appropriate) were stored at -20“C and sputum 
samples were transferred to a Petri dish and the volume and macroscopic characteristics 
of the whole sample were recorded. Sputum plugs were selected, if necessary using 
inverted microscopy, to minimise salivary contamination (256) and were split into two 
Eppendorfs. One was treated with fresh dithiothreitol (DTT) (Sigma U.K. Ltd) in a 
balanced salt solution and the other was centrifuged (13,000 rpm for 15 minutes) 
without prior treatment with DTT for endothelin assay, and the resulting supernatant 
stored at -70°C. Following incubation with DTT for 20 minutes the DTT-treated samples
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were filtered through 50/^m mesh (R Cadoch & Sons, London U.K.) to remove residual 
mucus clumps and a total cell count was made using a white cell counter (CBC5, 
Coulter Electronics Ltd. U.K.). The sample was centrifuged (3,000 rpm for 4 minutes), 
the supernatant removed and stored at -70°C prior to assay and the remaining pellet (re­
suspended at IxlO'’ cells/ml) was cytocentrifuged (500 rpm for 5 minutes) using a 
Shandon centrifuge. Differential cell counts were made from the resulting slides using 
Giemsa staining, and are expressed after exclusion of squamous epithelial cells which 
are taken to represent salivary contamination (256). Criteria were established for 
rejection of samples if viability was <40%, or squamous cells >20% although in fact no 
samples were rejected on these criteria (viability was typically >70% and squamous cell 
count around <10%). The bronchial epithelial cell count was very low in all samples 
(typically <2%).
Select viscid portion of sputum (using 
Inverted microscopy If necessary)
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Weigh and incubate with 4x volume of 
0.1% dithiothreitol (DTT)
I
Gently aspirate with pasteur 
pipette, vorte^for 15 seconds
Rock on bench rocker for 15 
minutes
I
Mix with equal volume (to DTT) of Dulbecco’s 
phosphate buffered saline (D-PBS)
Rock for 5 minutes
I
Filter (48|im nylon gauze)i
Centrifuge (10 mlns) _
Discard if low 
viability (<40%)
Resuspend cell pellet In 
D-PBS
I
Total cell count and 
— assess viability
I
Adjust cell suspension 
to 1 X 106 cells/ml
I
Prepare cytosplns for 
differential cell counts
Store supernatant
Measure fluid 
phase components
Figure 2.3.1
Laboratory processing of sputum samples 
(adapted from Pavord et al, Thorax 1997; 52: 498-501)
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2.4 ASSAYS 
E ndothelin -1 assay
ET-1 assay was performed by Dr J.J. Morton in the radionuclide laboratory of the 
Department of Medicine, Western Infirmary Glasgow, using a commercially available 
radio-immuno assay (RIA) (Nichols Institute Diagnostics Ltd, San Juan Capistrano, 
CA, U.S.A.) This assay has 100% sensitivity for ET-1, with some cross-reactivity for 
other ET species (67% for ET-2, 84% for ET-3, and much lower cross-reactivity for the 
precursor molecules big-ET-1/2/3). Our own results from reverse-phase high- 
performance liquid chromatography (RP-HPLC) however, suggest that ET-1 is the 
dominant species in sputum samples, with no signal being detected for ET-2 or ET-3 
(see below). The lower limit of detection of the RIA is c. 2 pg/ml in plasma, and assays 
were run in duplicate, with the mean value used for analysis. We found the coefficient 
of variation of the assay to be 11.4% for sputum samples. Sputum samples for ET-1 
assay were not treated with the reducing agent DTT, since there was concern that DTT 
might alter the ET-1 assay, based on a pilot assay using a small number of samples, as 
outlined below. Samples for ET-1 assay were thawed and pre-extracted using C-18 
columns prior to RIA. We performed plasma ET-1 assay on a sub-group (n=9) of 
patients both before and after sputum induction, and found that there was no difference 
in plasma ET-1 due to the procedure itself (data not shown).
E ffec t o f  D TT on ET-1 assay
To examine the effect of DTT on ET-1 measurements, assays were performed on ET-1 
control samples along with DTT, and we found that DTT altered the ET-1 standard 
curve with apparent elevation of ET measurements, when using pure ET-1 standards. 
This effect was not apparent with DTT treated clinical samples as opposed to control ET - 
1 samples, but to avoid potential confounding factors we modified the process to allow 
sputum plugs to be assayed without prior treatment with DTT. The mechanism for this 
possible interference is not known, but since RP-HPLC did not suggest an alteration in
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the ET-1 molecule following treatment with DTT, it is presumed that any interference 
might be with some component of the assay system rather than the ET-1 molecule itself. 
Due to an assay failure, with resultant loss of DTT-free samples, ET-1 assay was 
performed on DTT-treated samples from acute severe asthmatics and patients with acute 
exacerbation of chronic obstructive pulmonary disease presented in chapters 6 and 8 
respectively. No comparison is made between these data and non-DTT-treated samples.
Recovery o f  ET-1 fro m  sputum  samples
In order to assess recovery of ET-1 from sputum samples, sputum samples were 
"spiked" with a known concentration of ET-1, and assay techniques performed in the 
usual way. We found that recovery averaged 68%.
Other assays
Assays were perfomed on induced sputum samples for a variety of other mediators, 
including eosinophilic cationic protein, interleukin-IB, nitrite and albumin. The details of 
these assays are contained in the relevant chapters.
Reverse-phase high perform ance liquid chromatography
Reversed phase high performance liquid chromatography (RP-HPLC) was carried out 
on a number of saliva and sputum samples to identify the presence of ET-1 and confirm 
the findings of the RIA. RP-HPLC was performed by Dr Brian McGinn at Thistle 
Research, Glasgow UK. Dried samples from C-18 column extraction were dissolved in 
0.1ml water/acetonitrile (9:1) with 0.05% trifluoroacetic acid (TEA), and applied to a 
Vydac Peptide & Protein C18 HPLC column 4.6 x 250mm. The column was eluted 
with a 20-50% gradient of A: 0.05% TEA in water and B: 0.05% TEA in acetonitrile 
over 30 minutes at a flow rate of 1 ml/min. During the gradient elution, 10 x 1ml 
fractions were collected between 15 and 25 minutes, since a calibration analysis using 
synthetic ET-1 showed its elution point to be 21.1 minutes. Following elution, fractions 
were dried down for radio-immunoassay (RIA).
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2.5 DATA HANDLING AND STATISTICAL ANALYSIS
Statistics were performed on an Apple Macintosh desktop computer (Apple Computer 
Inc., Cupertino, CA, U.S.A.) using a statistical software package (Minitab Statistical 
Software, Mini tab Inc., State College, PA, U.S.A.). Non-parametric statistics (Mann 
Whitney-U test) were used to compare cell counts and concentrations of mediators, and 
values are expressed as median (interquartile range) unless stated otherwise. PC20 and 
PC 15 values were calculated by log-linear interpolation and are expressed as geometric 
mean and range. The geometric mean is the antilog i o of the mean of the logsi o of the PC 
values, and it is used because the dosage intervals in the bronchial challenge tests are 
doubling rather than linear. Analysis of variance (ANOVA) was used to compare blood 
pressure, pulse rate and pulse oximetry data in ET-1 inhalation studies.
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2.6 ETHICAL APPROVAL
Ethical permission for each study was obtained from the Glasgow West Ethical 
Committee prior to commencement of the studies. Written information was given to all 
subjects, and written informed consent was obtained from all subjects.
2.7 DRUGS
E ndothelin -1  - Dried purified ET-1 was obtained from Thistle Research, Glasgow 
UK for studies described in chapters 3 and 4, and from Calbiochem-Novabiochem 
(UK) Ltd. Nottingham, UK for the study described in chapter 5, reconstituted in each 
case using 0.9% saline prior to nébulisation, at a concentration of 0.2mg/ml. 
Salbu tam ol - (Ventolin®) Allen & Hanburys Ltd, Uxbridge UK. Metered dose 
inhalers or pre-prepared solution for nébulisation 2.5ml in normal (0.9%) saline. 
M ethacholine  - for inhalational challenge (acetyl-B methyl choline chloride) Sigma 
Chemical Company, Poole, Dorset UK, made up in phosphate buffered saline to pH 
7.4. Methacholine was prepared by sterile pharmacy in our institution.
A ngio tensin  11 - (Affiniti Research Products Ltd, Exeter, U.K.) prepared in 5% 
dextrose as a solution for intravenous administration at doses stated in chapter 5.
House dust mite allergen - (Allergy Therapeutics Ltd, Worthing, UK - previously 
SmithKline Beecham Pharmaceuticals PLC) Dertnayophagoidespteronyssinus aqueous 
extract 1.2% standard preparation, used for chapter 7.
CHAPTER 3
INHALED ENDOTHELIN-1 INDUCES 
BRONCHOCONSTRICTION IN ASTHMA
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3.1 INTRODUCTION
In view of reports from our own group and others of the highly potent 
bronchoconstrictor activity of ET-1 in vitro in both animal (85, 87) and human (60) 
bronchial preparations, we wished to examine the potential bronchoconstrictor effect of 
ET-1 in humans (asthmatic and non-asthmatic) in vivo. Bronchoconstriction is a central 
feature of asthma, and the highly potent bronchoconstrictor effects of ET-1 in vitro 
relative to other known bronchoconstrictor substances such as histamine and 
methacholine merit investigation in asthma, where increased airway ET-1 has been 
reported. In the guinea-pig, administration of ET-1 by intra-arterial infusion or by 
aerosol in isolated perfused lungs (61) or in anaesthetised and ventilated animals (67), 
produced dose-dependent bronchoconstriction, but there are no reports in humans of the 
in vivo bronchoconstrictor effects of ET-1. Interestingly, topical application of ET-1 to 
the nasal mucosa results in increased nasal secretions in healthy volunteers, with a 
greater increase in secretions in allergic rhinitis (114), suggesting increased upper 
airway sensitivity to the local effects of ET-1 in allergic subjects.
The objectives of the study were to examine the effects of inhaled ET-1 on lung function 
in asthmatics, in comparison with normal subjects, and to assess the in vivo 
bronchoconstrictor potency of ET-1 in compai'ison with methacholine.
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3.2 PILOT WORK
Since there are no reports of aerosol adminstration of ET-1 in human subjects, and it 
was necessary to base this study on human in vitro data from our own laboratory, pilot 
data was obtained, primarily to establish a dose range for use in the study. Bronchial 
challenge tests were performed as stated below initially on one non-asthmatic subject 
and thereafter one asthmatic subject, using an ET-1 starting dose below that recorded to 
produce any contraction in human bronchial tissue in vitro (0.03 nmol), with doubling 
doses up to the starting dose outlined in the study below. No bronchoconstriction was 
observed in either subject, nor was there evidence of a pressor effect, nor any change in 
pulse oximetry. Two further asthmatic subjects were then recruited, and repeat bronchial 
challenge performed using the dose-range outlined below, with resultant dose-dependent 
bronchoconstriction. This dose range was then used for the study as a whole, and data 
from these subjects is included in the study (asthmatic subject numbers 1 and 2).
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3.3 METHODS 
Subjects
13 adult subjects were studied, sub-divided in to 8 asthmatics and 5 normal volunteers, 
with numbers limited by the high cost of ET-1 (roughly £125 per inhalation). 
Asthmatics all had current asthma with stable symptoms at the time of study, no history 
within the preceding month of respiratory infection, antibiotics or oral corticosteroid use 
and other than house dust mite, none of the subjects had been exposed to allergens to 
which they were allergic in the preceding month. Asthma was defined according to the 
ATS definition (257), baseline lung function was recorded, and non-specific bronchial 
hyperresponsiveness was established using a methacholine challenge test, with all the 
asthmatics subjects having a methacholine PC20  of less than 8mg/ml. Normal subjects 
had no history of breathlessness or wheeze, normal baseline spirometry (FEVi> 70% 
predicted in the absence of symptoms) and had a methacholine PC20 of greater than 
16mg/ml. The study was approved by the West Ethics Committee, West Glasgow 
Hospitals University NHS Trust, and each subject gave written informed consent.
Protocol
The study was performed in randomised single-blind fashion. Asthmatic subjects 
attended for methacholine screening test, followed by three visits for ET-1 (2 visits) or 
methacholine ( 1 visit) inhalations. Asthmatics withheld B2-agonist therapy for 12 hours 
prior to each study visit. Normal subjects attended for screening methacholine challenge 
followed by a single visit for ET-1 inhalation. The inteiwal between visits was not fixed, 
but was generally around 1 week for most subjects. On the study days, blood was 
sampled for plasma ET-1 assay before and after each inhalation, and oxygen saturation 
(Sa02) recorded by pulse oximetry and non-invasive blood pressure were recorded at 
regular inteiwals through the inhalations. Both ET-1 and methacholine were administered 
using an air-driven dosimeter ('Nebicheck' PK Morgan Ltd, Gillingam, U.K.), 
calibrated to deliver 0.006ml/breath, with a doubling dose range for ET-1 of 0.96-15.36
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nmol, and methacholine of 0.33-21.0 ] A m o \ .  Dried purified ET-1 (Thistle Research, 
Glasgow, U.K.) was reconstituted in 0.9% saline prior to nébulisation, and 
methacholine was prepared by sterile pharmacy in our own hospital. The nebulisate was 
prepared by a second operator, with both patient and principal operator blinded to the 
contents of the nebuliser chamber. Measurements were made using a constant volume 
body plethysmograph (Erich Jaeger GmbH, Wuerzburg, Germany; "Master!ab v4.2"), 
with assessment of specific airways conductance (SGaw) and FEVi 5, 10 and 15 
minutes after each dose of study drug. The inhalation was stopped following a 15% fall 
inFEVi or following the maximum dose in the dosing schedule, whichever came first, 
and on all but 2 occasions albuterol (2.5mg nebulised) was given and measurements 
repeated after 10 minutes. On 2 occasions, albuterol was not given, and measurements 
were continued until the SGaw had returned to within 25% of pre-challenge value to 
assess the duration of bronchoconstriction in these patients (both asthmatic).
Laboratory processing and biochemical assays
Following venepuncture, blood was centrifuged at 3000 rpm for 10 minutes and the 
resulting supernatant frozen and stored for ET-1 assay. After thawing, plasma samples 
were pre-extracted using C-18 columns (Waters Ltd, Watford, U.K.) prior to ET-1 
assay by radio-immuno assay (RIA) (Nichols Institute Diagnostics Ltd, San Juan 
Capistrano, CA, U.S.A.). The lower limit of detection is c. 2 pg/ml in plasma, and 
assays were run in duplicate, with the mean value used for analysis. To ensure that ET-1 
was not altered by nébulisation, a sample of ET-1 was returned for ET-1 assay 
following nébulisation, and this confirmed that there was no loss of activity of ET-1.
Data handling and statistical analysis
Lung function values were calculated using the software linked to the constant volume 
body plethysmograph (Erich Jaeger GmbH, Wuerzburg, Germany; "Masterlab v4.2") 
and are expressed as percent of baseline value except where stated. Statistics were 
performed on an Apple Macintosh desktop computer (Apple Computer Inc., Cupertino,
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CA, U.S.A.) using a statistical software package (Mini tab Statistical Software, Mini tab 
Inc., State College, PA, U.S.A.). Demographic factors and baseline and maximum fall 
in lung function parameters were analysed using parametric statistics (t-test) with 
correction for multiple comparisons, and pre- and post-inhalation plasma ET-1 values 
compared using non-parametric statistics (Mann Whitney-U test), with significance 
accepted at the 95% level in each case.
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3.4 RESULTS 
Patient demographics
Comparison of demographic factors reveals that the asthmatic group were older 
(p<0.05) on average than the normal group. SGaw and FEVi (absolute and % 
predicted) were lower in the asthmatic group than in normals (table 3.1) and there was 
no difference between asthmatics' baseline values of FEVi, SGaw or SaOz on the three 
study days (table 3.2).
Pulse oximetry
In both asthmatics and normals, pulse oximetry was normal prior to methacholine and 
ET-1 inhalations, and did not alter significantly during any of the inhalations, with a 
mean variation of less than 1% for all the inhalations (table 3.2, appendix 3.1).
Pulse and blood pressure - (Appendix 3.2)
There was no significant change in pulse rates for any of the inhalations, in either 
asthmatics or normals. In the asthmatic group mean (S.D.) blood pressure 
(systolic/diastolic) was 120 (9.6)/75 (10.0) mmHg (pre-) and 119 (8.2)/72 (9.4) mmHg 
(post-) methacholine inhalation; 121 (8.7)/80 (6.1) mmHg (pre) and 123 (11.8)/76 (5.9) 
mmHg (post) for the first ET-1 inhalation; 121 (8.3)/73 (7.4) mmHg (pre) and 121 
(9.0)/73 (6.4) mmHg (post) for the second ET-1 inhalation. These represent percent 
changes of less than 4% in each case, and these changes were not statistically 
significant. In normal subjects mean (S.D.) blood pressure was 123 (6.8)/71 (2.8) 
mmHg (pre) and 113 {53)173 (5.0) mmHg (post) ET-1 inhalation, and the fall in 
systolic blood pressure does reach statistical significance (p=0.03).
Plasma endothelin-1
Normal subjects had no change in plasma ET-1 across the ET-1 inhalation (median 
(IQR) pre- and post ET-1 challenge values of 2.2 (2.1-2.5)pg/ml and 2.0 (1.5-
63
2.5)pg/ml respectively). In asthmatic subjects there was no change in plasma ET-1 
across the methacholine inhalation (median (IQR) pre- and post methacholine challenge 
values of 3.3 (2.1-3.9) pg/ml and 3.0 (2.0-3.5) pg/ml respectively), nor across either of 
the ET-1 inhalations (median (IQR) pre- and post ET-1 challenge values of 3.2 (2.9-4.S) 
pg/ml and 3.8 (2.S-4.6) for the first ET-1 inhalation, and 3.3 (3.0-4.0) and 4.0 (2.9- 
4,3) for the second ET-1 inhalation). Both pre- and post ET-1 inhalation values were 
higher in asthmatics than normals for both ET-1 inhalations, but this did not reach 
significance for the methacholine inhalation.
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Specific airways conductance (Sgaw)
Individual dose-response graphs for asthmatic subjects are presented (figure 3.1) 
indicating that all the asthmatic subjects experienced a dose-related fall in SGaw over the 
dose range used, with mean (S.D.) fall in SGaw of 69.7 (15.9)% for methacholine, and 
63.0 (11.8) % and 60.5 (14.9) % for the 2 ET-1 inhalations. The mean (S.D.) 
concentration required to produce a 35% fall in SGaw (PCssSGaw) in asthmatics was 
0,42 (0.18) jAmol for methacholine, 5.15 (4.4) nmol for the first ET-1 inhalation, and 
4.29 (2.5) nmol for the second ET-1 inhalation, suggesting that ET-1 is around 100 x 
more potent as a bronchoconstrictor in asthma than methacholine on a molar basis (range 
30-350 X for individual patients). Treatment with albuterol (2.5mg nebulised) 
completely reversed bronchoconstriction in all cases. The correlation between 
methacholine PCssSGaw and ET-1 PCssSGaw was not significant (in contrast to 
PCisFEVi below). None of the normal subjects experienced a significant fall in SGaw 
(mean (S.D.) fall in SGaw of 9.2 (10,6) %) even at the top of the dose range (15.36 
nmol) of ET-1 (figure 3.2) (ET-1 PCssSGaw for normals is >15.36 nmol).
Forced expiratory volume in 1 second (FEVi)
Individual dose response graphs for asthmatic subjects are presented in figure 3.1. 
Although the mean (S.D.) fall in FEVi was 20.1 (8.9) % for methacholine, 18.3 (6.9)
% for the first ET-1 inhalation, and 16.25 (5.1) % for the second ET-1 inhalation (table 
2), and all had a dose-related fall in FEVi, 2 of the asthmatic patients had a fall in FEVi 
of less than our target of 15% following the maximum dose of ET-1 (15.36 nmol). 
Figures for provoking concentrations of ET-1 required to produce a 15% fall in FEVi 
(PCisFEVi) are therefore calculated using geometric extrapolation of the fall at the 
maximum dose for these 2 patients (3 ET-1 inhalations). Mean PCisFEVi 
concentrations for the asthmatic group were 0.93 (0.66)/nnol for methacholine, 10.52 
(11.6)nmol for the first ET-1 inhalation, and 12.15 (8.12)nmol for the second ET-1 
inhalation, again suggesting that ET-1 is roughly 100 x as potent a bronchoconstrictor in 
asthma as methacholine on a molar basis (range 25-200 x for individual patients). The
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correlation between methacholine PCisFEVi and ET-1 PC15FEV1 was strong (r=0.912 
and 0.816 for each ET-1 inhalation) and statistically significant (p=0.002 and 0.014 
respectively). None of the normals experienced any significant fall in FEVi with mean 
(S.D.) change of 0.4 (0.9) % from baseline (figure 3.2) (ET-1 PC15FEV1 for normals 
is > 15.36nmol).
Duration of bronchoconstriction
Duration of bronchoconstriction was not examined as a formal part of the study 
protocol, but in 2 asthmatic patients, albuterol was not given at the end of the inhalation 
of ET-1 on their final visit, and these patients serial lung function measurements were 
made until the SGaw had returned to within 25% of baseline values. In one patient this 
took 60 minutes, and in the other 90 minutes.
Repeatability
Repeatability of the two ET-1 inhalations was assessed using the method described by 
Bland and Altman (258) to establish a repeatability coefficient, by comparing the 
standard deviations of the differences in PC35SGaw values for each asthmatic patient for 
the two ET-1 inhalations (figure 3.3). This gives a repeatability coefficient (2x S.D. of 
the differences) of 8.47 nmol for a PCssSGaw evaluation, with 7 out of 8 values lying 
within this range (the value outwith this range was a difference of 8.93 nmol), 
suggesting reasonable repeatability for PCssSGaw estimation.
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Figure 3.1
Individual percent change in specific airway conductance (SGaw) and 
FEV 1 during two endothelin-1 inhalations in eight asthmatic subjects.
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Figure 3.2
Mean (SD) percent change in specific airway conductance (SGaw) and FEV 1 during 
endothelin-1 inhalation in five normal subjects.
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Figure 3.3
Biand-Altman plot of repeatability of bronchial reactivity to endothelin-1 in asthmatic 
subjects (expressed as ET-1 PClsFEVl). The coefficient of variability for FEVI is 
14.82 nmol, and for SGaw is 8.47 nmol.
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3.5 DISCUSSION
We have demonstrated for the first time that endothelin-1 (ET-1) is a highly potent 
bronchoconstrictor in asthma, with a relative potency to methacholine of c. 100 x on a 
molar basis, and that asthmatics exhibit bronchial hyperreactivity to ET-1 compared to 
normal subjects. Relatively rapid onset (<5 minutes) bronchoconstriction occurs in a 
dose-dependent fashion, and we conclude that ET-1 can be safely given by inhalation to 
asthmatics and normal subjects as a bronchial challenge test in a dose range of 0.96- 
15.36nmol. We observed no change in blood pressure, oxygen saturation or plasma ET- 
1 levels related to the inhalation of ET-1. Albuterol completely reverses ET-1-induced 
bronchoconstriction and the duration of bronchoconstriction was at least 60 and 90 
minutes in the 2 patients formally assessed.
We observed bronchoconstriction within 5 minutes of ET-1 inhalation, which is in 
keeping with animal studies using aerosol!sed ET-1 where the maximal response was 
reached in around 4-5 minutes (67), and Henry et al (53) observed a similar time to 
reach maximal contraction (5-10 minutes) in human isolated bronchi. Henry et al 
expressed the contractile potency of ET-1 as the concentration needed to produce a 
contraction 30% of the maximum contractile response to 10/fM carbachol (excitatory 
concentration "ECso"), with a value of 35nM. While it is difficult to directly relate that 
figure to a dose given in vivo, allowing for the increased sensitivity we have observed in 
asthmatics, it is of similar order of magnitude and relative potency to methacholine as we 
found in this study expressed as ET-1 provoking concentrations for SGaw and FEVi. 
The dose range used in this study was based on in vitro studies of the 
bronchoconstrictor response in human airways (60), along with pilot work on healthy 
volunteers starting with inhalations of significantly lower concentrations of ET-1 to 
establish overall safety of the technique. The nature of nébulisation even with a 
dosimeter means that although it is possible to be reasonably accurate in terms of the
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dose nebulised, the effective dose reaching the lungs is much harder to assess, but is 
probably of the order of 20-30% of the doses stated.
We found increased plasma ET-1 in asthmatics compared with normals both before and 
after the 2 ET-1 inhalations (although with no change across the inhalations), but no 
significant difference on the day of the methacholine inhalation. This finding does not 
reflect our own previous experience with plasma levels (unpublished data) where we 
found no difference between mild asthmatics and normals, and although we are aware of 
one study which correlates plasma ET-1 with lung function (120), we presume pending 
further data that this finding is a consequence of the small numbers in each group. The 
lack of change in blood pressure during ET-1 inhalation is in keeping with animal 
studies using aerosolised ET-1 (67).
The contractile activity of ET-1 on bronchial smooth muscle has been assessed in animal 
models, and in human tissue in vitro. Aerosol administration of ET-1 in animal studies 
produces a dose-dependent bronchoconstriction, with no blood pressure response (67), 
no increase in bronchial hyperreactivity or histamine response (259), and no 
inflammatory reaction (57) and there is evidence from animal studies that the responses 
to intra-arterial and aerosolised ET-1 are mediated by different mechanisms (61). In vitro 
studies have confirmed the bronchoconstrictor activity of ET-1 in human bronchi (58), 
although in contrast to our findings in vivo, Goldie et al (55) found no difference 
between asthmatic and non-asthmatic bronchi in sensitivity to ET-1 in vitro, and in the 
same study demonstrated no increase in ET-1 binding sites in asthmatic bronchi (nor in 
asthmatic peripheral lung (112) in a study from the same group), suggesting that the 
bronchial hyperreactivity to ET-1 that we observed does not depend simply on increased 
ET-1 receptor numbers in asthma. In human isolated bronchi, ET-1 exerts its contractile 
effect mainly through the action of the ETb receptor subtype (68) which is the most 
numerous receptor in this tissue, although interestingly, bronchial smooth muscle from 
asthmatic lung appears to be less sensitive to the contractile effects of a specific ETb
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receptor agonist, sarafotoxin S6c (84), presumably due to a decrease in receptor 
sensitivity. The above data, with our finding that asthmatics exhibit bronchial 
hyperreactivity to ET-1 in vivo, suggests that factors other than receptor numbers and 
sensitivity contribute to this increased sensitivity to ET-1 in asthma, since it would not 
be predicted from the in vitro receptor data. Epithelial disruption is a feature of the 
inflammation associated with asthma (91), and it has been demonstrated that epithelial 
removal significantly enhances the contractile activity of ET-1 in the human isolated 
bronchus (63), raising the possibility that epithelial disruption contributes to increased 
contractile activity of ET-1 in asthma. It has also been demonstrated in vitro that ET-1 
may interact with other mediators implicated in asthma, with potentiation of its 
contractile activity, including prostaglandins (PG)-D2 , PGP2a, leukotriene 04 (260), 
and angiotensin II (261), but other than the finding of increased nasal mucosal 
sensitivity to ET-1 in allergic rhinitis (114) and a rise in endothelin-like 
immunoreactivity 24 hours after allergen challenge in sensitised guinea-pig airways 
(262), there is no direct data on the contribution of airway inflammation to ET-1 activity. 
The absence of response to inhaled ET-1 in normals is striking, and supports the 
observation that an intact airway epithelium modulates the response of airway smooth 
muscle to ET-1 (64). While the mechanism for this is not known, an intact epithelium in 
normal subjects might form a physical barrier to ET-1 coming into contact with 
submucosal target cells, or increase clearance and metabolism of ET-1, either by binding 
and internalisation of ET-1 by ETb receptors (33), or by enzymatic degradation. There is 
also evidence in non-asthmatic human tissue that ET-1 can act on ETa receptors in 
bronchial epithelium causing release of relaxant factors including nitric oxide (65) which 
could attenuate the bronchoconstrictor effects of ET-1 in normal airways.
There is debate about the mechanism of action of ET-1 in the airways, with animal 
studies suggesting that contractile activity is at least in part mediated by arachidonic acid 
metabolites (in particular thromboxanes(86)), leukotrienes and histamine (87), but this 
has not been confirmed by studies using human bronchi (60), where ET-1 appears to act
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directly on smooth muscle, without the involvement of acetylcholine, leukotrienes, 
histamine or platelet activating factor (88). Although this study was not designed to 
examine the mechanism of action of ET-1, the strong correlation that we observed 
between methacholine reactivity and ET-1 reactivity (at least for FEVi response) lends 
indirect support to the suggestion that ET-1, like methacholine, exerts its 
bronchoconstrictor effect directly on bronchial smooth muscle, rather than through a 
second mediator. This is not conclusive however, and ET-1 is known to have other 
effects which could lead to muscular or non-muscular bronchial narrowing. ET-1 acts 
on glandular ET receptors in human nasal mucosa, inducing lactoferrin and mucous 
glycoprotein release (92), induces cytokine production (GM-CSF, IL-6 and IL-8) in 
human bronchial epithelial cell culture (93), and potently stimulates release of TNF-a, 
IL-IB, and IL-6 from monocytes and monocyte-derived macrophages (94), all of which 
could contribute to non-muscular airway obstruction. In addition, ETb receptor 
activation has been shown to potentiate cholinergic nerve-mediated contraction in human 
bronchial preparations (113), suggesting that ET-1 might exert an additional neurally 
mediated bronchoconstrictor effect.
Further work is needed to clarify the mechanism of action of ET-1 in human airways, 
and in particular to examine the influence which the specific bronchial micro- 
enviromnent associated with asthmatic airway inflammation might have on the increased 
sensitivity to ET-1 that we have observed in asthma. These data support a role for ET-1 
in the pathophysiology of asthma, and provide a potential means of further exploring 
this role through the use of ET-1 in bronchial challenge testing.
CHAPTER 4
SPUTUM CELLULAR AND CYTOKINE 
RESPONSES TO INHALED ENDOTHELIN-1 IN
ASTHMA
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4.1 INTRODUCTION
Having established the technique and dose range for inhalational challenge testing using 
ET-1, and that ET-1 has bronchoconstrictor activity in asthmatics, we wished to 
examine other mechanisms by which ET-1 might contribute to asthma symptoms. The 
importance of airway inflammation in the pathophysiology of asthma is established, and 
we were interested in reports that ET-1 may pro-inflammatory activity in the airways. In 
vitro data shows that ET-1 promotes the inflammatory activity of neutrophils (20) and 
macrophages (102), and increases the expression of adhesion molecules on endothelial 
cells. Additionally, ET antagonists have been shown to inhibit airway inflammation in 
animal studies (103, 263) in response to a number of stimuli. The production from 
mononuclear cells from asthmatics of the proinflammatory cytokines TNF-a (100) and 
IL-IB (105) are increased by ET-1 in vitro, and exogenous ET-1 has been shown to 
decrease NO production and inducible NO synthase (iNOS) expression in lung epithelial 
cells (264). Like NO, sputum concentratrions of nitrite and nitrate, which are stable 
metabolites of NO representing iNOS activity, have been shown to be elevated in asthma
(265). We have therefore investigated the effect of inhaled ET-1 on cellular influx, and 
the concentrations of tumor necrosis factor (TNF)-a, interleukin (IL)-IB, nitrite and 
albumin (assessed as a measure of airway epithelial permeability) in induced sputum 
obtained 30 minutes and 4 hours after inhalation of ET-1 or placebo in 10 subjects with 
clinically stable asthma.
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4.2 METHODS 
Subjects
10 non smoking asthmatic subjects participated in the study (table 1) All subjects had 
current asthma with stable symptoms at the time of study, no history within the 
preceding month of respiratory infection, antibiotics or oral corticosteroid use and other 
than house dust mite, none of the subjects had been exposed to allergens to which they 
were allergic in the preceding month. Asthma was defined according to the ATS 
definition (257), baseline lung function was recorded, and non-specific bronchial 
hyperresponsiveness was established using a methacholine challenge test, with all the 
asthmatics subjects having a methacholine PC20 of less than 8mg/ml. The study was 
approved by the West Ethics Committee, West Glasgow Hospitals University NHS 
Trust, and each subject gave written informed consent.
Protocol
The study was performed in randomised blinded fashion. Subjects attended for 
screening methacholine challenge, followed by two visits for either ET-1 (dose range 
0.96-15.36 nmol) or placebo inhalation, having withheld 82-agonist therapy for 12 
hours prior to each study visit. Blood was sampled for ET-1 assay at the beginning of 
each visit, following the inhalation, and 4 hours after the inhalation. Both ET-1 and 
placebo were administered using an air-driven dosimeter ('Nebicheck' PK Morgan Ltd, 
Gillingam, U.K.), calibrated to deliver 0.006ml/breath. Dried purified ET-1 (Thistle 
Research, Glasgow, U.K.) was reconstituted in buffered 0.9% saline, and buffered 
saline was used as placebo. Non-invasive blood pressure and pulse oximetry were 
monitored throughout the inhalations. Unlike the previous study, where constant 
volume body plethysmography was used to assess changes in airway resistance, in this 
study spirometry was measured 1, 2, 5 and 10 minutes after each dose of ET-1/placebo. 
The inhalation was stopped following a 15% fall in FEVi or following the maximum 
dose in the dosing schedule, whichever came first. Following each inhalation.
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salbutamol was given (200/<g) by inhalation, and sputum induction was performed 30 
minutes and again 4 hours after each inhalation.
Sputum induction, laboratory processing and biochemical assays.
Sputum induction was performed as outlined in chapter 2, the sample was collected in a 
sterile container and was transferred to the laboratory on ice as soon as possible, and in 
all cases in less than 2 hours. Laboratory processing of sputum samples is outlined in 
chapter 2. Criteria were established for rejection of samples if viability was <40%, or 
squamous cells >20% although in fact no samples were rejected on these criteria 
(viability was typically >70% and squamous cell count <10%). The bronchial epithelial 
cell count was very low in all samples (typically <2%). Plasma ET-1 was assayed using 
a radio-immuno assay (RIA) (Nichols Institute Diagnostics Ltd, San Juan Capistrano, 
CA, U.S.A.), with a lower limit of detection of 2 pg/ml in plasma, and assays were run 
in duplicate, with the mean value used for analysis. IL-IB was assayed using enzyme- 
linked immunosorbent assay (ELISA) (R&D Systems, Abingdon, U.K.), TNF-a was 
assayed using an in-house ELISA using paired antibodies and cytokine standard from 
R&D Systems. Nitrite was measured by the Griess reaction (in-house assay) and 
albumin by radial-immuno diffusion (The Binding Site Ltd, Birmingham, U.K.).
Data Handling and Statistical Analysis
Statistics were performed using a statistical software package (Minitab Statistical 
Software, Minitab Inc., State College, PA, U.S.A.). Non-parametric statistics (Mann 
Whitney-U test) were used to compare cell counts and concentrations of mediators, and 
values are expressed as median (interquartile range) unless stated otherwise. PC20 and 
PC15 values were calculated by log-linear interpolation. Analysis of variance (ANOVA) 
was used to compare blood pressure, pulse rate and pulse oximetry data.
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4.3 RESULTS 
General
Patient demographics and airway responsiveness to methacholine and ET-1 are outlined 
in table 4.1. All the subjects completed the study, and airway challenge with ET-1 was 
well tolerated. Mean (S.D.) baseline FEVI was similar on the two study days [ET-1 
2.79 (0.6) litres, placebo 2.75 (0.7) litres]. ET-1 produced progressive, dose-dependent 
bronchoconstriction in all subjects, with all but one subject attaining a fall in FEV 1 of > 
15% at or before the maximum dose used (15.36 nmol). The remaining subject (subject 
3) achieved a 12% fall in FEVi, and PCl5 is calculated by interpolation. Mean (SD) 
FEVi at the end of the challenge test was 2.25 (0.5) litres for ET-1 and 2.94 (0.23) 
litres for placebo (p=0.016), and 4 hours after challenge testing was 2.9 (0.69) litres for 
ET-1 and 2.9 (0.76) litres for placebo. Comparing ET-1 with placebo inhalations, there 
was no change in blood pressure, oxygen saturation or pulse rate.
Sputum Cell Counts
Total sputum cell counts are given after exclusion of squamous epithelial cells, and 
expressed as cells per ml of sputum plug. Total cell counts were not different 30 minutes 
after challenge tests comparing ET-1 with placebo (median (IQR) 3.55 (1.6-11.4)xl0^ 
cells/ml vs 3.2 (2.3-6.4)xl0^ cells/ml respectively), nor at 4 hours following ET-1 
compared with placebo inhalation (median (IQR) 3.7 (3.1-5.3)xl0^ cells/ml vs. 3.55 
(2.2-4.8)xl0^ cells/ml respectively). Sputum cell differentials are presented in figure 
4.1, and are expressed as % of total cell count after exclusion of squamous epithelial 
cells. The percent of lymphocytes in induced sputum was very low for both ET-1 
(lymphocytes median (IQR) 0 (0-1) % at 30 minutes and 1 (0-1) % at 4 hours) and 
placebo inhalations (median (IQR) 0 (0-1) % at 30 minutes, and 0 ( 0-1) % at 4 hours) 
so this data has been omitted from figure 4.1. There was no significant difference in the 
sputum cell differentials comparing ET-1 and placebo, either at 30 minutes or at 4 hours, 
whether expressed as % of total cell count or as cells/ml of sputum, with the exception
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that the sputum percent macrophage count (but not absolute macrophage numbers) was 
lower at 4 hours after placebo inhalation than at 30 minutes (median (IQR) 36 (16-53)% 
vs. 64 (32-79)% respectively, p=0.05). This reduction in % macrophages is largely 
explained by a nonsignificant rise in the % neutrophil count (figure 4.1).
TN F-a, IL-lfi, N 0 2  and Albumin
Figure 4.2 illustrates that we found no significant change in sputum concentrations of 
TNF-a, IL-IB, nitrite or albumin comparing placebo with ET-1 challenge at either 30 
minutes or 4 hours. Comparing concentrations of TNF-a, IL-IB, N 02 and albumin at 4 
hours compared with 30 minutes following ET-1 inhalation did not show any significant 
change.
Plasma Endothelin-1
There was no difference in plasma ET-1 comparing median (IQR) levels for ET-1 
inhalation compared with placebo inhalation (2.5 (2.0-3.9) vs. 3.4 (2.0-4.7) pg/ml at 
baseline, 3.1 (2.0-4.2) vs. 3.0 (2.0-4.6) pg/ml at 30 minutes, and 2.8 (2.2-3.8) vs. 2.8 
( 1.9-3.0) pg/ml at 4 hours) respectively.
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Table 4.2
Absolute sputum differential cell counts 30 minutes and 4 hours after 
placebo and ET-1 inhalations - expressed as median (IQR) cells x 10^/ml 
of sputum plug.
Macrophages
(xlO^/ml)
Neutrophils
(xlO^/ml)
Eosinophils
(xlO^/ml)
Lym phocytes
(xlO<^/ml)
Placebo
30 minutes 1 .8 3 1 .0 9 0 .0 9 0 .0
(0.9-4.5) (0.7-1.4) (0.02-0.5) (0-0.03)
4 hours 1.14 1 . 36 0 . 12 0 . 0
(0.7-1.6) (0.7-2.3) (0-0.8) (0-0.04)
ET-1
30 minutes 1.57 1.0 0 .15 0 . 0
(0.9-3.3) (0.6-2.2) (0.05-0.5) (0-0.03)
4 hours 1.76 1.3 0 .18 0.01
(1.0-2.4) (0.8-2.2) (0.05-0.9) (0.-.04)
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10 0
%  o f  
t o t a l  
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Figure 4.1
Percentage differential cell counts 30 minutes and 4 hours after placebo and 
endothelin-1 inhalations; values expressed as median (interquartile range).
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Figure 4.2
Sputum nitrite (N02), interleukin (IL)-ip, tumour necrosis factor (TNF)a, and 
albumin, 30 minutes and 4 hours after endothelin-1 inhalation; median (IQR).
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4.4 D ISCU SSIO N
Using the non-invasive technique of sputum induction, we have shown that 
bronchocon8trictor doses of inhaled ET-1 in asthma do not provoke an acute 
inflammatory response as assessed by cellular influx, changes in the concentrations of 
the pro-inflammatory cytokines TNF-a and IL-IB, nitrite production, or albumin 
extravasation at 30 minutes or 4 hours after ET -1 inhalation.
Our group of patients contained 7 subjects who were taking inhaled steroids (mean daily 
dose of 685 pig beclomethasone or equivalent). It has been shown that treatment with 
steroids decreases bronchial epithelial expression of ET-1 in asthmatic patients (123), 
and in a rat model of lung inflammation the increase in lung ET-1 content in response to 
the inflammatory stimulus (Sephadex) was reduced by pre-treatment with budesonide
(266). While these data suggest that corticosteroids may decrease ET-1 production, there 
is no specific information on the impact of corticosteroids on the potential airway 
response to ET-1, and this cannot be inferred from the effect of steroids on ET-1 
production. Although we did not observe any obvious differences in bronchoconstrictor 
or inflammatory responses between those patients taking or not taking inhaled steroids, 
the study was not designed to detect differences between these groups, and a possible 
effect of inhaled steroids cannot be excluded.
ET-1 is produced in response to a number of inflammatory stimuli both in vitro and in 
vivo , and ET-1 can also trigger the release of other locally acting mediators, including 
TNF-a, IL-IB, IL-6, IL-8 and granulocyte-macrophage colony-stimulating factor (GM- 
CSF) (267), which are involved in inflammatory cell attraction and activation in the 
lung, some of which may also stimulate ET production. Endothelin receptor antagonists 
have been shown to inhibit lung inflammation induced by antigen in mice (103), and 
airway inflammation induced using dextran in rats (110), with some evidence that ETb 
receptor-antagonists may inhibit the early allergic response, and ET A antagonists the late
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allergic response in sensitised guinea-pigs (109). These data however, only provide 
indirect evidence that ET-1 may be involved in the inflammatory process, and it is not 
clear whether ET-1 has direct pro-inflammatory activity in the airways.
In allergic rhinitis, while nasal administration of ET-1 increased symptoms and secretion 
weights, it did not increase secretion of albumin or histamine (114), and we found no 
increase in albumin secretion, suggesting that the bronchoconstriction induced by ET-1 
in asthma is not associated with significant alteration in bronchial epithelial permeability. 
Chanez^Za/ (100) have shown that BAL mononuclear cells from stable asthmatics (but 
not control subjects) respond to stimulation with ET-1 in vitro by increasing release of 
TNF-a. In cells from patients with unstable asthma in the same study, in vitro TNF-a 
release was already increased compared to control cells, and did not further increase on 
stimulation with ET-1. We did not observe an increase in sputum TNF-a following ET- 
1 administration in vivo, and the reason for this difference in TNF-a response to ET-1 
not known. It has been shown that cytokines can alter cellular responsiveness to ET-1 
(106), and clearly factors may be present in vivo which may modify the TNF-a 
response to ET-1.
There is increasing evidence that endogenous nitric oxide (NO) is involved in the 
pathophysiology of asthma (268). Similarly, increased levels of NO derivatives 
including nitrite have been demonstrated in induced sputum in asthma, with a 
relationship between levels of NO derivatives in sputum and eosinophil numbers (265). 
Regulation by ET a  receptors of ET -1-induced NO release in guinea-pig trachea has been 
described (269), but there appear to be species differences in the impact of ET-1 on NO 
production (264). We found no alteration in sputum nitrite concentrations in response to 
ET-1 inhalation in asthma. Sputum concentrations of the pro-inflammatory cytokine IL- 
IB are increased in symptomatic asthma (270), and ET-1 is known to stimulate the 
production of IL- IB in human monocytes in vitro (105). We did not observe an increase 
in IL-IB in response to ET-1 inhalation in this study.
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Overall, there appears to be uncertainty about a postulated pro-inflammatory rôle for ET - 
1 in the airways. Inter-species differences have been described in the mechanism of ET- 
1-induced bronchoconstriction (57, 60), but it is not yet known if such differences exist 
for pro-inflammatory activity. The route of administration of ET-1 may also be 
important, since intravenous or intra-arterial administration is associated with cellular 
accumulation and mediator release in the lungs in animal studies (61, 108, 271), 
whereas aerosolised administration of ET-1 in the guinea-pig does not result in airway 
edema, TxB2 release (61), nor in eosinophil accumulation in the lungs or bronchial 
hyperresponsiveness (95). Similarly, our own study using inhaled ET-1 in asthma does 
not show evidence of cellular influx or albumin secretion. While the reasons for this 
observation are not known, the ETB receptor is the most numerous ET receptor in 
airway smooth muscle (84), and it is possible that through its postulated function as a 
clearance receptor it could modify the ability of ET-1 to exert pro-inflammatory activity. 
In both its bronchoconstrictor activity and mitogenic activity, there is evidence for 
interactions between ET-1 and other humoral and cytokine factors, and more 
investigation is needed into the potential for such interactions in airway inflammation. 
The evidence for the ability of ET receptor antagonists to modify inflammatory 
processes in particular suggests that ET-1 may play a role in airway inflammation, even 
if not as a direct pro-inflammatory agent.
CHAPTER 5
EFFECT OF INFUSED ANGIOTENSIN II ON 
THE BRONCHOCONSTRICTOR ACTIVITY OF 
INHALED ENDOTHELIN-1 IN ASTHMA
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5.1 INTRO D U CTIO N
While a large number of bronchoconstrictor substances have been identified, there has 
been relatively little work reporting interactions between these substances. Having 
established that ET-1 is a potent bronchoconstrictor in asthma, we wished to examine a 
potential interaction between it and another endogenously produced peptide angiotensin 
II, based on previously reported work from our laboratory. Angiotensin II (Ang II) is a 
product of the renin-angiotensin system (RAS), and, like ET-1, it is a potent 
vasoconstrictor which also has bronchoconstrictor activity, causing contraction of 
isolated human bronchial rings (272). Our group has shown that the RAS is activated in 
acute severe asthma with increased plasma levels of Ang II (119, 273), but not in 
chronic stable asthma, and that infusion of Ang II in mild asthmatics to plasma levels 
found in acute severe asthma causes bronchoconstriction (273). Plasma ET-1 is also 
increased in acute severe asthma (120), and a reduction in BAL ET-1 following 
treatment with oral steroids and inhaled bronchodilators has been described (274).
Although the bronchoconstrictor potency of angiotensin II is modest, there is evidence 
of synergy in bronchoconstriction between Ang II and other bronchoconstrictors, 
including the acetyl choline analogue methacholine, and ET-1. Ang II potentiates 
methacholine-induced bronchoconstriction in human airway, both in vitro and in mild 
asthmatics in vivo (272), and potentiates ET-1-induced bronchoconstriction in bovine 
bronchial rings (261). We sought to extend this last observation, and our work on the 
bronchoconstrictor activity of ET-1, by examining the potential interactive effect of 
angiotensin II on ET-1-induced bronchoconstriction in mild asthmatics in vivo. Ang II 
infusion was used to simulate the elevation of plasma Ang II observed in acute severe 
asthma, but sub-bronchoconstrictor doses of Ang II were used to ensure that 
bronchoconstrictor effects were not simply additive to the effects of inhaled ET-1. ET-1 
was given by inhalation as a bronchial challenge test. Interactions between potential 
mediators in asthma may provide important information about the pathophysiology of
the condition, and we felt that the in vitro bronchoconstrictor synergism between ET-1 
and Ang II required investigation in vivo.
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5.2 METHODS 
Patients
8 mild asthmatics were recruited, with stable symptoms at the time of study and no 
history within the preceding month of respiratory infection, antibiotics or oral 
corticosteroid use. Asthma was defined according to the ATS definition (257), baseline 
lung function was recorded, and non-specific bronchial hyperresponsiveness was 
established using a methacholine challenge test, with all the asthmatics subjects having a 
methacholine PC20 of less than 8mg/ml. Long-acting p-agonist bronchodilators were 
withheld for 24 hours, and short acting p-agonist bronchodilators for 6 hours prior to 
each study visit. The study was approved by the West Ethics Committee, West Glasgow 
Hospitals University NHS Trust, and each subject gave written informed consent.
Protocol
Asthmatic subjects attended for methacholine screening test, followed by three visits for 
ET-1 inhalation, and infusion of angiotensin II (Affiniti Research Products Ltd, Exeter, 
U.K.) at either 1 ng/kg/min or 2 ng/kg/min or placebo in a randomised double-blind 
fashion. The interval between visits was not fixed, but was generally around 1 week. 
Randomisation and preparation of angiotensin II was carried out by sterile pharmacy in 
our institution. On attending the laboratory, spirometry was checked, with all subjects 
having a pre-challenge FEV1 of > 70% predicted. After a period of rest (15 minutes) in 
a recumbent position, blood was sampled for baseline measurement of plasma 
angiotensin II, and the infusion of angiotensin II or placebo was started, using a syringe 
pump (IVAC P2000, IVAC Ltd. Hampshire, U.K.). After a further 30 minutes to reach 
steady state, another blood sample was taken, and the bronchial challenge with ET-1 
was started. Dried purified ET-1 (Calbiochem-Novabiochem (UK) Ltd. Nottingham, 
UK) was reconstituted using 0,9% saline prior to nébulisation to a concentration of 0.2 
mg/ml, and administered using an air-driven dosimeter ('Nebicheck' PK Morgan Ltd, 
Gillingham, U.K.), calibrated to deliver 0.006ml/breath, with a doubling dose range for
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ET-1 of 0.96-15.36 nmol. Spirometry was checked 1, 3, 5, 10 and 15 minutes after 
each dose, and the challenge test was discontinued once a 15% fall in FEVi had been 
observed, or at the maximum dose in the dosing schedule, whichever came first. We 
have previously reported the use of ET-1 as a bronchial challenge test, and although we 
observed bronchoconstriction which persisted for up to 1 hour, the onset of 
bronchoconstriction was within 5 minutes in each case (275). A final blood sample for 
plasma angiotensin II was taken at the conclusion of the ET-1 challenge test (defined as 
a fall in FEVI of > 15% or on reaching the maximum dose in the dosing schedule). 
Pulse oximetry (Datex Ltd, Helsinki, Finland), non-invasive blood pressure, pulse rate, 
and spirometry (Vitalograph, Buckingham, U.K.) were monitored at regular intervals 
throughout the study visit, with the patient in a recumbent position throughout. 
Albuterol 200 jAg was given, and spirometry repeated to ensure that the 
bronchoconstriction had been reversed.
Laboratory Processing and Assays
Plasma angiotensin II was assayed using an in-house assay which has previously been 
described (276), with inter-assay and intra-assay coefficients of variation of less than 
10% in each case.
Data Handling and Statistical Analysis
Statistics were performed on an Apple Macintosh desktop computer (Apple Computer 
Inc., Cupertino, CA, U.S.A.) using a statistical software package (Minitab Statistical 
Software, Mini tab Inc., State College, PA, U.S.A.). Demographic factors and baseline 
and maximum fall in lung function parameters were analysed using parametric statistics, 
plasma angiotensin II levels by non-parametric (Mann-Whitney U test) and values for 
provoking doses of ET-1 on each visit compared by analysis of variance (ANOVA) with 
significance accepted at the 95% level in each case. Provoking concentrations (PC 
values) of bronchoconstrictor substances are expressed as geometric mean (range). The
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geometric mean is used because the scale of dose increase is non-linear, and it is 
obtained by calculating the antilog of the mean log PC values.
92
5.3 RESULTS
Demographics & lung function
The 8  subjects had a mean (SD) age of 37.1 (9.8) years, and spirometry showed a mean 
(SD) FEV 1 of 2.72 (0.5) litres (87.9 (12.8) % predicted). See table 5.1 for demographic 
factors and asthma treatment. All subjects had bronchial hyperreactivity with geometric 
mean (range) PC20FEV1 to methacholine of 1.8 (0.47-8.0) mg/ml. There were no 
differences in mean (SD) FEVi at baseline on each study day (placebo 84 (11) % 
predicted; angiotensin II 1 ng/kg/min 84 (15) % predicted; angiotensin II 2 ng/kg/min 80 
(16) % predicted).
Plasma angiotensin II
Plasma angiotensin II concentrations (at baseline, prior to and on completion of each 
ET-1 inhalation) were median (inter-quartile range (IQR)) 8 .1 (6.2-13.8), 11.25 (6 .1- 
15.8) and 5.7 (4.1-9.0) pg/ml after placebo, 9.3 (6.8-10.8), 20.8 (12.2-25.4) and 15.3 
(12.0-19.6) pg/ml after angiotensin II 1 ng/kg/min and 8.4 (6.3-11.5), 28.4 (18.4-51.3) 
and 23.8 (17.1-53.3) after angiotensin II 2 ng/kg/min respectively (figure 5.1 - 
presented as mean (SEM) for clarity). Plasma levels were not different to placebo at 
baseline for either angiotensin II infusion dose, and greater than placebo pre- and post- 
ET-1 inhalation for both angiotensin II doses.
Airway responses
Angiotensin II infusion per se did not result in bronchoconstriction at either 1 ng/kg/min 
(mean (SD) FEVi 85 (13) % predicted) or 2 ng/kg/min (mean (SD) FEVi 80 (15) % 
predicted), ET-1 inhalation produced dose-dependent bronchoconstriction in all subjects 
as previously demonstrated (275), with geometric mean (range) PC15FEV1 ET-1 of 
3.20 (0.48-15.36) nmol for placebo, 3.76 (1.04-10.86) nmol for angiotensin II at 1 
ng/kg/min, and 3.53 (0.64-11.3) nmol for angiotensin II at 2  ng/kg/min (figure 5.2 and
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table 5.1), but there was no difference in bronchial responsiveness to ET-1 (ANOVA 
p.0.05) comparing placebo infusion with the 2 doses of angiotensin II.
Blood pressure, pulse and oxygen saturation
There were no differences between mean blood pressures at baseline on each of the three 
study visits (placebo, angiotensin II 1 ng/kg/min and angiotensin II 2 ng/kg/min). The 
higher dose of infused angiotensin II resulted in an increase in mean (SEM) diastolic 
blood pressure compared with placebo prior to the ET-1 inhalation (82 (2.7) vs 73 (2.9) 
mmHg respectively), and an increase in both systolic and diastolic mean (SEM) blood 
pressure at the end of the study visit compared with placebo (SBP 136 (6.6) vs 117 
(4.7), DBP 86 (2.4) vs 75 (2.1) mmHg respectively) (figure 5.3). Pulse rates and 
oxygen saturation measured by pulse oximetry did not alter significantly on any of the 
study days (Appendix 5.1).
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Ang n  2 ng/kg/min
I I I
Baseline Pre ET-1 Post ET -1
Figure 5.1
Plasma angiotensin II levels (mean (SEM)) at baseline, steady state infusion 
(pre-ET-1 inhalation) and post-ET-1 inhalation, during infusion of placebo, 
angiotensin II 1 ng/kg/min and angiotensin II 2 ng/kg/min.
* (p<0.05) compared with placebo value.
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Figure 5.2
Provoking concentration of ET-1 required to produce a fall in FEV l of 15% (PC15FEV1) 
during infusion of placebo, angiotensin II 1 ng/kg/min and angiotensin II 2ng/kg/min. 
Log scale with geometric mean values shown for placebo and angiotensin II 2 ng/kg/min. 
There were no significant differences between bronchial reactivity to ET-1 on any of the 
study days.
97
BP a fte r ET-1 inhalation
mmHg
140 -1
120  -
T SBP
1 0 0 -
+ MAP
80 -
DBP
60
Placebo Ang II Ang II
1 n g /kg /m in  2 n g /kg /m in
Figure 5.3
Non-invasive blood pressure comparing average values of systolic, 
diastolic and mean arterial pressure during infusion of placebo, 
angiotensin II 1 ng/kg/min and 2 ng/kg/min
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5.4 DISCUSSION
We have demonstrated that inhaled ET-1 produces bronchoconstriction in mild 
asthmatics, but did not show any potentiation of this effect by infusion of sub- 
bronchoconstrictor doses of Ang 11.
The lack of potentiation of ET-l-induced bronchoconstriction by Ang 11 was contrary to 
our expectations, having previously demonstrated potentiation by Ang 11 of ET-l- 
induced bronchoconstriction in bovine bronchial preparations in vitro (261). Similarly, 
our group has demonstrated potentiation by Ang 11 of methacholine-induced 
bronchoconstriction in both human bronchial rings in vitro and in asthma in vivo (272), 
although in contrast, there was no evidence of potentiation by Ang II of histamine- 
induced bronchoconstriction, either in human bronchi in vitro or in vivo in asthma 
(277), suggesting that potentiation of bronchoconstriction by Ang 11 may vary according 
to the spasmogen used.
ET-l-induced bronchoconstriction in human airways is mediated mainly by the ETb 
receptor (6 8 ), but the exact mechanism of bronchoconstriction is not known in man. In 
contrast to animal tissues, ET-1 appears to exert bronchoconstrictor activity in human 
airways directly on smooth muscle (60), without the involvement of acetylcholine, 
leukotrienes, histamine or platelet activating factor (8 8 ), although there is evidence that 
ETb receptor activation may potentiate cholinergic nerve-mediated contraction in human 
bronchial preparations (113). Interestingly, Ang II has also been shown to potentiate 
neural cholinergic bronchoconstriction evoked by electrical field stimulation (278) in 
rabbit airw ay sm ooth m uscle. The finding that methacholine-induced 
bronchoconstriction is potentiated by Ang II in asthmatics in vivo, while histamine and 
ET-l-induced bronchoconstriction are not, may therefore suggest that potentiation of 
bronchoconstriction by Ang 11 is specific to cholinergic agents. In addition, while the in 
vitro component of the study by Millar et d  (272) suggests that Ang II potentiates
99
methacholine bronchoconstriction post-junctionally, the influence of pre-junctional 
factors in vivo is not known, and may account for differences in potentiation between 
different bronchoconstrictors.
ET and histamine receptors in the airway are coupled to specific G proteins, with signal 
transduction in each case involving (among other pathways) stimulation of 
phospholipase C with subsequent synthesis of 1,4,5-inositol triphosphate (IP3 ) and 
diacylglycerol (DAG) with activation of protein kinase C (279, 280). Similarly, 
cholinergic muscarinic receptors in the airways are also coupled to membrane 
phospholipid hydrolysis to form IP3 , but there are differences in the pathways involved 
(280), and cross-talk at the second messenger level between Ang II intracellular 
pathways and ET or cholinergic second messenger pathways may account for the 
differences in interactions between Ang II and ET or methacholine in the airways.
Ang II is a weak bronchoconstrictor, and the infusion doses of Ang II were deliberately 
chosen to fall below the levels required to produce bronchoconstriction per se. We 
found no bronchoconstriction in our subjects which could be attributed to the effects of 
Ang II alone, but it could be argued that potentiation of ET-l-induced 
bronchoconstriction might occur at higher plasma levels of Ang II. Potentiation of 
methacholine-induced bronchoconstriction in asthma by sub-bronchoconstrictor doses 
of Ang II was observed in a previous study from our group (272), in which an increase 
in bronchial responsiveness to methacholine was observed in 6  of 7 patients during 
infusion of Ang II at 2 ng/kg/min. Comparing plasma Ang II levels with this study 
showed that we achieved similar elevation in mean plasma levels of Ang II prior to the 
ET-1 inhalation, and elevated but slightly lower levels at completion of the study for 
both doses of Ang II. The reasons for this small difference are not clear, and while this 
could account for a difference in potentiation of bronchoconstriction, we observed no 
evidence of potentiation in those patients whose plasma Ang II levels exceeded the mean 
levels observed in the previous study. The median (IQR) peak plasma levels of Ang II
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observed in this study (28.4 (18.4-51.3) pg/ml during infusion of Ang II 2 ng/kg/min) 
were lower than those reported in acute severe asthma (median 56 (12-109) pg/ml) (273) 
and there is therefore potential for interaction in acute severe asthma which could not be 
demonstrated in this study, if such interaction is dependent merely on the plasma 
concentration of Ang II. In the previous study showing potentiation by Ang II of ET-l- 
induced bronchoconstriction in bovine airways (261) the levels of Ang II used in vitro 
(lCf7 or 3x10"'^ M) were higher than plasma levels in our study at baseline (around 
8x10-1^ M) or at peak levels (around 3xlO-ii M), and higher also than plasma levels in 
acute severe asthma (around 5xl0"ii M) (273), and it is possible that this difference in 
concentration of Ang II accounts for the lack of interaction with ET-1 in asthma in vivo.
In conclusion, the role of the renin-angiotensin system in asthma is not fully 
understood, and in particular interactions between Ang II and bronchoconstrictors which 
may be implicated in asthma appear to be diverse, with potentiation of the effects of 
methacholine, but not histamine or ET-1 in asthma.
CHAPTER 6
INDUCED SPUTUM ENDOTHELIN-1 LEVELS IN
ASTHMA
a) stable asthmatic and non-asthmatic subjects
b) acute exacerbation of asthma
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6.1 INTRODUCTION
Having established the bronchoconstrictor activity of ET-1 in vivo, and demonstrated 
bronchial hyperreactivity to ET-1 in asthmatic subjects, we wished to examine whether we 
could use induced sputum to measure airway levels of ET-1 in asthma. ET-1 is produced by 
human bronchial epithelial cells, and histological studies show increased expression of 
endothelin in the bronchial epithelial cells of asthmatic patients compared with normal 
subjects (47). Similarly, elevated levels of endothelin have been reported in bronchoalveolar 
lavage in symptomatic and non-steroid treated asthmatic patients (124). Induced sputum has 
potential advantages over bronchoscopic techniques in that it is non-invasive, and can easily 
be repeated in an individual subject to compare parameters over time.
Since there have been no previous reports of sputum levels of ET-1, we first wished to 
assess whether or not ET-1 could be measured in induced sputum using a commercially 
available immunoassay, and sought to confirm this using reverse-phase high-performance 
liquid chromatography (RP-HPLC). We further wished to compai’e induced sputum ET-1 in 
asthmatic and non-asthmatic subjects, and sputum ET-1 levels in acute exacerbation of 
asthma compared with levels following treatment and recovery. This chapter is therefore a 
combination of pilot work using RP-HPLC to identify ET-1 in sputum, and 2 further 
studies, the first comparing sputum ET-1 measured by ELISA in asthmatic and non­
asthmatic subjects (baseline study), and the second a study comparing sputum ET-1 in acute 
exacerbation of asthma and in convalescence (acute study).
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6 .2  METHODS 
Subjects
(a) Baseline study
28 stable asthmatics and 9 non-asthmatic subjects who were non-smokers were studied. 
Asthma was defined by clinical symptoms, response to inhaled beta-2 agonist, and 
methacholine PC20 <8 mg/ml. Normal subjects were asymptomatic, and had a methacholine 
PC20 >16 mg/ml, with normal baseline spirometry. The study was approved by the West 
Ethics Committee, West Glasgow Hospitals University NHS Trust, and each subject gave 
written informed consent.
(b) Acute study
9 subjects with a previously established diagnosis of asthma (2M, 7F) were recruited 
following admission to our unit with an acute exacerbation of asthma (5 non-smokers, 2 ex­
smokers and 2 current smokers). Entry criteria were established for an age group of 18 - 75 
years, with a known history of asthma (GP or hospital diagnosis). At the time of 
presentation, subjects were required to have a respiratory rate of >25/min, peak expiratory 
flow rate of <60% of predicted/usual and a pulse rate of >110 beats per minute. The study 
was approved by the West Ethics Committee, West Glasgow Hospitals University NHS 
Trust, and each subject gave written informed consent.
Protocol
(a) Baseline study
The study involved 2 visits to the laboratory, the first for methacholine challenge testing, 
and the second for sampling of blood and saliva and sputum induction, with spirometry 
monitored throughout the induced sputum procedure in the usual way.
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(b) Acute study
Spontaneous sputum samples were obtained within 24 hours of admission to hospital in 
all cases (in most cases within 12 hours), and blood was sampled concurrently. Patients 
were managed according to clinical requirements (in all cases oral corticosteroid therapy 
was started or increased, and in 2  cases antibiotics were commenced), and a review visit 
was arranged for roughly 6  weeks after admission, or once symptoms had been stable 
for 3 weeks thereafter. At the review visit, spirometry was measured, blood sampled, 
and induced sputum performed following pretreatment with salbutamol 2 0 0 /fg, with 
spirometry monitored through the procedure.
Sputum Induction
This was performed as described in chapter 2.3. Additionally, in the baseline study saliva 
samples were obtained prior to sputum induction to measure salivary levels of ET-1. In a 
subgroup from the baseline study (n=9), blood was taken pre- and post-sputum induction to 
ensure no change as a result of the procedure.
Laboratory Processing
Sputum was processed as described in chapter 2.3, with the exception for the acute study 
mentioned under biochemical assays, with the laboratoiy staff unaware of the clinical details 
relating to the sample.
Reversed-phase high-performance liquid chromatography (RP-HPLC)
RP-HPLC was carried out on saliva and sputum samples as described in chapter 2.4.
Biochemical Assays
Endothelin was assayed as described in chapter 2.4, but in the acute study, due to a failed 
assay on the first attempt, sputum ET-1 was not able to be measured on sputum which had 
not been treated with the reducing agent dithiothreitol (DTT), and this was repeated on DTT- 
treated samples. Sputum ET-1 levels are therefore not directly comparable between the
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baseline and acute studies. Recovery of ET-1 from sputum was 8 8 %. Eosinophilic cationic 
protein (ECP) was assayed using a radio inimuno-assay (lower limit of detection 2 ;^g/l in 
plasma) (Pharmacia U.K. Ltd, Milton Keynes, U.K.).
Statistical Analysis
Non-parametric statistics were used to compare cell counts, ECP and ET-1 values using the 
Mann-Whitney U test, with differences in paired data analysed by subtraction followed by 
1-sample Wilcoxon test. Significance was accepted at the 95% level. Power calculations 
suggest a power of >85% to detect a difference in sputum ET-1 of ± 1 S.D.
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6.3 RESULTS - REVERSE-PHASE HIGH-PERFORM ANCE LIQUID  
CHROMATOGRAPHY
Presence of ET-1
RP-HPLC was performed initially on pure ET-1 standards to establish the elution point for 
ET-1 resulting in a retention time of 21.0 minutes. RP-HPLC was then performed on 
clinical samples under the same conditions, which confirmed the presence of ET-1 in saliva 
and sputum, with a single peak corresponding to the pure ET-1 standard in each case (figure 
6 .1), with elution points for saliva and sputum being 2 1 .0  minutes and 2 1 .1  minutes 
respectively.
Effect of dithiothreitol (DTT)
In order to examine the potential influence of DTT on the ET-1 molecule, an ET-1 standard 
was prepared in the presence of DTT, and as above for the pure ET-1 standard, the elution 
point was measured. This revealed a phase shift of 5 fractions for DTT-treated ET-1 
standard, with an elution point of 25.5 minutes and fractionation was therefore shifted for 
the DTT-treated sputum sample. In fact, however, the elution point for the DTT-treated 
sputum sample proved to be identical to the saliva and sputum samples which were not 
treated with DTT, and to that of the pure ET-1 standard at 21 minutes (figure 6.1). There 
was a difference in magnitude of the peak in the DTT-treated sputum sample, measuring 
around twice that of the non-DTT-treated sputum sample.
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Figure 6.1
RP-HPLC retention time for saliva, DTT-treated sputum and non-DTT-treated 
sputum
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6.4 RESULTS - BASELINE STUDY 
Demographics
Demographic data is summarised in table 6.1. The asthmatic group was older (mean (S.D.)
41.4 (10) years vs. 31.8 (8 .8 ) years), and had lower FEVi than normals, both as absolute 
values (2.99 (0.9) litres vs. 3.93 (1.08) litres) and percent predicted (84.0 (14)% vs. 99.2 
(11.4) %). Mean daily inhaled corticosteroid dose was 400/<g beclomethasone or equivalent 
in the asthmatic group.
Sputum cell counts
Sputum eosinophils were higher in asthmatics (median 3%) than normal subjects (median 
0 %), and no differences were seen in total cell counts, nor in macrophage, neutrophil or 
lymphocyte proportions (table 6 .2 )
Eosinophilic cationic protein
In asthmatics and normals, median (IQR) sputum ECP (129.0 (100-340) ]Agl\ and 340.0 
(134-710) ;^g/l respectively) was greater than serum ECP, with serum ECP greater in 
asthmatics than normals (9.0 (3-11) pigH vs. 1.0 (0-7) Saliva levels of ECP were 
assayed in a sub-group of the subjects (n=7), drawn from each of the groups at random to 
compare with sputum. In this group, saliva ECP (median (IQR) 10.0 (5-69) ;^g/l) was 
lower than sputum ECP (210 (26-460) //g/1).
Endothelin-1
Comparing median (IQR) plasma, saliva and sputum levels of ET-1 between each group 
showed no significant differences between asthmatics and normals for each fluid (median 
(IQR) ET-1: Asthmatics, saliva 23.8 (14.4-33.7) pg/ml; sputum 11.2 (9.4-18.9) pg/ml; 
plasma 3.6 (2.B-4.5) pg/ml: Normals, saliva 30.1 (20.1-43.4) pg/ml; sputum 15.5 (10.0- 
21.4) pg/ml; plasma 3.1 (1.7-4.8) pg/ml.) Plasma ET-1 did not alter as a result of sputum 
induction per (subgroup n=9, data not shown). Pairwise analysis of asthmatic subgroups
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revealed no differences between asthmatics taking inhaled steroids (n=16) and those taking 
inhaled 132-agonists alone (n=12). There were significant differences within each patient 
group in the levels of ET-1 in the order saliva > sputum > plasma (figure 6.2 and table 6.3). 
We found no significant direct correlation between plasma or sputum ET-1 and the 
asthmatics' FEVi or methacholine PC20 .
Table 6.1
Demographic data - Baseline study
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No. Age
(years)
Sex FEVI
(litres)
FEVI (%) 
picdicted
Treatment PC20
(mg/ml)
Norm al
volunteers
1 30 M 3.78 76 none >16
2 23 M 4.50 107 none >16
3 45 F 2.54 96 none >16
4 31 M 4.83 109 none >16
5 25 M 4.66 110 none >16
6 23 M 5.65 108 none >16
7 33 F 2.41 90 none >16
8 47 M 3.35 93 none >16
9 29 M 3.66 104 none >16
Mean 3 1 . 8 7 M 3 . 9 3 9 9 . 2
2F
(S.D.) (8.8) (1.08) (11.4)
Asthm a
1 36 F 1.33 49 S 0.04
2 37 M 3.04 81 S 4.4
3 45 M 3.47 83 S 4.21
4 39 M 4.21 81 s 0.19
5 46 F 1.97 84 S 1.27
6 23 M 4.64 104 s 7.4
7 30 F 3.47 113 s 7.8
8 47 M 2.80 71 s 1.33
9 37 F 2.62 93 s 0.84
10 34 F 3.09 103 s 6.21
11 31 M 3.55 85 s 1.29
12 29 F 2.34 75 s 0.33
13 30 M 4.86 102 s  Bud 800 7.6
14 69 M 2.19 70 S Flut750 1.31
15 51 M 2.54 63 S BDP800 Sm 3.2
16 33 M 3.95 84 S BDP 400 2.65
17 57 F 2.31 86 S BDP800 0.34
18 48 M 3.32 92 S BDP400 4.9
19 48 M 4.02 83 S BDPlOOO 4.2
20 39 M 3.87 105
Sm
S BDPlOOO 0.26
21 34 M 3.05 83 S BDP400 3.28
22 38 M 2.80 72 S BDP800 Sm 0.62
23 47 F 2.23 88 S BDP400 6.86
24 54 M 2.50 77 S BDP1500 2.64
25 47 F 2.14 80 S Bud400 0.47
26 49 F 2.41 101 S BDP800 1.13
27 35 M 2.78 72 S BudSOO 4.92
28 45 F 2.02 70 S BDP400 0.27
Mean “ITTÏ™"“™T7M 2 . 9 9 geom etric 2.9
(S.D.) (10.0)
11F
(0.88) . (14)
mean
range 0.04-7.8
key PC20 Provoking concenti'atioii of raetliaclioline producing a 20% fall in FEV1 
S Salbutamol 200 j4 g  p.r.n.
Bud Budesonide total daily dose in p ig
Pint Fluticasone propionate total daily dose in p ig
BDP Beclometliasone dipropionate total daily dose in p ig
Sin Salmeterol 100 p ig  daily
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Table 6.2
Baseline Study - Sputum cell counts
total cell count Macrophage Neutrophil Eosinophil Lymphocyte
(xlQ6/ml) (%) (%) (%) (%)
Normals 8 .5  8 1 .0  1 9 .0  0 .0  2 .0
(4.3-23.2) (65.0-90.0) (6.0-35.0) (0-0) (0-3.5)
Asthmatics 6 .2 5  6 4 .5  2 3 .5  3 .0 *  2 .0
(B.2-9.8) (50.8-78.8) (5.3-37.0) (1.0-7.0) (1.0-5.0)
key values expressed as median (IQR)
differential counts expressed as % cell count after exclusion of epithelial cells 
greater than normals (p<0.05)
I l l
Table 6.3
Baseline study - Endothelin-1 and eosinophilic cationic protein in saliva, 
sputum and plasma/serum (Median (interquartile range))
Endothelin-1
Saliva
(pg/ml)
Sputum Plasma
ECP(pg/l)
Sputum Serum
Normals 30.1 15.5 3.1 340.0 1.0
(20.1-43.4) (10.0-21.4) (1.7-4.8) (134-710) (0-7.0)
Asthmatics 23.8 11.2 3.6 129.0 9.0*
(14.4-33.7) (9.4-18.9) (2.8-4.S) (100-340) (3.3-11.0)
key * significantly greater than normal volunteers
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Figure 6.2
Baseline study
Plasma and sputum ET-1  in normals and asthmatics (median (IQR)) 
* greater than plasma value
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6.5 RESULTS - ACUTE STUDY 
Demographics
Demographic data is presented in table 6.4. The patients in this study were more severe 
asthmatics than in the baseline study, with a mean FEV i when stable of 71% predicted, but 
a range from 31% to 102%. All were prescribed inhaled corticosteroids prior to 
exacerbation, with a mean daily dose of beclomethasone (or equivalent) of 1900 pg/day, 
and 3 were prescribed maintenance oral corticosteroids (prednisolone dose range l-20mg 
daily) prior to exacerbation. Mean (SEM) peak expiratory flow rate (PEER) on admission 
was 32.6 (4.5)% predicted/best, and on recovery 75.0 (13.7)% predicted/best (p=0.004).
Sputum cell counts
Sputum cell counts are summarised in table 6.5. There was no significant difference 
between total sputum cell counts in exacerbation (median (IQR) 9.7 (7.5-40.4) cells 
xlOQml) and in recovery (median (IQR) 6 .8  (5.2-17.4) cells xlOQml), and comparing 
paired data, the only significant change in differential cell counts comparing acute 
exacerbation and convalescence was a fall in total eosinophil numbers (p=0.04), and a rise 
in macrophage proportion (p=0.03), reflected by a non-significant rise in neutrophil 
proportion. There was significant neutrophilia both in acute exacerbation and in 
convalescence (median (IQR) 64 (50-82)% and 58 (21-81)% respectively), with a modest 
eosinophilia (median (IQR) 4 (2-18)% and 3 (1-10)% respectively).
Endothelin-1
There was no difference between plasma ET-1 in acute exacerbation (median (IQR) 4.1 
{2.1-5.5) pg/ml) and plasma ET-1 in convalescence (median (IQR) 4.1 (2.6-4.7) pg/ml). 
Due to a failure of our initial assay, sputum ET-1 was measured in samples which had been 
pre-treated with DTT, and are therefore not directly comparable with values from other 
studies, including the baseline study. There was no difference between sputum ET-1 in
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acute exacerbation (median (IQR) 4.75 (3.6-17.9) pg/ml) and sputum ET-1 in 
convalescence (median (IQR) 3.2 (1.7-27.6) pg/ml) (figure 6.3).
.15
Table 6.4
Acute study - Demographic data
No. Age
(yrs)
Sex FEVi
(litres)
FEVi
(%
pred)
Prior inhaled 
steroid 
treatment 
(//g BDP/ 
equiv)
Additional asthma treatment
1 19 p 3.05 1 0 2 3000 S. Ef. NS. Bam
2 63 F 0.91 42 2500 S. NS. Ipr.Th.
3 49 F 0.79 31 2 0 0 0 P20. S. NS. Ipr. NBud. Th
4 47 M 1.75 43 2 0 0 0 PIO. S, Sm. NBud
5 40 M 1.24 38 4000 PI. STb. NS. Ipr. Sm
6 37 F 2.87 99 800 S.
7 40 F 2.25 87 800 S.
8 58 F 2.09 101 1600 S. Sm. Tb. Th
9 35 F 2.59 95 400 S.
Mean 43 .1 3M 2 .0 9 71 1900
(S.D.) 13.1 6F (0.50 (31) (1160)
Key
S . Inhaled salbutamol 200//g as required
NS Nebulised salbutamol 2.5 mg as required
Ef Efoimoterol 24//g daily
Bam Bambuterol 20mg daily
Ipr Nebulised ipratropium bromide 0.5mg as required
Th. Oral theophyllines
NBud Nebulised budesonide 2mg daily
Sm Salmeterol 100//g daily
STb Subcutaneous terbutaline 10mg/24hours
Tb Terbutaline 0.5mg as required
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Table 6.5
Sputum total and differential cell counts - Acute study
median (IQR)
Total cell Macro- Neutrophil Eosinophil Lympho-
count phage cyte
Cell numbers
(cells xlO^/ml) 
Exacerbation 9 . 70
(7.5-40.4)
2 . 56
(0.8-5.9)
6 . 28
(3.6-24.7)
0.78*
(0.3-2.5)
0 . 0
(0-0.04)
Convalescence 6 . 8 0
(5.2-17.4)
2 . 88
(1.2-6.3)
3 . 75
(1.3-11.9)
0.31
(0.08-0.8)
0 . 0
(0 -0 )
Cell
proportions
(%)
Exacerbation 19.0*
(8.5-34.0)
64 . 0
(50-82)
4 . 0
(2-18)
0 . 0
(0-0.5)
Convalescence 37 . 0
(15-60)
5 8 . 0
(21-81)
3 . 0
( 1-1 0 )
0 . 0
(0 -0 )
Key * p<0.05
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Acute study - Sputum ET-1 in exacerbation and convalescence in 
asthma
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6.6 DISCUSSION
We report that it is possible to measure ET-1 by RIA, and confirm its identity by RP-HPLC 
in sputum obtained by sputum induction, and that saliva and sputum levels of ET-1 are 
significantly elevated when compared with plasma in stable asthmatics and non-asthmatics. 
We found no difference in sputum ET-1 levels between asthmatics and non-asthmatics, but 
unexpectedly found saliva ET-1 levels to be significantly higher than sputum levels in both 
groups. We aie not aware of any previous study which has made this comparison, either in 
asthmatics or normal subjects. In the study examining sputum ET-1 levels in acute 
exacerbation of asthma, plasma and sputum ET-1 were not different comparing exacerbation 
and convalescence, although the possible influence of other factors on this finding will be 
discussed. The different components of this chapter will be discussed under separate 
headings.
Reverse-phase high-performance liquid chromatography
The pilot work examining using RP-HPLC was designed to confirm the presence of ET-1 in 
sputum and saliva samples, to allow us to accurately interpret the RIA results, since we 
were not aware of any reports of the measurement of ET -1 in sputum using RIA or any 
other assay technique. The results confirm that ET-1 is present in sputum and saliva. We 
extended this to examine the potential action of the reducing agent DTT on sputum samples, 
and although it is possible to speculate on the interpretation of this, this aspect was not 
pursued further. We found a difference in the elution points for DTT -treated pure ET-1 
compared with DTT-treated sputum samples, and a difference in the magnitude of the ET-1 
peak comparing DTT -treated and non-DTT-treated sputum. There are several possiblities 
which might explain aspects of this, although these remain speculations;
(1) Effect o f DTT on disulphide bonds in ET-1 molecule.
DTT would be expected to disrupt the ET-1 molecule at its 2 disulphide bonds, but this 
process is pH-dependent, and differences in pH between the pure-ET standard (which was 
prepared at optimal pH for reduction) and the sputum sample might result in different
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degrees of reduction or failure of reduction by DTT. This may account for the differences 
seen in the elution points of the DTT-treated ET-1 standard and the DTT-treated sputum 
sample. Alternatively, reduction may have taken place, but subsequent to RP-HPLC ET-1 
was oxidised again to regain its original structure.
(2) Protective effect o f DTT against oxidation
We found an increase in the magnitude of the signal for the ET-1 in the DTT-treated sputum 
sample compared with the non-DTT-treated sample. ET-1 has a methionine residue at 
position 7, which is sensitive to oxidation. This could result in impaired antibody binding in 
the RIA, with resultant underestimation of the ET-1 measurement. Sputum prepared in the 
presence of DTT may be protected from oxidation, with resultant higher values for ET-1 
measured in this way.
Baseline Study
In the baseline study asthmatic patients were studied while their lung function was stable 
with minimal symptoms, not in exacerbation, and no bronchoconstrictor stimulus was given 
prior to sputum induction, to allow us to examine basal levels of ET-1. Differential cell 
counts show an elevation in eosinophils in the asthmatic group which is consistent with, but 
notas pronounced as some previous studies (246, 281)^ and in contrast to other workers, 
we did not find an elevation in sputum ECP in the asthmatic group compared to normals. 
We believe that this finding reflects a largely asymptomatic group of patients, the majority of 
whom have relatively mild asthma (overall mean daily dose of inhaled corticosteroid 400/^g 
beclomethasone dipropionate or equivalent) since the methodology used, and commercially 
available assay kit were identical to other groups as far as can be ascertained. A relationship 
between FEVi (282), symptoms (283), and induced sputum eosinophil counts has been 
described in asthmatic patients, with lower eosinophil counts in asymptomatic patients, and 
patients with higher FEVi. Since ECP is produced by activated eosinophils, we believe that 
the absence of an elevation in ECP is consistent with the median eosinophil count of 3% in 
our asthmatic group. Nonnal subjects were recruited who did not complain of symptoms of
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breathlessness, and whose spirometry was within normal limits, to act as a control group 
for the asthmatic subjects.
The finding that ET-1 levels in saliva are higher than ET-1 in sputum is unexpected, and 
may suggest release of ET-1 either from the salivary glands or the epithelial cells of the oral 
mucosa. Animal studies have revealed staining for immunoreactive ET-1 in the rat parotid 
gland (284) and the presence of ET-1 in human saliva has been reported using fast protein 
liquid chromatography (FPLC) separation and RIA (285) although at levels around 6  times 
lower than we have observed. Differences in assays and laboratory processing can influence 
levels, but the reason for this discrepancy is not known. Little evidence is available 
regarding any potential physiological or pathological role of endothelin in saliva but one 
speculation on the basis of its known mitogenic activity is that it may be involved in the 
maintenance of mucosal integrity. Recovery of ET-1 (8 8 %) from sputum samples using the 
technique of "spiking" the sample with a known quantity of ET-1 suggest that the levels of 
ET-1 measured by RIA following separation are a reasonable approximation of the 
concentration of ET-1 in the sputum supernatant.
In addition to questions about the physiological role of ET-1 in saliva, the finding of higher 
ET-1 in saliva than in sputum plugs, raises an important methodological issue regarding the 
technique of sputum processing. As mentioned in chapter 1.4, there are two principal 
methods of sputum induction, the first involving sputum plug separation, and the second 
involving the use of the whole sputum sample without prior separation of the viscid portion. 
Separation of sputum plugs is taken to minimise salivary contamination of sputum samples, 
and in keeping with this we found that ECP levels in sputum plugs were significantly higher 
than in saliva. While this study was not designed to test the hypothesis that plug separation 
allows distinction of supra-glottic and infra-glottic secretions, our data does suggest that 
separation produces qualitatively different samples from saliva, and allowed comparison of 
ET-1 levels in each fluid. Further, despite evidence from cell counts and measurement of 
ECP that selected sputum and entire sputum have similar diagnostic value in distinguishing
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asthmatic from non-asthmatic subjects (226) the unexpected finding that ET-1 is present in 
saliva at higher concentration than in sputum suggests that it is incorrect to presume that 
salivary "contamination" will have no significant effect on the levels of relevant mediators in 
induced sputum.
The plasma levels of ET-1 that we report are consistent with other groups, who similarly 
found no increase in plasma endothelin in asthmatics with daytime (274) or nocturnal 
symptoms ( 127) other than in exacerbation (120),
Allowing as far as can be determined for dilution of BAL samples, our finding of sputum 
levels of ET-1 of around 10-15 pg/ml accord reasonably with levels found by other groups 
in BAL fluid (124, 274). Both these studies however report an increase in BAL ET-1 in 
untreated asthmatics which we did not observe in our asthmatic group (nor in the subgoup 
taking inhaled beta-2 agonists alone). In contrast to this, a fall in BAL ET-1 was observed at 
0400 hours in the group of patients mentioned above with nocturnal symptoms (127), and it 
was postulated that this may reflect increased tissue binding of ET-1 in nocturnal asthma. 
Among the limitations of the use of bronchoscopy and BAL as a technique to investigate 
mediators in asthma is the possibility that the procedure may itself influence mediator levels. 
In addition, BAL is subject to uncertainty regarding the site of sampling, variable recovery 
of BAL fluid, and variable dilution of mediators. The reproducibility and validity of sputum 
induction has been demonstrated (2 2 1 ), and while other groups have demonstrated the 
presence of cytokines and soluble factors in induced sputum (e.g. Keatings c/a/(180)), it 
should be noted that samples obtained by sputum induction are not identical to those 
obtained by BAL (228, 230). A direct comparison of BAL ET-1 and induced sputum ET-1 
in the same group would be necessary to exclude any difference caused by the techniques of 
obtaining and processing the samples, and it not possible to exclude such an influence on 
ET-1 levels in this study or those involving BAL.
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The fact that ET-1 is present in sputum and saliva at levels higher than that in plasma 
suggests that ET-1 is produced or released locally within the respiratory tract. Endothelin 
immunoreactivity is present in airway epithelia and submucosal glands throughout the lung 
(56) in addition to airway smooth muscle and parasympathetic ganglia in the airways (54). 
Endothelin is secreted by bronchial epithelial cells in cell culture (52) and in the same cells 
isolated from biopsy samples from asthmatics (125). The presence of pro-endothelin-1 (56) 
and preproendothelin-1 have also been demonstrated in airway epithelial cells (47). 
Endothelin binding-sites are seen in lung parenchyma, airway smooth muscle and airway 
epithelia in decreasing order of density (56) and it is suggested that endothelin released from 
airway epithelial cells may act as a paracrine factor on airway smooth muscle producing 
bronchoconstriction. Other putative roles for endothelin, such as a neuromodulatory 
function based on its presence in parasympathetic ganglia require further investigation, but 
may be of relevance to asthma.
Acute study
A role for ET-1 in acute severe asthma was postulated originally in a case report of increased 
BAL ET-1 from a patient in status asthmaticus (121). Increased plasma ET-1 has been 
reported in acute severe asthma, with a relationship between plasma ET-1 levels and airflow 
obstruction (120). Although other studies examining ET-1 in acute severe asthma are 
lacking, there is evidence of increased BAL ET-1 in symptomatic versus asymptomatic 
asthmatics and that exposure of asthmatic bronchial epithelial cells to histamine and IL-1 
induces endothelin synthesis and release, (125), although in contrast there was reduced 
BAL ET-1 in nocturnal samples from subjects with predominantly nocturnal asthma (127).
As mentioned above, the problems which we experienced with our initial ET-1 assay in the 
acute study meant that the assay was repeated using sputum supernatant following treatment 
with the reducing agent DTT. Although our results from RP-HPLC show a similar position 
for the elution point of DTT-treated ET-1, there were differences in magnitude of the levels 
compared with non-DTT-treated ET-1, and there is no definitive data to clarify any potential
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effect of DTT on either the ET-1 peptide or on the RIA assay system. DTT is known to 
disrupt disulphide bonds, and the structure of the ET-1 peptide is known to contain 2 
disulphide bonds (see chapter 1.1). It is not therefore possible to directly relate the values 
for ET-1 obtained in the acute study to those observed in the baseline study, and although it 
was possible to obtain measurements of ET-1 in DTT -treated sputum, the change in 
methodology adds a potentially confounding variable to analysis of the acute study.
Several studies have examined the influence of corticosteroids on ET-1 production, with in 
vitro evidence that corticosteroids decrease production of immunoreactive ET-1 (47) in 
asthmatic bronchial epithelial cells, and in vivo evidence that corticosteroids decrease ET-1 
in BAL (274) and in bronchial biopsies (123) in asthma. In our study, all the subjects had 
received intravenous and/or oral corticosteroids by the time of sputum and blood sampling, 
and in some cases this had been started prior to admission to hospital with acute severe 
asthma. We cannot exclude the possiblity that ET-1 levels were reduced by the effect of 
coritcosteroids, resulting in our finding that there was no difference between induced 
sputum ET-1 levels on admission or in convalescence.
Contraiy to expectations we did not find an increase in plasma ET-1 in acute exacerbation of 
asthma in the acute study, and the levels of plasma ET-1 found were lower than that 
observed in a previous study of acute asthma from our own group (119). The reasons for 
this are not known, although it is possible that blood samples were obtained earlier in the 
course of the admission in our previous study, or that patients had received more treatment 
(particularly oral corticosteroids) by the time of sampling.
Despite an improvement in mean PEER from 32.6% predicted/best on admission to 75% 
predicted/best in convalescence, we found only modest changes in induced sputum 
inflammatoiy cell numbers or proportions. There was a slight fall in eosinophil numbers 
(although not eosinophil proportions), and a rise in macrophage proportions, but the most 
striking finding from the sputum cell counts was the significant degree of neutrophilia, both
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on admission and in convalescence, without any reduction in neutrophil numbers or 
proportions comparing acute and convalescent sputum samples. Although cigarette smoking 
is associated with airway neutrophilia (286), only 2 of the subjects were current smokers, 
and 2 ex-smokers, and neutrophil numbers were not elevated only in smokers or ex­
smokers. Other groups have reported significant neutrophilia in sputum (287) and BAL 
(288) in acute severe asthma but without follow-up data, suggesting that the neutrophil may 
have a role in airway inflammation in acute severe asthma. Our own data with follow-up 
sputum samples did not show any reduction in neutrophil numbers or proportions in 
recovery, suggesting an association between sputum neutrophilia and severity of asthma, 
not only in acute severe asthma.
C onclusions
The evidence presented above supports the observation of local production of ET-1 within 
the bronchial tract, and confirms that this can be assessed non-invasively using sputum 
induction. This data establishes a basis for the following chapters which explore a role for 
ET-1 in asthma and other airway diseases. Disappointingly, interpretation of the acute study 
is hampered by a technical failure in the original ET-1 assay, which limits its application in 
comparison with other data obtained.
CHAPTER 7
EFFECT OF IMMEDIATE ALLERGIC 
REACTION IN ASTHMATICS ON 
ENDOTHELIN-1 LEVELS IN INDUCED
SPUTUM
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7.1 INTRODUCTION
In view of the potent bronchoconstrictor activity of ET-1 in asthma, and having 
demonstrated that induced sputum can be used to obtain bronchial secretions for the 
measurement of ET-1, we were interested to use sputum induction to examine the 
potential contribution of ET-1 to allergen-induced bronchoconstriction in asthma.
Animal studies have demonstrated an early increase in ET-1 mRNA following 
experimental eosinophilic airway inflammation (289), a rise in BAL ET-like 
immunoreactivity following allergen provocation (262) and inhibition of antigen-induced 
airway inflammation in mice by ET receptor antagonists (290). Pro-inflammatory 
mediators are known to stimulate ET-1 release from airway epithelial cells (129), and 
ET-1 itself appears to have pro-inflammatory activity in the lung (105, 108). In the 
guinea-pig, ETb selective antagonists inhibit the immediate response, while ET A 
antagonists inhibit the late response (109), suggesting that ET-1 may have a role in both 
components of the airway responses to allergen.
We chose to perform sputum induction during the immediate allergic response, to 
examine if bronchoconstriction induced by allergen is accompanied by an increase in 
ET-1 release in the airways.
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7 .2  METHODS 
Patients
12 asthmatic patients were recruited, all of whom had demonstrated sensitivity to house- 
dust mite allergen (skin test or RAST), and bronchial hyperresponsiveness with a 
provoking concentration of methacholine to produce a 20% fall in FEV i (PC20) of 
<8mg/ml. Patient demographics are summarised in table 1. All subjects had current 
asthma with stable symptoms at the time of study, no history within the preceding 
month of respiratory infection, antibiotics or oral corticosteroid use and other than house 
dust mite, none of the subjects had been exposed to allergens to which they were allergic 
in the preceding month. Asthma was defined according to the ATS definition (2 5 7 ), 
baseline lung function was recorded, and non-specific bronchial hyperresponsiveness 
was established using a methacholine challenge test, with all the asthmatics subjects 
having a methacholine PC20 of less than 8nig/ml. The study was approved by the West 
Ethics Committee, West Glasgow Hospitals University NHS Trust, and each subject 
gave written informed consent.
Study Design
Bronchial challenge tests were carried out on three separate visits using placebo, 
methacholine (prepared by sterile pharmacy in house), or purified HDM allergen 
(SmithKline Beecham Pharmaceuticals U.K.) in a blinded, placebo controlled, 
randomised fashion. Challenge tests were administered using a dosimeter ("Nebicheck" 
- PK Morgan, Gillingham U.K.), with allergen dose expressed in breath units (BU - 
where 1 BU = 1 breath of 10-3 dilution) and were discontinued following a 20% fall in 
FEVi (with the exception of placebo). Plasma samples were taken before and after 
bronchial challenge tests, and sputum induction using 3% saline given by ultrasonic 
nebuliser ("Sonix 2000" - Medix Ltd, Lutterworth, U.K.) was performed 15 minutes 
after each challenge test, as previously described (291).
127
Sputum Induction and Laboratory Processing
Sputum induction and laboratory processing of sputum and plasma samples were 
performed as described in chapter 2.
Expression of Results and Statistics
Airway reactivity is expressed as provoking concentrations required to produce a 20% 
fall in FEVi (PC20), with methacholine values in mg/ml, and allergen values in breath 
units (1 BU = 1 breath of 10-3 dilution). Sputum cell counts were expressed following 
exclusion of squamous cells, as these were taken to represent salivary contamination. 
Non-parametric statistics (Mann Whitney-U and Wilcoxon rank sum) were used to 
compare values, and results are expressed as median (interquartile range) unless 
specified otherwise, with significance accepted at the 95% level. Spearman rank 
correlation (rg) was used where indicated. Statistical analysis was performed using a 
dedicated software package ('Minitab' - Mini tab Inc., State College, PA, USA) on a 
Macintosh desktop computer (Apple Computer Inc., Cupertino, CA, USA).
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7.3 RESULTS 
Demographic Data
Demographic data including lung function, asthma therapy and airway responsiveness to 
methacholine and allergen are summarised in table 7. L There was no correlation 
between methacholine and allergen responsiveness. All subjects demonstrated bronchial 
reactivity to methacholine (geometric mean (range) PC20 to methacholine of 1.47 (0.26 - 
6.86) mg/ml) and house dust mite allergen (geometric mean (range) PC20 to allergen of 
324 (71 - 860) BU).
Sputum Cell Counts
Sputum cell counts showed no significant differences between the challenge tests at this 
time point, with the exception of a slight but significant reduction in lymphocyte 
percentage following allergen challenge compared to placebo (table 7.2).
Eosinophilic Cationic Protein
Serum ECP did not alter across any of the challenge tests. Sputum ECP was greater than 
serum ECP in all cases, with no differences in sputum ECP comparing the challenge 
tests with placebo (table 7.2).
Endothelin-1
Plasma ET-1: Plasma samples taken before and after each inhalation (placebo, 
methacholine and allergen) showed no change in plasma ET-1 in relation to any of the 
challenge tests. Plasma ET-1 did not correlate with airway reactivity in either 
methacholine or allergen challenge tests.
Sputum ET-1: Median (IQR) sputum ET-1 was higher than plasma ET-1 in each case. 
Median (IQR) sputum ET-1 was 11.0 (4.9-19.6) pg/ml after placebo challenge, 19.2 
(5.6-25.4) pg/ml after methacholine, and 19.8 (11.7-32.3) pg/ml after allergen. 
Assessing change in sputum ET-1 following allergen compared with placebo, there was
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a trend towards an increase after allergen (median change +5.1 pg/ml) which did not 
reach statistical significance (p=0.071) (figure 1). Sputum ET-1 did not correlate with 
airway reactivity in either methacholine or allergen challenge tests, but the change in 
sputum ET-1 from placebo to allergen samples correlated strongly with the eosinophil 
count of the placebo sample (i's=0.67, p=0.025) (figure 7.2).
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Figure 7.1
Change in sputum ET-1 (pg/ml) comparing allergen challenge with 
placebo challenge. Median (IQR) marked, with p value for comparison 
with "no change".
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Figure 7.2
Relationship between sputum eosinophilia at placebo visit and the 
difference between sputum ET-1 (pg/ml) at allergen challenge and 
placebo challenge.
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7.4 DISCUSSION
Comparing allergen challenge with placebo challenge, there was a trend towards an 
increase in sputum ET-1 which approached significance, and a positive conelation 
between this change and sputum eosinophilia, suggesting that an increase in sputum ET- 
1 may occur in response to allergen challenge in those subjects with most marked airway 
inflammation. Methacholine challenge testing does not acutely alter ET-1 in plasma or 
sputum obtained by sputum induction.
Sputum induction is a relatively recent technique which allows bronchial secretions to be 
obtained non-invasively, and which allows repeated sampling of bronchial secretions, 
and which has been shown to be reliable and reproducible in the analysis of cells and 
soluble mediators in lung disease (220).
The role of ET-1 and ET-1 receptor blockade in antigen-induced airway responses have 
been examined in animal models, with evidence of a differential role for the two ET 
receptors, ETa and ETg. Rodent studies indicate that ET A receptor antagonism results in 
a reduction in the airway cellular infiltration (103) and bronchoconstrictor response in 
the late allergic response, while the immediate bronchoconstrictor response was 
inhibited by ET g antagonists (109). An increase in BAL ET-1 one day after experimental 
airway inflammation in rats has also been demonstrated, with a relationship between 
BAL ET-1 and total BAL cell count, BAL eosinophils and BAL neutrophils (110). In 
asthma, there is increased imniunostaining for ET-1 in bronchial biopsies in stable 
asthmatics (122), and this has been shown to relate to the severity of airway 
inflammation and to bronchoconstrictor responses to distilled water (97). One study 
from Redington etal (130) has examined the influence of the bronchoscopic technique 
of segmental allergen challenge on ET-1 in BAL, and contrary to expectations found a 
reduction in BAL ET-1 10 minutes after challenge, compared with sham challenge with 
saline. It was speculated that allergen challenge may lead to increased proteolytic activity
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with resultant breakdown of ET-1, although there is at present no direct evidence to 
support this. A similar finding has been observed in a study of BAL ET-1 in nocturnal 
asthmatics (127) in which a reduction in BAL ET-1 was observed during nocturnal 
symptoms, with similar speculations as to the mechanism. The influence on ET-1 
production of the local anaesthetic used in bronchoscopy is not known, although there is 
potential for this to be a confounding factor in bronchoscopic studies, since bronchial 
epithelial cells are an important source of ET-1 in the airways. We did not find a 
reduction in sputum ET-1 following allergen challenge, and although not attaining 
statistical significance, there was a trend towards a rise in sputum ET-1. Our sampling 
point at 30 minutes was chosen to reflect the immediate allergic reaction, and was a little 
later than that of Redington etal (130), which would have represented the earliest phase 
of immediate allergic reaction. The time course of ET-1 generation in response to 
allergen challenge is not known, although it is known that ET-1 appears not to be stored 
in granules in cells, but produced by rapid induction of ET-1 messenger RNA (mRNA), 
with synthesis and secretion of ET-1 within minutes in response to certain stimuli (8).
In this study 8 of the 12 asthmatics were taking inhaled steroid therapy (mean daily dose 
825 pig beclomethasone dipropionate or equivalent). It has been shown that treatment 
with steroids decreases bronchial epithelial expression of ET-1 in asthmatic patients 
(123), and although we did not observe such a difference comparing groups of 
asthmatics using induced sputum (291), it is possible that treatment could have an effect 
on the release of ET-1 in response to an appropriate stimulus. There was no clear 
difference between steroid-naive and steroid-treated subjects although the numbers are 
too small for formal analysis, and one steroid-naive subject did demonstrate a more 
pronounced rise in sputum ET-1 comparing allergen and placebo challenge.
As might be expected from our sampling time point, we found no immediate change in 
sputum total or differential cell counts or eosinophilic cationic protein (ECP). The 
immediate allergic response is primarily characterised by bronchoconstriction in the
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absence of significant airway inflammation, while the late response is thought to be due 
in whole or in part to airway inflammation (292). Sputum induction has been shown to 
be useful in assessing airway inflammation in the late allergic response (148), but 
inflammatory cellular or mediator changes would not be expected in the immediate 
response. The absence of a rise in sputum ET-1 following methacholine challenge 
suggests that ET-1 is not involved in the bronchoconstrictor response to methacholine. 
This was primarily included as a "positive control" which would induce 
bronchoconstriction as opposed to the placebo challenge which was not 
bronchoconstrictor. On this evidence, ET-1 release is not associated with 
bronchoconstriction per se.
The relationship which we observed between sputum eosinophilia at baseline (taken 
from the placebo visit, since this did not involve an active airway challenge) and the 
change in sputum ET-1 following allergen challenge may suggest that those subjects 
with the most prominent airway inflammation respond to allergen challenge by increased 
ET-1 production or release. This is supported by in vitro data from a study by Endo et al 
(293) showing increased release of ET-1 from cultured epithelial cells following co­
culture with eosinophils stimulated by lL-5 or GM-CSF, but not from unstimulated 
eosinophils. In additionET-1 synthesis by airway epithelial cells is upregulated by a 
number of proinflammatory cytokines (129), and as mentioned above, ET-1 is present 
in increased quantities in BAL from patients with symptomatic asthma (124). The 
immediate allergic reaction is accompanied by the release of histamine, prostaglandins 
and leukotrienes by activated mast cells (294), and both mast cells (295) and bronchial 
epithelial cells in some asthmatics (126) have the capacity to synthesise ET-1 in response 
to exposure to cross-linked IgE. There is insufficient information on the factors 
controlling ET-1 synthesis in the airways and their relationship to asthmatic airway 
inflammation, but it is possible to speculate that the influence of allergen on eosinophils, 
mast cells and possibly epithelial cells in the proinflammatory milieu of asthmatic airway 
inflammation might lead to increased ET -1 synthesis and release.
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In conclusion, we have found that it is possible to use induced sputum to measure ET-1 
following bronchial challenge tests, and that there is evidence for an increase in sputum 
ET-1 in the immediate allergic reaction at least in subjects with evidence of active 
asthmatic airway inflammation, and a trend towards an increase in the group as a whole. 
The influence of treatment on this response and the involvement of ET-1 in the late 
allergic reaction remain to be assessed.
CHAPTER 8
THE IMPACT OF SMOKING AND CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE 
(COPD) ON SPUTUM ENDOTHELIN 1
a) smokers with and without airflow 
limitation
b) acute exacerbation of COPD
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8.1 INTRODUCTION
The actions of ET-1 in the airway which prompted our investigations in asthma may be 
of relevance to diseases other than asthma, where bronchoconstriction, airway 
inflammation and airway remodelling are known to be a feature. Chronic obstructive 
pulmonary disease (COPD) is one such condition, with cigarette smoking as an obvious 
aetiological factor, and a number of the known properties of ET-1 could contribute to 
pathogenesis in COPD (figure 8.1). Like asthma, airflow obstruction is present in 
COPD, but unlike asthma this is not generally reversible by inhaled p-2 agonists. 
Similarly, airway inflammation is a feature of COPD, but whereas in asthma this is 
commonly (although not invariably) associated with a degree of airway eosinophilia, in 
COPD neutrophilia is predominant (180). There are no reports of airway production of 
ET-1 in COPD, and we wished to examine sputum levels of ET-1 in COPD, and the 
influence of exacerbation of COPD on sputum ET-1 levels. This chapter is therefore a 
combination of 2 studies, one baseline study examining sputum ET-1 levels in COPD 
compared with healthy smokers (baseline study), and the second a study examining 
sputum ET-1 in acute exacerbation of COPD and in convalescence (acute study).
Modest increases in plasma ET-1 have been reported following acute cigarette exposure 
in healthy smokers (296), but a pathological study did not find increased 
immunoreactive ET-1 staining in bronchial epithelial cells from smokers (297). There 
are however no reports of baseline levels of induced sputum ET-1 in smokers, so we 
chose to compare healthy smokers with smokers with COPD.
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Potential actions of endothelin-1 in COPD
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8.2 METHODS
Subjects 
Baseline Study
10 healthy smokers (3 male, 7 female) without symptoms of lung disease and 9 smokers 
with COPD (2 male, 7 female) were studied. Smokers were asymptomatic and COPD 
patients had stable symptoms at the time of the study, and none had suffered a 
respiratory infection, or had received antibiotics or oral corticosteroids in the month 
preceding the study visits. Smokers had no history of wheeze or shortness of breath, 
and baseline lung spirometry was within normal limits (taken as greater than or equal to 
70% of predicted FEVi in the absence of symptoms). The study was approved by the 
West Ethics Committee, West Glasgow Hospitals University NHS Trust, and each 
subject gave written informed consent.
Acute study
10 subjects with established COPD (6M, 4F) were recruited following admission to our 
unit with a stated diagnosis of an acute exacerbation of pre-existent COPD (5 current 
smokers and 5 ex-smokers). Entry criteria were established for an age group of 45 - 85 
years, with a known history of COPD (GP or hospital diagnosis), and a smoking 
history. At the time of presentation, subjects were required to have 3 or more of the 
following 5 criteria to suggest an acute exacerbation - increased cough, increase in 
sputum production, increased dyspnoea, fever (>38“C), and new chest X ray 
abnormalities. The study was approved by the West Ethics Committee, West Glasgow 
Hospitals University NHS Trust, and each subject gave written informed consent.
Protocol 
Baseline study
The study involved a single visit to the laboratory for blood sampling, salivary sampling 
and sputum induction, with spirometry monitored throughout the induced sputum
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procedure in the usual way. All subjects were pre-treated with salbutamol 200pig prior to 
sputum induction.
Acute study
Spontaneous sputum samples were obtained within 24 hours of admission to hospital in 
all cases (in most cases within 12 hours), and blood was sampled concurrently. Arterial 
blood gases were sampled as part of clinical management. Patients were managed 
according to clinical requirements (in all cases oral steroid therapy was started or 
increased, and antibiotics given), and a review visit was arranged for roughly 6 weeks 
after admission, or once symptoms had been stable for 3 weeks thereafter. At the review 
visit, spirometry and pulse oximetry were measured, blood sampled, and induced 
sputum performed following pretreatment with salbutamol 200pig, with spirometry 
monitored through the procedure.
Sputum induction
This was performed as described in chapter 2.3. Additionally, in the baseline study 
saliva samples were obtained prior to sputum induction to measure salivary levels of ET- 
1.
Laboratory Processing
Sputum was processed as described in chapter 2.3, with the exception mentioned under 
biochemical assays, with the laboratory staff unaware of the clinical details relating to 
the sample.
Biochemical Assays
Endothelin was assayed as described in chapter 2.4, but in the acute study, due to a 
failed assay on the first attempt, sputum ET-1 was not able to be measured on sputum 
which had not been treated with the reducing agent dithiothreitol (DTT), and this was 
repeated on DTT-treated samples, with the result that the results are not directly
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comparable between the baseline and acute studies. Assays were run in duplicate with 
the mean value used for analysis.
Statistical Analysis
Results are expressed as median and inter quartile range unless otherwise specified. 
Non-parametric statistics were used to compare cell counts and ET-1 values (Mann- 
Whitney U test), and parametric statistics used to compare demographic factors. 
Significance was accepted at the 95% level.
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8.3 RESULTS - BASELINE STUDY 
Demographic factors and lung function
Healthy smokers were younger on average than subjects with COPD (Mean (SD) 39.8 
(9.0) years vs. 59.3 (7.4) years respectively), and had better lung function, whether 
expressed as mean (SD) absolute FEVi (2.63 (0.5) litres vs. 0.66 (0.1) litres 
respectively) or % predicted FEVi (89.1 (11.8) % vs. 26.9 (6.6) % respectively). 
Smoking history was greater for COPD patients (mean (SD) 50.9 (17.8) pack years) 
than for healthy smokers (mean (SD) 23.9 (16.2) pack years). Demographic data is 
presented in table 8.1.
Endothelin-1
Plasma ET-1
Plasma ET-1 was not different between healthy smokers and COPD patients (median 
(IQR) 4.35 (3.5-6.3) pg/ml vs. 3.3 (2.7-4.2) pg/ml respectively), but was greater in 
healthy smokers than that in healthy non-smokers (n=17) (median (IQR) 3.1 (1.7-4.4) 
pg/ml, p=0.042) (data for healthy non-smokers presented in chapter 9).
Sputum ET-1
As with plasma ET-1 there was no difference between healthy smokers and COPD 
subjects (median (IQR) 19.2 (15.3-25.6) pg/ml vs. 16.4 (6.8-38.2) pg/ml), but sputum 
ET-1 in both healthy smokers and COPD were greater than that obseiwed in healthy non- 
smokers (n=17) (median (IQR) 6.0 (2.8-14.8) pg/ml, p=0.004 and p=0.04 
respectively) (data for non-smokers presented in chapter 9) (figure 8.2). There was no 
significant relationship between sputum ET-1 and lung function in either healthy 
smokers or COPD subjects (Spearman rank correlation rs=0.1 and 0.36 respectively, 
p>0.05) (Appendix 8.1).
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Saliva ET-1
Median (IQR) salivary ET-1 was 29.9 (22.1-38.4) pg/ml for healthy smokers and 20.7 
(16.3-42.3) pg/ml for COPD subjects, which were not significantly different, nor were 
either different from values observed in healthy non-smokers (median (IQR) 28.8 (18.3- 
34.5) pg/ml) (data for healthy non-smokers presented in chapter 9).
Sputum cell counts
Sputum cell counts are summarised in table 8.2. Total cell counts were higher in COPD 
(median (IQR) 12.4 (4.9-23.0) xlO^ cells/ml) than in healthy smokers (median (IQR) 
3.7 (2.7-9.9) xlO^ cells/ml). There was sputum neutrophilia in COPD compared to 
healthy smokers, both in absolute cell counts (median (IQR) 9.7 (3.9-16.4) xlO^ 
cells/ml vs. 1.6 (0.5-5.4) xlO^ cells/ml respectively) and in relative cell counts (median 
(IQR) 78 (74-80) % vs. 38 (19-56) % respectively), with a consequent reduction in 
macrophage percentage (median (IQR) 2.6 (1.0-3.6) xlO^ cells/ml: 21 (18-24) %) in 
COPD compai'ed to healthy smokers (median (IQR) 2.1 (1.3-3.3) xlO^ cells/ml: 53 (42- 
80) %). Absolute eosinophil numbers were higher in COPD (median (IQR) 0.15 (0-0.3) 
xlO^ cells/ml: 1 (1-2)%) than in healthy smokers (0 (0-0.04) xlO^ cells/ml; 0 (0-1) %). 
There was no difference in sputum lymphocyte numbers between the groups. 
Comparing these results with normal subjects presented in chapter 9 revealed no 
differences in sputum total and differential cell counts between normal subjects and 
healthy smokers, but a significant neutrophilia in the COPD group compared to normals 
(median (IQR) 0.81 (0.31-3.57) xlO^ cells/ml: 24 (9-40) %), and increased sputum 
eosinophils in COPD compared to normal subjects (median (IQR) 0 (0-0) xlO^ cells/ml: 
0(0-0) %).
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Figure 8.2
Sputum ET-1 in healthy non-smokers (data presented formally in chapter 9), 
healthy smokers and subjects with stable COPD (baseline study)
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8 . 4 RESULTS - ACUTE STUDY 
Demographic factors, lung function and blood gas analysis
The mean (SD) age of the patients was 68.3 (9) years, with a mean (SD) smoking 
history of 45 (24) pack years. Mean (SD) FEVi in convalescence was 0.77 (0.4) litres 
(29.0 (12)% predicted). Mean (SD) arterial p02 was 9.0 (1.9) kPa (the majority of 
arterial blood gases were taken with the patient receiving supplementary oxygen) and 
mean (SD) arterial pC02 was 6.9 (2.1) kPa. Demographic data is presented in table 8.3.
Endothelin-1
Plasma ET-1 was not different comparing acute with convalescent visits (median (IQR)
5.5 (5.4-Ô.8) pg/ml vs. 5.2 (3.9-6.5) pg/ml. There was a mean reduction of 5.0 pg/ml 
in sputum ET-1 comparing convalescent with acute samples, but this was not significant 
(median (IQR) sputum ET-1 in exacerbation was 1.8 (0.6-12.4) pg/ml, compared with 
1.0 (0-2.0) in convalescence). In 4 patients there was a clear reduction in sputum ET-1 
from acute exacerbation to convalescence (figure 8.3), but there was no pattern of 
smoking history, sputum cell counts, lung function, co-morbidity or the presence or 
absence of arterial hypoxaemia which appeared to distinguish these patients. Comparing 
smoking and ex-smoking patients with COPD there were no differences in sputum ET-1 
either in exacerbation or convalescence (Appendix 8.2).
Sputum cell counts
Total cell counts were not different comparing acute exacerbation with convalescence 
(median (IQR) 14.7 (9-42) xlO^/ml vs. 11.1 (8-23) xlO^/ml respectively). As would be 
expected in COPD, there was a significant sputum neutrophilia (median (IQR) sputum 
neutrophils 12.1 (5-36) xlOVml: 81.5 (73-90)% in acute exacerbation) with no 
significant reduction in neutrophilia in convalescence (median (IQR) 9.1 (6-19) xlO^/ml:
76.5 (69-82)%). There were no differences in sputum macrophages, eosinophils or 
lymphocytes comparing acute and convalescent samples (table 8.4).
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Figure 8.3
Sputum ET-1 in exacerbation and convalescence in COPD
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8.5 DISCUSSION
We found no difference in plasma, sputum or salivary ET-1 levels comparing healthy 
smokers with smokers with established COPD. Both groups of smokers however had 
higher plasma and sputum ET-1 than healthy non-smoking controls, suggesting that 
cigarette smoke may result in increased ET-1 production. Sputum ET-1 levels were 
higher than plasma levels in both groups, suggesting local production of ET-1 within the 
respiratory tract. In the acute study, although some individuals had a reduction in 
sputum ET-1 from acute exacerbation to convalescence, there was no significant overall 
difference in sputum ET-1 comparing acute and convalescent samples. Methodological 
differences in sputum processing resulting from the loss of sputum samples in a failed 
assay mean that comparison between the studies is not possible.
The available data on the impact of cigarette smoke on ET-1 production is neither 
complete nor entirely consistent. An animal study (abstract only) has shown an acute 
dose-dependent increase in plasma ET-1 following experimental exposure to cigarette 
smoke in rats, which is sustained for several days after a single smoke exposure (298).
In humans the effect is less pronounced, with a very modest rise in plasma ET-1 after 
acute smoke exposure, which is short-lived (around 10 minutes), related in magnitude to 
the "strength" (high tar vs. low tar) of the cigarette (296), and not related to nicotine per 
se , since the topical administration of nicotine by a transdermal nicotine patch did not 
increase plasma ET-1 in non-smokers (299). In contrast, although bronchial epithelial 
cells are known to produce ET-1, a study by Shokeir eta l (297) examining samples 
from lobectom y/pneum onectom y specimens found no increase in ET-1 
immunoreactivity comparing bronchial epithelial cells from smoking and non-smoking 
subjects. The same study examined a small number of samples from smokers with 
evidence of bronchial hyperreactivity to methacholine prior to surgery, and similarly 
found no increased imniunostaining for ET-1 in this group. It is difficult however, to 
relate this pathological finding directly to the in vivo situation, since immunostaining is
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not quantitative for ET-1 production, and it is possible that the determinant of airway 
ET-1 levels is not the number of cells which are positive on staining, but the amount of 
ET-1 which they produce. Additionally, the majority of samples used in the Shokeir's 
study were from patients with lung tumours, and an effect on ET-1 production at distant 
sites in the lung cannot be excluded, since increased ET-1 immunostaining has been 
reported in airway epithelium adjacent to tumours (300). In the acute study described in 
this chapter we did not find any difference in sputum ET-1 between current smokers or 
ex-smokers with COPD, suggesting that the effect of smoking on ET-1 production 
persists regardless of continuing smoking, at least in established COPD. More work is 
needed to establish the effect of smoking on ET-1 production, and the mechanisms by 
which it has any effect. We are not aware of any studies examining airway production of 
ET-1 in COPD, either by sputum induction or by bronchoalveolar lavage.
Cigarette smoke is a complex mixture of over 4,000 chemical compounds, which has 
the capacity to damage the bronchi in a number of ways including direct toxicity to the 
bronchial epithelium, oxidative damage, recruitment of inflammatory cells and increased 
epithelial permeability (301). Cigarette smoking results in airway inflammation, with 
cigarette-dose related increases in BAL neutrophils and macrophages, along with a 
number of pro-inflammatory cytokines including lL-8 (286), and in smokers with 
airway limitation, the extent of the airway limitation has been shown to be related to the 
extent of the airway inflammation (302), and to the smoking history (180). We found a 
significant sputum neutrophilia in both stable and acute COPD groups, although in these 
studies the extent of the neutrophilia did not correlate significantly with their lung 
function. While there is no evidence that neutrophils can synthesise ET-1 per se, 
neutrophils may be able to influence local levels of ET-1, since they can convert the ET- 
1 precursor big-ET-i to the more biologically active ET-1 (303). Bronchial epithelial 
cells (52), neuroendocrine cells and human macrophages (48), can all synthesise ET-1 
de novo, and the presence of increased neutrophil numbers and activity could increase 
available ET-1 by increasing conversion from big-ET-1 to ET-1.
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In the acute study we did not observe any reduction in neutrophil numbers or proportion 
in response to treatment with antibiotics and oral corticosteroids, similar to a report of an 
elective trial of oral corticosteroids in COPD, where induced sputum eosinophilia was 
reduced if present, but no change was observed in neutrophils (304). Other studies in 
COPD have observed similar levels of sputum neutrophilia (180), and it has also been 
demonstrated that the cellular profile of sputum in COPD is not different comparing 
induced and spontaneous sputum samples (224). The studies described in this chapter 
include both spontaneous and induced sputum samples, and we did not observe 
differences in cell counts between these samples. Although sputum induction has been 
shown to be safe in severe asthma (218), bronchoconstriction can occur, and in the 
setting of an acute exacerbation of COPD with severe impairment of lung function we 
chose to use spontaneous sputum samples rather than induced.
The study examining sputum ET -1 in acute exacerbation of COPD did not demonstrate 
increased ET-1 in all patients, although a subgroup of patients did demonstrate a fall 
following treatment and recovery. One possible confounding factor in this is the effects 
of corticosteroids, either inhaled or orally administered, since corticosteroids are known 
to inhibit ET-1 production in vitro (47), and to diminish ET-1 in BAL (124) and ET 
immunoreactivity in bronchial biopsies (123) in asthma. Sputum samples in the acute 
study were obtained after oral corticosteroids had been started, albeit within around 12 
hours in most cases, but since ET-1 is produced by rapid induction of ET-1 messenger 
RNA, (8), and is extensively cleared by the lungs during first passage (9), the effect of 
oral corticosteroids may have diminished airway expression of ET -1 in the airway prior 
to sampling.
The potential for interaction between ET-1 and nitric oxide (NO) also merits 
consideration in the context of cigarette smoking. Exhaled NO is reduced in smokers 
(305), but the mechanism for this is not yet clear. Cigarette smoke itself contains high
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concentrations of NO, which may inhibit NO synthase (306), and smoke may inhibit 
NO synthase gene expression (307). Similarly, ET-1 can inhibit the expression of 
inducible NO synthase and NO release in rat bronchial epithelium (264), but it is also 
postulated that the bronchoconstrictor effects of ET-1 may be balanced to some degree 
by bronchodilator effects of NO (308), and there is animal evidence for NO release in 
response to ET a receptor activation in the airway (309). In the vascular system, similar 
reduction of NO production has been observed in smokers, with enhanced 
vasoconstriction to exogenously administered ET-1 following acute smoking in long­
term smokers (310). If the balance between ET-1 and NO is important in the 
maintenance of aii*way tone, the effects of cigarette smoke in reducing NO release while 
increasing ET-1 release could lead to bronchoconstriction, even at normal or modestly 
elevated levels of ET-1.
The obseiwation of increased sputum ET-1 in cigarette smokers with or without airflow 
limitation requires further investigation, since the mechanism of the increase in ET-1 is 
not known. There is potential for interaction between ET-1 and NO, with possible 
potentiation of the bronchoconstrictor effects of ET-1. Exacerbation of COPD does not 
appear to be consistently associated with acute elevation of sputum ET-1, although this 
is seen in some patients, and may be influenced by concurrent administration of 
corticosteroids.
CHAPTER 9
SPUTUM ENDOTHELIN-1 IN CYSTIC
FIBROSIS
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9.1 INTRODUCTION
As discussed in previous chapters, the properties of ET-1 in the lung include 
bronchoconstriction, mitogenesis and pro-inflammatory activity, with resultant 
speculation about a potential role for ET-1 in airway diseases. The finding of a modest 
elevation of ET-1 in chronic obstructive pulmonary disease (COPD) has been described 
in chapter 9, and we speculated also that ET-1 might have a pathogenic role in cystic 
fibrosis, another condition which affects the airways. Cystic fibrosis (CF) is 
characterised by recurrent infection leading to the development of bronchiectasis, and by 
peribronchial and peribronchiolar fibrosis leading to airway remodelling with airflow 
obstruction. Like COPD, sputum neutrophilia is characteristic. While most patients with 
CF will over the course of their disease demonstrate a variable degree of reversibility to 
bronchodilators (311), progression to fixed airflow obstruction with associated 
secondary fibrosis is expected. Cell proliferation rates may be very high in CF airways 
(312), although the growth factors which may be associated with cellular proliferation in 
CF remain to be fully characterised.
The objectives of the study were to establish whether ET-1 could be measured in the 
sputum of CF patients, to compare the levels of ET-1 in sputum, saliva and plasma, and 
to compare levels of ET-1 between CF patients and normal subjects.
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9 .2  METHODS 
Subjects
12 CF patients (7M, 5F) attending the West of Scotland Adult Cystic Fibrosis Unit were 
studied, in comparison with 17 healthy volunteers (lOM, 7F) (table 9.1). None of the 
CF patients or healthy subjects were smokers. Informed written consent was obtained 
from all subjects, and the study was approved by the West Ethics Committee, West 
Glasgow Hospitals University NHS Trust.
Protocol
The study involved a single visit to the unit for consent and to obtain the samples of 
blood, sputum and saliva. Spontaneous sputum samples were obtained from the CF 
patients, and sputum induction using 3% saline was performed on the normal subjects.
Laboratory Processing
Sputum plugs were processed as outlined in chapter 2.3, with the exception that samples 
from CF patients were incubated for 10 minutes with recombinant DNAse (50/^g/ml) 
(Genentech Inc., San Francisco, CA, USA) to reduce the viscosity of CF sputum due to 
its high DNA content (DNAse did not alter the ET-1 standard curve). Differential cell 
counts (Giemsa stained) are expressed after exclusion of squamous cells, which are 
taken to represent salivaiy contamination. The numbers of bronchial epithelial cells were 
in general very low (<2%) and these are excluded from cell counts. Endothelin-1 was 
assayed as described in chapter 2.4.
Statistical Analysis
Results are expressed as median and inter-quartile range unless otherwise specified. 
Non-parametric statistics were used to compare cell counts, ECP and ET-1 values 
(Mann-Whitney U test) using a software package (Minitab Statistical Software, Minitab
158
Inc, State College, PA, U.S.A.) on an Apple Macintosh desktop computer (Apple 
Computer Inc. Cupertino, CA, U.S.A.). Significance was accepted at the 95% level.
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9.3 RESULTS 
Patient Demographics
Comparison of demographic factors reveals that the CF patients were younger on 
average than the normal subjects, and CF patients had lower baseline spirometry than 
normals, with a mean (S.D.) FEVi of 44.2 (22)% predicted and 98.8 (9.66)% predicted 
respectively (table 9.1).
Sputum Cell Counts
Absolute and relative sputum cell counts are expressed after exclusion of squamous and 
bronchial epithelial cells and summarised in table 9.2. Absolute and relative sputum 
neutrophilia is present in both CF compared with normal subjects, with CF neutrophil 
counts exceeding those described in chapter 8 for COPD (p<0.05). There is a 
corresponding reduction in relative macrophage numbers in CF compared with normal 
subjects.
EndotheIin-1
Assay
Recovery of ET-1 from sputum samples averaged 68% (n=2), and coefficient of 
variation for the ET-1 assay in sputum was 11.4%. DNAse had no effect on the ET-1 
standard curve.
Plasma and saliva ET-1
Levels of ET-1 were examined in the plasma of all normal subjects and 10 patients with 
CF, and in saliva from 10 CF patients and a sub-group of 8 normal subjects (table 9.3). 
Plasma levels were mildly elevated in CF compaied to normals (median (IQR) 5.3 (3.2- 
6.0) pg/ml vs 3.1 (1.7-4.4) pg/ml).There was no difference in median (IQR) salivary 
ET-1 between CF (21.0 (10.9-32.3) pg/ml) and normals (28.8 (18.3-34.5) pg/ml) 
although in both groups salivary ET-1 is greater than plasma ET-1.
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Sputum ET-1
Sputum ET-1 was measured in all subjects, and was markedly elevated in CF compared 
to normals (median (IQR) 77.6 (29.0-122.8) pg/ml vs. 6.0 (2.8-14.8) pg/ml 
respectively) (figure 9.1). We found no direct correlation between the sputum ET-1 and 
FEVi in CF, nor between plasma and sputum ET-1. In CF sputum ET-1 is greater than 
in saliva, whereas in normals the converse is tme, reflecting differences in sputum ET-1 
rather than saliva ET -1.
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Table 9.2
Absolute and relative median (IQR) sputum cell counts for normal 
subjects and subjects with cystic fibrosis. Values expressed after  
exclusion of squamous and bronchial epithelial cells.
Normals _____ Cystic fibrosis
absolute cell
counts (xlO<>/ml)
total count 6.9 (2.4-11.3) 35.2 (16.0-53.6)*
neutrophil 0.8 (0.3-3.6) 30.8 (14.7-52.2)*
macrophage 5.8 (1.5-7.3) 2.1 (0.9-6.3)
eosinophil 0.0 (O.O-O.O) 0.0 (0.0-0.7)
lymphocyte 0.03 (0.0-0.2) 0.0 (0.0-0.3)
relative cell
counts (%)
neutrophil 19.0 (6-35) 92.0 (88-95)*
macrophage 81 (65-90) 6.5(5-10)t
eosinophil 0 (0-0) 0.0 (0-1)
lymphocyte 2 (0-4) 0.0 (0-0.3)
key - * greater than normals t  less than normals (p<0.05)
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Table 9.3
Endothelin-1 in Sputum, Saliva and Plasma (median (IQR))
Sputum Saliva Plasma
Normal 6 .0 2 8 .8 3 .1
(2.8-14.8) (18.3-34.5) (1.7-4.4)
Cystic Fibrosis 9 3 .6 * 2 1 .0 5.3*
(59.6-142.6) (10.9-32.9) (3.2-6.0)
key significantly greater than normals
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Figure 9.1
Sputum ET-1 in normal subjects and subjects with cystic fibrosis 
* p<0.05
9.4 DISCUSSION
We have demonstrated for the first time that it is possible to measure ET-1 in the sputum 
of patients with CF, and that sputum levels of ET-1 are significantly elevated in CF 
compared with nonnal subjects. Plasma ET-1 is mildly elevated in CF compared to 
normals, but much less so than sputum ET-1. Sputum induction allowed us to obtain 
sputum from normal subjects for comparison. Our CF patient group was sampled 
during a period of relative stability of symptoms, but although they had a wide range of 
impairment of lung function (FEVi 19-79% predicted), none had normal lung function, 
and as might be expected from their average age they represent a group with established 
disease. Differential cell counts show a prominent sputum neutrophilia in CF.
The presence of ET-1 in sputum and saliva at higher concentration than plasma in both 
groups suggests that ET-1 is produced or released locally within the respiratory tract, as 
demonstrated in other chapters for other patient groups, with an increase in production 
or release in the lower respiratory tract in CF compared to normal subjects. The factors 
leading to this increase in ET-1 in CF are not known. ET-1 is present in normal lung, 
and ET-1 immunoreactivity has been demonstrated in airway epithelia and submucosal 
glands throughout the lung (56) as well as in airway smooth muscle and 
parasympathetic ganglia in the airways (54). Release of ET-1 has been described from 
bronchial epithelial cells (52), neuroendocrine cells and human macrophages (48), and 
although human neutrophils can convert big-ET to ET-1 (303), there is no evidence that 
neutrophils can synthesise ET-1 de novo.. Increased ET-1 has been described in 
bronchial biopsy (122) and bronchoalveolar lavage (BAL) (124) in asthma, but we are 
not aware of any report of increased ET-1 in BAL, biospy or sputum in CF.
Spontaneous sputum was obtained from the CF subjects, but normal subjects do not 
expectorate spontaneous sputum, and sputum induction was therefore performed in 
these subjects. While it is accepted that spontaneous and induced sputum are not
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identical in all respects, and that formal comparison of sputum ET-1 between 
spontaneous and induced sputum has not been reported, it has been demonstrated that 
total cell counts and measurement of soluble factors in sputum have good agreement 
between spontaneous and induced sputum (214), with better cell viability in induced 
sputum samples. The same study found increased numbers of squamous cells in 
spontaneous sputum, but this should be minimised by sputum plug separation to limit 
salivary contamination. The fact that sputum ET-1 levels were higher in sputum than 
saliva in CF suggests that salivary contamination is not responsible for the elevated 
levels of ET-1 in CF sputum. Sputum samples from CF subjects were treated with 
DNAse to facilitate processing of the unusually viscous sputum produced in CF, and 
while we did not use DNAse for normal samples, we tested for an effect of DNAse on 
the ET-1 assay, and found that DNAse did not alter the standard curve for the assay.
Saliva levels of ET-1 were greater than plasma levels in both groups, and although 
immunoreactivity to ET-1 has been demonstrated in rat parotid gland and human saliva 
(284), no physiological explanation for this has been offered.
ET-1 is a potent bronchoconstrictor in human bronchi in vitro (60), and we have 
previously demonstrated that inhaled ET-1 has bronchoconstrictor activity in asthma 
with bronchial hyperreactivity to ET-1 in asthmatics compared with normal subjects 
(Chapter 3) (275), supporting a putative role for ET-1 as a mediator in asthma. In CF, 
bronchial hyperresponsiveness to methacholine has been demonstrated in 50 to 77% of 
patients (313), and although the response to bronchodilators is less predictable than in 
asthma, many patients with CF are treated with bronchodilators (311), including 8 of the 
CF patients in this study. While the mechanisms of airway narrowing in asthma and CF 
may differ, the presence of a bronchoconstrictor with the potency of ET-1 at increased 
concentration in the sputum of patients with CF merits further investigation.
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Activity of a number of inflammatory and growth factors has been described in CF 
lungs. Among other cytokines, tumour necrosis factor-alpha (TNF-a) and its receptor 
(314) are elevated in BAL fluid in CF. In normal lung tissue TNF-a increases the 
expression of ET-1 in bronchial epithelial cells (315), and TNF-a release is itself 
increased by ET-1 (100). ET-1 has been shown to be mitogenic for airway smooth 
muscle by a number of mechanisms both in vitro and in vivo (74) in animal studies. The 
precise nature of the various interactions between growth factors is by no means clear, 
nor are the cellular sources and identity of other potential mediators of peribronchial 
fibrosis and airway remodelling known. The presence of ET-1 in increased 
concentration in CF airways suggests that further investigation of its role in 
bronchoconstriction and airway remodelling is justified, and potential interactions of ET- 
1 with other growth factors in CF remain to be clarified.
CHAPTER 10
CONCLUSIONS
168
10 - CONCLUSIONS
10.1 PRINCIPAL FINDINGS
This series of studies is the first to demonstrate in vivo bronchoconstrictor activity of 
ET-1 in humans, and in particular asthmatics, confirming the presence of bronchial 
hyperreactivity to ET-1 in asthma, and the potency and prolonged activity of inhaled ET- 
1 as a bronchoconstrictor. Extending our exploration of the bronchoconstrictor activity 
of ET-1 in asthma in vivo, we found no evidence of an immediate inflammatory reaction 
following ET-1-induced bronchoconstriction in asthma, and no potentiation of ET-1- 
induced bronchoconstriction by another bronchoconstrictor peptide angiotensin II. We 
have demonstrated for the first time that ET-1 can be measured in sputum obtained by 
sputum induction, although we did not find a difference in sputum ET-1 levels 
comparing asthmatic and non-asthmatic subjects, nor any difference in sputum ET-1 
comparing asthma in acute exacerbation and in recovery. Following allergen challenge 
we found a trend towards an increase in sputum ET-1 in those subjects who also had 
increased sputum eosinophil proportions, suggesting an association between airway 
inflammation and ET-1 release in response to allergen. Sputum ET-1 is increased in 
sputum from smokers and from subjects with COPD, with a trend towards a reduction 
in response to treatment in acute exacerbation of COPD, and sputum ET-1 is very 
markedly increased in patients with cystic fibrosis. These findings are both novel and 
exciting, and although this area of research is in its early stages, they suggest that ET-1 
may have an important role in a number of airway diseases. The technique of sputum 
induction allows non-invasive measurement of ET-1, and demonstration of the use of 
ET-1 as an inhaled bronchial challenge test may provide the basis for initial exploration 
of the utility of ET-1 antagonists in asthma.
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10.2 STRENGTHS AND WEAKNESSES INHERENT TO THE STUDIES 
AND IN RELATION TO OTHER STUDIES
The initial studies explored the bronchoconstrictor activity of ET-1 given by aerosol 
(chapters 3, 4 and 5). The first study demonstrated that ET-1 given by aerosol is a 
highly potent, reproducible bronchoconstrictor with a prolonged duration of action. The 
study was randomised, blinded, and had a positive (bronchoconstrictor) control. We 
used the technique of constant volume body plethysmography to make measurements of 
specific airway resistance (SGaw), which is one of the most accurate methods available 
of assessing airway tone. This allowed us to measure accurately the changes in airway 
resistance which occurred as a result of inhalation of ET-1, and in addition to relate the 
increase in resistance to the decrease in FEVi, which is a robust, but much less sensitive 
test of airway function. The use of the piethysinograph is however much more time 
consuming than simple spirometry, and having taken the dual end-points of changes in 
SGaw and FEVi for the first study we were then able to use spirometry for subsequent 
studies. Reassuringly, we found ET-1-induced bronchoconstriction to be repeatable 
when comparing 2 challenge tests in the same subjects. Dose-dependent 
bronchoconstriction was observed in all the asthmatic subjects, although the high cost of 
ET-1 prevented us from extending the dose range high enough to observe 
bronchoconstriction in non-asthmatic subjects and therefore prevented quantification of 
the difference in sensitivity between asthmatic and non-asthmatic subjects. The cost of 
ET-1 together with the relative inefficiency of nébulisation also meant that we could only 
study limited numbers of patients for these studies, which in turn prevented exploration 
of certain aspects of the bronchoconstrictor activity of ET-1. We did not differentiate 
between atopic and non-atopic asthmatics, although it would have been interesting to do 
so, since a paper by Riccio etal (114) shows differences in the responses of the nasal 
mucosa to exogenous ET-1 in atopic rhinitis compared with normal subjects, but there is 
little data examining any relationship between atopy and ET-1 production or responses 
in atopic and non-atopic asthma (although genetic linkage studies have looked for
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relationships between ET-1 gene polymorphisms and atopy and asthma (316)) In 
addition, although there were no apparent differenees in bronchial reactivity to ET-1 in 
the three bronchoconstrictor studies between asthmatics grouped according to treatment, 
we did not specifically examine any effect which treatment with inhaled corticosteroids 
or other therapy might have on bronchial responsiveness to ET-1. While corticosteroids 
are known to affect the basal production of ET-1 from bronchial epithelial cells and 
macrophages (317), there is no data to indicate the effect of corticosteroid therapy on 
bronchial responsiveness to ET-1. Assessment of this could however be time- 
consuming, since effects of inhaled corticosteroids on bronchial hyperreactivity to other 
spasmogens can take several months to reach a plateau (318), although it would be 
interesting to combine this with an assessment of the effect of inhaled corticosteroids on 
ET-1 production in asthmatics over time. Other than in a research setting, the high cost 
of ET-1 would make it an unlikely choice for use in routine bronchial challenge testing, 
unless it were found to be significantly more disease-specific than currently available 
substances.
The second study examining airway cellular and mediator responses to ET-1-induced 
bronchoconstriction showed no acute change in sputum cell types, levels of the pro- 
inflammatory cytokines TNF-a and IL-1(3, nitrite or albumin production at 30 minutes 
and 4 hours after bronchoconstrictor challenge with ET-1. The study was blinded, 
plaeebo controlled, and randomised for order. While it is tentatively possible to conclude 
from the data that ET -1 given by inhalation does not exert an immediate proinflammatory 
influence in the airways, this study is limited in a number of ways. One of the 
limitations of the use of induced sputum is the quantity of fluid available for analysis, 
particularly if the technique of separation of the viscid portion of the sputum ("plug 
separation") is employed, as we have done. While there are advantages in plug 
separation which are discussed in ehapter 1.3, and reinforced by our finding of higher 
levels of ET-1 in saliva than in sputum in chapter 6, the available volume of sputum on 
which all analyses must be carried out may be less than 1 ml, and this is further reduced
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by the processing involved in obtaining a differential cell count, with the result that only 
a limited number of assays or analyses can be carried out. Modern assay systems, 
particularly ELISA can operate on very small quantities of substrate, but most require at 
least 100 - 200 pi\ of sputum supernatant to ensure accuracy, and are routinely run in 
duplicate. As a result of this, it is possible to measure only a limited number of potential 
mediators, and in this study we were able to measure 4 parameters in addition to a 
differential cell count. These were chosen primarily to relate to known aspects of 
endothelin biology which could impact on asthma, but since work on the potential role 
of ET-1 in asthma is limited, the range of activity of ET-1 in relation to known mediators 
in asthma remains unclear, and the likely impact of administration of ET-1 on the loeal 
activity of markers and mediators such as eosinophilic cationic protein, IL-4, IL-5, GM- 
CSF and adhesion molecules for example, can only be the subject of speculation at 
present. The parameters measured were chosen carefully, but it is possible to argue that 
another combination of markers might give more information, or that other specific 
mediators might be a more accurate way of assessing similar processes. Similarly, the 
time points chosen to obtain sputum were intended to relate to a known property of ET- 
1, namely bronchoconstriction, rather than to all possible effects of ET-1. It is not 
known if ET-1-induced bronchoconstriction is associated with a late phase response 
such as that found with allergen, and in retrospect it would have been interesting to 
recall the patients after 24 hours to repeat sputum induction and spirometry at that time 
point, although that would introduce potential confounding factors, since repeat sputum 
induction has been shown to alter eellular proportions at 24 hours in both asthmatic and 
normal subjects (250, 251), with an increase in neutrophils characteristic (we found a 
trend towards an increase in neutrophils even at the 4 hour time point). It should be 
noted however that none of our patients reported symptoms suggestive of a late-phase 
response. Whatever the markers or time points chosen, this study represents a selection 
of individual responses at given time points, and eannot be used to suggest that ET-1 
does not exert proinflammatory activity in the airways. Indeed, the weight of evidence
172
from studies using ET antagonists would suggest that ET-1 may have an active role in 
inflammatory processes in the aimay.
The third bronchoconstrictor study reported data suggesting that the bronchoconstrictor 
activity of inhaled ET-1 is not potentiated by the presence of an infusion of angiotensin 
(Ang) II at sub-bronchoconstrictor levels. The study was placebo-controlled double­
blind and randomised, with appropriate time intervals allowed for Ang II infusions to 
reach steady state, the patients remained reeumbent throughout to prevent posture 
altering circulating Ang II levels, and the technique of ET-1 inhalation as a challenge test 
had been proved by prior work. The finding was contrary to our expectations based on 
previous in vitro work with ET-1 by Nally et al (261) from our own group, and 
although the data appears clear, this does merit investigation. The paper by Nally et al 
(261) reports potentiation by Ang II in bovine tissue, although some work was done by 
the same authors with a small number of human samples, apparently with similar results 
(unpublished - personal communication). Nonetheless, the possibility of species 
differences does exist, and since there is data to suggest that the mechanism of 
bronchoconstriction is different comparing humans with other species (60, 85), it is 
reasonable to speculate that interactions with other spasmogens may also differ between 
species. Potentiation by Ang II of bronchoconstriction induced by methacholine in the 
human both in vitro and in vivo has been reported by Millar et al (272), but no such 
interaction was found with histamine (319), suggesting that differences exist between 
spasmogens even within one species. The in vitro study by Nally et al (261) 
demonstrating potentiation of ET-1-induced contraction by Ang II was carried out using 
supraphysiological concentrations of Ang II, which might also account for differences 
between in vivo and in vitro findings. Direct comparison with the study by Millar etal 
(272) whi ch showed potentiation by Ang II of m ethacholine-induced 
bronchoconstriction indicates that we achieved similar plasma levels of Ang II, 
suggesting that there was no deficit in the amount of circulating Ang II, although in both 
studies the plasma levels of Ang II are lower than that observed in acute severe asthma
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(119), and lower than the in vitro studies. A clear effect on blood pressure was also 
observed in response to Ang II, confirming the biological activity of the Ang II being 
used. The study was carried out with identical methodology to Millar's study, which 
suggests that differences in results between ET-1 and methacholine are not due to 
methodological differences, lending credence to our findings, despite the in vitro data in 
bovine tissue with a contrasting result. Clearly, regulatory mechanisms may exist in the 
in vivo setting which are not active in vitro, and differences between laboratory and 
clinical data should not be unexpected. We studied a group of asthmatics with mild 
stable disease, and it would be interesting particularly to examine responses in patients 
with more severe asthma, since the presence of active airway inflammation might 
contribute to interactions between bronchoconstrictor substances which are not present 
in stable asthma.
The remaining studies (chapters 6 - 9 )  report the measurement of ET-1 in induced 
sputum (or in some cases spontaneous sputum), and although we found that ET-1 can 
be measured in sputum in a number of subject groups and that the measurement 
technique is sensitive to differences between groups, the application of the assay 
techniques to sputum is new. There are potential confounding influences, some of 
which are specific to ET-1, some to the use of sputum and some of which would apply 
to any measurement and processing techniques. As indicated in chapter 1.3, induced 
sputum is not identical to bronchial washing or BAL, and does not give the same 
information as bronchial biopsies in the assessment of airway inflammation and 
mediators. The technique is newer than some of the alternatives, and although much 
work has been done to establish its utility in the research setting, information is still 
accumulating about issues of methodology, processing of samples, and measurement of 
specific mediators. Our procedures for obtaining and processing the samples are widely 
used, and have been developed in collaboration with other centres, particularly that of 
the group under the direction of Professor F. Hargreave at McMaster University, 
Ontario, Canada, but there is as yet no universal agreement about methodology in this
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area. In addition, there are methodological issues relating specifically to ET-1 
measurement. The reducing agent dithiothreitol (DTT) is commonly used in the 
processing of sputum samples, but we found that DTT appears to have an effect the 
measurement of ET-1 by radio-immunoassay (RIA). The exact nature of this is not 
clear, since an effect was apparent with pure ET-1 mixed with DTT, but not so apparent 
with sputum samples mixed with DTT, and reverse-phase high performance liquid 
chromatography (RP-HPLC) did not suggest disruption of the ET-1 molecule by DTT. 
This problem merits further investigation, but we chose to process samples for ET-1 
measurement in the absence of DTT, with the exception of those samples affected by an 
assay failure as stated in the relevant chapters, where we only had DTT -treated samples 
remaining (the results of which were not compared with results from non-DTT-treated 
samples). DTT is widely used in the processing of sputum, and although some authors 
have tested to see if it has an effect on the mediator being measured or on its assay, this 
is not universal. Sputum samples for ET-1 measurement were transported to the 
laboratory on ice, but we did not pre-treat the samples with pro tease inhibitors, since 
their effect on subsequent assays is not known, and we cannot rule out the loss of some 
ET-1 activity in transit and preparation time. Pathological samples do not allow easy 
quantification of the levels of ET-1 in bronchial biopsies, and PCR is at best semi- 
quantitative, so it is difficult to relate levels of ET-1 in sputum (or BAL) to tissue levels 
in health or disease. As mentioned in chapter 1, there is evidence to suggest that the 
majority of the ET-1 produced by tracheal epithelial cells is released basally, with only a 
small proportion being released luminally (11), and if the same is true in the bronchial 
epithelium, assay of bronchial secretions may under-represent the concentration of ET-1 
being produced in the lung, and in addition, because of the relative proportions of basal 
and luminal release, a large change in basal secretion of ET-1 may be reflected only by a 
small change in the luminal concentrations of ET-1, rendering the assay of ET-1 in 
bronchial secretions relatively insensitive to changes in local production of ET-1. The 
influence of disease on the polarity of ET-1 release has not been explored, and the extent 
to which this might alter is unknown, and although it is assumed that the proportion of
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ET-1 released luminally will be consistent relative to the total productions, this is not yet 
known. These questions are speculative, and other influences such as epithelial damage 
in disease could in fact amplify changes in sputum or BAL, but further investigation of 
the factors influencing ET-1 release and measurement is warranted.
Chapter 6 reports the measurement of sputum ET-1 in mild stable asthmatics compared 
with normal subjects (baseline study), and in acute severe asthma in exacerbation and in 
convalescence (acute study). Asthmatics were identified on the basis of symptoms and 
bronchial hyperreactivity in the baseline study, and entry criteria established for the acute 
study to try to ensure the presence of acute severe asthma. In the baseline study we 
performed ET-1 assay on blood, saliva and sputum samples, and were able to show 
differences between these three fluids, indicating local production in the upper and lower 
respiratory tract. We also confirmed the presence of ET-1 in sputum samples by RP- 
HPLC. The finding of higher levels of ET-1 in saliva than in sputum supports the use of 
sputum plug separation in the processing of induced sputum. The fact that we did not 
find a difference in sputum ET-1 between asthmatic and non-asthmatic subjects is in 
contrast to the findings of other investigators using BAL (124, 274), although elevation 
of BAL ET-1 is not invariable in asthma, an a study in nocturnal asthma reported a 
decrease at 4 am (127). The reasons for this difference are not known, and while it 
could be argued that induced sputum is somehow less effective at obtaining bronchial 
secretions that BAL, the levels of ET-1 which we observed in sputum were of a similar 
order of magnitude as those found in BAL allowing for dilutional effects in BAL, and 
data presented elsewhere in this thesis show that we have been able to measure quite 
high levels of ET-1 in sputum. While we could have strengthened this observation by 
the addition of BAL samples in the same group of patients, that would have involved the 
use of bronchos copie techniques, for which we did not seek ethical penuission. In the 
acute study we did not find a difference between sputum ET-1 in acute exacerbation and 
sputum ET-1 in convalescence, but the findings presented in the acute study are weaker 
than the baseline study in a number of ways, both avoidable and unavoidable. Firstly,
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delays in presentation and a preference by both patients and their General Practitioners to 
treat asthma exacerbations out of hospital meant that some patients included in the study 
had presented acutely to the accident and emergency services, while others had been 
treated at home for several days prior to admission. Even after they had been admitted to 
hospital, the acute admissions pattern in our institution meant that the majority of 
patients were not admitted directly to the care of the respiratory team, and together these 
factors made it impossible to control for the duration of the exacerbation prior to 
admission to hospital. Similarly, the fact that patients were not admitted directly to the 
respiratory team meant that we could not obtain sputum samples immediately on 
admission, although all samples were obtained within 24 hours of admission. Secondly, 
although entry criteria for the study were set to try to correctly identify patients with 
exacerbation of asthma, we could not control for treatment of the exacerbation prior to 
the sputum sample being obtained, and in particular this meant that we could not obtain 
samples prior to the administration of oral corticosteroids, which were given to all the 
patients in the study. It is known that the production of ET-1 is downregulated by 
glucocorticoids (317), and it is not possible to exclude an effect on sputum ET-1 which 
is the result of treatment with oral corticosteroids, masking an effect of the exacerbation 
perse. Thirdly, as stated above, we suffered a failure of the original ET-1 assay on the 
samples which were not processed using DTT, and were therefore forced to repeat the 
assay using DTT-treated samples. It is not possible to retrospectively quantify the effect 
of DTT on the assay system (if any), and this means that we are not able to compare the 
results from the acute study with other measurements of sputum ET-1. ET-1 
concentrations in the convalescent samples were lower than those observed in the 
baseline study, but we cannot tell if that is a result of the use of DTT, or if it results from 
differences in the patient groups, or differences in treatment, particularly the acute use of 
oral corticosteroids. The fourth main difficulty with the acute study is common to any 
study of acute severe asthma, namely that the patient group who present with acute 
severe asthma often represent a specific subgroup of asthmatics whose asthma is by 
nature unstable, difficult to manage, and subject to frequent alterations in therapy,
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particularly oral corticosteroids. Convalescent samples were obtained 6 weeks after 
admission or once "stable" for at least 3 weeks thereafter, but stability in this group of 
asthmatic patients is relative, and for some patients it would be more accurately 
described as "the absence of acute exacerbation". In addition, all of the patients were 
taking inhaled or oral corticosteroids, even in recovery, which could have influenced 
sputum ET-1 concentrations. The acute study was a carefully perfoimed, serious attempt 
to examine a possible role for ET-1 in acute severe asthma, but it was subject to 
avoidable and unavoidable limitations, and has fallen short of providing definitive data 
on the subject.
In chapter 7 we report the influence of allergen challenge on sputum ET-1 concentrations 
in stable asthmatics. The study was placebo controlled, randomised and performed in a 
single blind manner, since the operator had to monitor dose increments in the 
administration of allergen. An important aspect of the study design is the timing of the 
sputum sample, and as with many aspects of study design, several options could have 
been chosen. The release of ET-1 is not based on storage of ET-1 in secretory granules, 
but rather on rapid upregulation of protein synthesis with synthesis and secretion of ET- 
1 within minutes in response to certain stimuli (8). The study was designed to examine 
the possible contribution of ET-1 to bronchoconstriction in an allergic model of asthma, 
and therefore the sputum sample was obtained a relatively short time after the allergen 
challenge (30 minutes). It is recognised that sputum obtained at this time point will not 
reflect inflammatory changes resulting from allergen exposure, and this is reflected in 
the cellular data from this study, in which the only significant difference in sputum cell 
counts comparing placebo and allergen was a slight reduction in lymphocytes following 
allergen challenge. Animal work published after the study had started examining 
experimental eosinophilic airway inflammation suggests that although there is rapid 
upregulation of ET-1 mRNA, a rise in BAL ET-1 is not seen until 3 hours after the 
inflammatory stimulus, and peaks at 24 hours (289), suggesting that ET-1 may play a 
greater role in the induction and maintenance of airway inflammation than in the acute
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bronchoconstrictor response in this context. If this animal data were reflected the 
situation in asthma, a change in design might have resulted in different results in this 
study, but would also have reflected a different component of the response to inhaled 
allergen. In retrospect, repeat sputum induction at 12 or 24 hours might have helped to 
examine both immediate bronchoconstrictor response and any potential later 
inflammatory response, but would have been subject to the confounding factor of 
repeated sputum induction, as discussed earlier. We attempted to use the polymerase 
chain reaction (PCR) to demonstrate ET-1 mRNA expression from samples obtained in 
this study, but experienced technical difficulties, and are not able to present this data. 
PCR data if available would have strengthened the observations reported. Despite this, a 
rise in sputum ET-1 was observed in some patients, with a relevant correlate in terms of 
airway inflammation, and there is in vitro experimental data to support a mechanism for 
the observed increase in ET-1 through the effects of activated eosinophils (293). The 
study design could have been different, perhaps with "positive" results, but we are 
confident that the findings are sound, although limited to the acute situation.
Chapters 8 and 9 present data on the levels of sputum ET-1 found in smokers with and 
without airflow limitation, acute and convalescent COPD and in cystic fibrosis (CP). 
These studies are exploratory in nature, since there is little background data on the 
presence or role of ET-1 in these conditions, and the studies were motivated by 
speculation based on the known physiological properties of ET-1 and the 
pathophysiology of the conditions concerned. The considerations discussed above about 
the use of sputum induction to assess airway ET-1 apply here also, although there are 
some specific questions relating to the conditions studied.
In the studies examining ET-1 in smokers and COPD we examined a mixture of 
spontaneous and induced sputum, for reasons of practicality and also safety in acute 
exacerbation of COPD, and although there is evidence that the cellular profile of COPD 
sputum does not differ between induced and spontaneous samples (224), information is
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lacking about any influence on soluble mediators in sputum. There was no obvious 
difference in the COPD studies comparing induced with spontaneous samples 
comparing either sputum ET-1 or cell counts, but the studies were not designed to 
answer this question. The samples were of course processed in the same way, and 
assays performed identically, regardless of the method of obtaining the sample. It is not 
possible to assess on the basis of the data obtained whether those patients who were able 
to provide spontaneous samples (particularly for the acute study) somehow represent a 
different sub-group of COPD from those who did not, although our experience in acute 
severe exacerbation was that sputum production was almost universal, with very few 
patients failing attempted recruitment on the basis of failure to provide a sputum sample.
In the baseline study it was not practicable to match subjects on the basis of age and total 
smoking history, and the COPD group were older and had smoked more than the 
healthy smokers. However, the amount of cigarettes smoked per day is comparable in 
the 2 groups, and it is possible that similar levels of sputum ET-1 result from similar 
recent smoking history rather than from the cumulative effect of cigarette smoking. We 
have not examined the acute effect of cigarette smoking on sputum ET-1. Similarly, 
since the COPD group were receiving treatment and the healthy smokers were not, the 
effect of treatment could influence sputum ET-1 levels. In the COPD group, 7 of the 9 
patients were taking regular inhaled steroids, and as discussed above this could 
influence sputum ET-1 concentrations, with the possibility that ET-1 production is 
increased in COPD over and above the increase related to smoking, but suppressed to 
these levels by the influence of inhaled steroids. As discussed in relation to the acute 
asthma study in chapter 6, difficulties with an assay meant that we had to use sputum 
treated with DTT for analysis of the acute COPD study, making it impossible to compare 
values with stable COPD, and as in the acute asthma study, treatment was initiated prior 
to the sputum sample being obtained, which could have influenced sputum ET-1 levels. 
Despite these limitations, the acute study demonstrated a trend towards a fall in sputum 
ET-1 between exacerbation and convalescence. More work is needed to clarify the effect
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of smoking and any additional effect of COPD on airway production of ET-1, but these 
studies lay the basis for further work in this area.
We demonstrated a marked increase in sputum ET-1 in cystic fibrosis (CF) compared 
with healthy subjects, using spontaneous samples of sputum. In some respects this 
study is a break from the theme of the work presented here, since asthma and COPD are 
traditionally characterised as "airway diseases", while CF is recognised to consist of a 
variety of pathological processes, not confined to the airway. In practice, however, 
involvement of lung tissue other than the conducting airways is present in both asthma 
and COPD, and variable airflow obstruction is a common feature of CF (311), although 
there ar e of course substantial differences between the conditions and their causes. This 
study was the result of speculation about the potential for ET-1 to contribute to both 
bronchoconstriction and airway remodelling in CF, and followed from some pilot work 
in which the possibility of very high levels of ET-1 in sputum was raised. It is a 
descriptive study, reporting the presence of ET-1 in sputum, but in the absence of 
pathological examination it is only possible to speculate about the source of ET-1 in CF. 
The study group represent a population with a range of disease, although it includes 
those with advanced disease, and it would be interesting to examine sputum ET-1 levels 
in children with more mild disease, to try to establish if the release of ET-1 is secondary 
to lung damage, or a primary contributor to the process. We used the enzyme DNAse to 
allow measurements to be made with the extremely viscid sputum produced in CF, and 
although we demonstrated that this does not appear to influence ET-1 assays, more 
work is needed to establish methodology for the use of sputum in CF.
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10.3 POSSIBLE MECHANISMS AND IMPLICATIONS FOR PATHO­
PHYSIOLOGY AND TREATMENT
Asthma
The bronchoconstrictor activity of ET-1 in asthma has been established, with the 
demonstration of a potent, dose-dependent and prolonged effect following the 
administration of exogenous ET-1. The studies examining the bronchoconstrictor effect 
of ET-1 do not give direct information about the mechanism of action, although it is 
possible to speculate that ET-1 may act as a direct bronchoconstrictor on the basis of the 
relationship between bronchial reactivity to ET-1 and methacholine in asthma. It is not 
yet known if the bronchoconstrictor action of ET-1 is specific to asthma since we were 
not able to provoke bronchoconstriction in normals with the dose range used, and 
further work will be needed to examine responses to exogenous administration of ET-1 
in normals and in subjects with other airway diseases. If the bronchoconstrictor activity 
were specific to asthma, then despite the high cost of ET-1 there would be the potential 
to use it as a diagnostic test, perhaps initially for research rather than clinical purposes. 
Demonstration of the activity, potency and duration of bronchoconstriction of ET-1 in 
asthma strongly supports a potential role for ET-1 in the pathophysiology of the disease, 
quite apart from the other potential actions of ET-1 which could contribute to asthma. In 
the studies examining induced sputum ET-1, although we did not find elevated levels in 
stable asthmatics compared with normal subjects, the concentrations of ET-1 which we 
measured in sputum were at least as high (and in most cases higher) than the doses 
required to produce bronchoconstriction when given exogenously in asthma, even when 
the inefficiencies of nébulisation are taken into account. This would suggest that subject 
to regulatory mechanisms, the levels of ET-1 present in the airway even in stable asthma 
are capable of exerting bronchoconstrictor activity. Asthmatic airways have increased 
sensitivity to the bronchoconstrictor effects of ET-1, and in this setting, even normal 
levels of ET-1 may have unwanted effects, and investigation of the potential use of ET 
antagonists as bronchodilators or inhibitors of bronchoconstriction in asthma is justified.
182
ET-1-induced bronchoconstriction does not appear to be associated with an early 
inflammatory response in the airways as assessed by sputum induction up to 4 hours 
after administration, but several animal studies have demonstrated the ability of ET-1 
antagonists to modify inflammatory responses in the airway (290, 320), and more work 
is needed to clarify the mechanisms of this action, to examine the possible pro- 
inflammatory effects of inhaled ET-1 at later time points and to investigate the possibility 
that ET antagonists might have anti-inflammatory activity in asthma. We did not find 
potentiation of ET-1-induced bronchoconstriction by Ang II in asthma, although sub- 
bronchoconstrictor doses of Ang II were deliberately chosen, with resultant plasma 
levels of Ang II which were lower than that observed in acute severe asthma (273), so it 
is not possible to rule out an effect in acute severe asthma which we did not demonstrate 
in our study. We have shown that it is possible to use the non-invasive technique of 
sputum induction to obtain fluid to measure ET-1 in asthmatic and non-asthmatic 
subjects, with higher concentrations of ET-1 in sputum and saliva than in plasma, 
suggesting local production in the respiratory tract, in keeping with evidence that ET-1 
tends to have predominantly autocrine or paracrine activity. We did not find an increase 
in sputum ET-1 in acute severe asthma, nor therefore a fall in response to treatment, 
although this study was limited as discussed above, and it is difficult therefore to draw 
conclusions about any role that ET-1 might have in the induction or maintenance of acute 
exacerbations of asthma. Although not all asthmatics had an increase in sputum ET-1 in 
the acute phase following allergen inhalation, in those in whom there was a rise, this 
was related to the extent of the asthmatic eosinophilic airway inflammation, suggesting a 
link between asthmatic airway inflammation and ET-1 production or release. The 
relationship between ET-1 and eosinophilic airway inflammation has been explored in 
animal studies (110, 289, 321) which support a link between ET-1 production and 
asthma, and which provide further incentive to explore the role of ET antagonists in 
asthma. The mechanism whereby eosinophilic airway inflammation is related to ET-1 
production is not yet clear, although animal data indicates that eosinophils activated by 
IL-5 or GM-CSF can stimulate the release of ET-1 from airway epithelial cells (293),
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and since these cytokines and others are clearly relevant to asthma, a similar mechanism 
may exist in asthma. Overall, our investigations support a role for ET-1 in the 
pathophysiology of asthma, although many aspects of its role and the mechanisms of 
action remain to be further clarified, and it seems likely that some aspects of the action of 
ET-1 in the lung will have greater bearing on asthma than others. Further work is need 
to clarify the influence of asthma treatment (in particular corticosteroids) on ET-1 
synthesis and release, since we did not find any difference in sputum ET-1 between 
steroid-naive and steroid-treated asthmatics. Our group of steroid-naive asthmatics were 
however very mild, with few ongoing symptoms, and there is evidence for increased 
ET-1 expression in symptomatic compared with asymptomatic asthmatics (125). 
Similarly, bronchial biopsy studies have shown increased ET-1 immunostaining in 
steroid-naive asthmatics compared with steroid-treated asthmatics (123), and there is in 
vitro evidence that steroids reduce ET-1 expression in bronchial epithelial cells and 
macrophages (317). Bronchodilator drugs such as salbutamol do not appear to reduce 
ET-1 expression in asthma (125), and the general consensus that inhaled (or oral) 
corticosteroids should be included in the treatment of symptomatic asthma (242) may 
have potential additional benefits through the influence of corticosteroids on the 
production of ET-1 in asthma. At present it is only possible to speculate on the potential 
therapeutic role of ET-1 receptor antagonists or ET converting enzyme inhibitors in 
asthma, but the data so far would support phamiaceutical research in this direction.
Smoking and chronic obstructive pulmonary disease
We found increased sputum ET-1 in cigarette smokers without symptoms of lung 
disease, and in smokers with established COPD, suggesting that cigarette smoking may 
increase ET-1 production or release in the airways, although the mechanism for this is 
not known. Cigarette smoke has the capacity to damage the bronchi in a number of ways 
including direct toxicity to the bronchial epithelium, oxidative damage, recruitment of 
inflammatoi7  cells and increased epithelial permeability (3 0 1 ), in addition to structural 
changes. Cigarette smoking is also associated with bronchial hyperreactivity, with
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smokers demonstrating airway reactivity to methacholine (322) as well as to cigarette 
smoke itself (323). We have not explored the potential bronchoconstrictor effects of ET- 
1 in smokers, although it would be interesting to see if there is bronchial hyperreactivity 
to ET-1 in the absence of asthma. While the short term effects of ET-1 in smokers lungs 
is of interest, perhaps of greater importance are the potential results of increased ET-1 
production and release in the long-term. In particular, the properties of ET-1 could play 
a role in the pathophysiology of COPD, through its mitogenic and profibrotic actions as 
well as potential proinflammatoiy actions, and more speculatively, mitogenesis and co- 
mitogenesis could also contribute to the pathogenesis of lung cancer, a condition where 
local ET-1 expression has been described (300). Smoking cessation is the only treatment 
which has been shown to be of value in the prevention of COPD, and although there is a 
need to explore the value of drugs which could modify the processes resulting in COPD 
(including corticosteroids and potentially also drugs influencing ET-1 production and 
action) smoking cessation crucial. Much more information is needed on the mechanism 
by which smoking alters ET-1 production, and its role in pathogenesis of lung disease 
before studies could be planned to investigate therapeutic modification of the harmful 
effects of cigarette smoke by ET antagonists or ECE inhibitors.
Cystic fibrosis
We are not aware of any other work examining the role of ET-1 in CF. The levels of 
sputum ET-1 observed are markedly greater than in healthy subjects, and raise a number 
of questions about the potential contribution of ET-1 to the disease. As mentioned 
above, we do not know if the increase in ET-1 observed is secondary to lung damage, 
or is involved in the pathophysiology of CF. Several actions of ET-1 could contribute to 
pathophysiology in CF, including bronchoconstriction, mitogenesis, fibrogenesis, 
proinflammatory action and stimulation of mucus secretion, but at present we can only 
speculate about the likely contribution of each of these to CF. CF is characterised by 
neutrophilic airway inflammation, although there is evidence of eosinophil activation 
(324), with elevated levels of a number of proinflammatory cytokines (314), some of
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which (in particular IL-1 and TNF-a) may be involved in the upregulation of ET-1 
expression (317). An important additional component of airway disease in CF is the 
presence of infection or colonisation by bacteria, and although it is known that bacterial 
endotoxin can stimulate ET-1 production in vitro (129), little is known about the effects 
of bacteria or bacterial products on ET-1 production in vivo in general, or in CF in 
particular. Although the observation of markedly increased ET-1 in CF provokes 
questions and speculation, the main requirement at this stage is to pursue further studies 
to try to establish the relationship between CF and ET-1, and hopefully thereafter to 
investigate possible therapeutic modification of the effects of ET-1 in CF if appropriate.
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10.4 UNANSWERED QUESTIONS AND FUTURE RESEARCH
Although a number of studies have identified cells capable of producing ET-1 in the 
airway (principally airway epithelial cells and macrophages), the contribution of disease 
to ET-1 production requires further exploration, in terms of direct release of ET-1 from 
structural and inflammatory cells, autocrine regulation of that release, the effects of 
airway inflammation on ET-1 release from other cells, and the effects of treatment on 
ET-1 production and release. A number of techniques would be applicable in this area, 
including polymerase chain reaction, immunocytochemistry and cell culture techniques, 
and although most experience has been gained with biopsy samples, PCR and cell 
culture are applicable also to cells obtained by sputum induction, which would allow 
non-invasive assessment. A study examining BAL and induced sputum ET-1 in the 
same group of asthmatics would allow direct comparison between the 2 methods of 
assessment, and would be helpful in characterising the utility of each method in the 
assessment of airway levels of ET-1. The studies presented here have concentrated on 
the acute effects of ET-1 in the airway, but it may be of even greater importance to try to 
examine the long-term activity of ET-1 in asthma, with particular reference to airway 
remodelling. A longitudinal study examining sputum ET-1 along with lung function, 
biopsy samples and possibly some non-invasive measure of remodelling such as high- 
resolution CT scanning would be ideal, but extremely difficult to perform in view of the 
time period involved, and perhaps more realistic in the short-term would be a cross- 
sectional study comparing sputum ET-1 with measures of aiiivay remodelling.
We have demonstrated the bronchoconstrictor activity of ET-1 in asthma, but we were 
not able to pursue this with non-asthmatic subjects beyond the dose range specified, to 
determine if the action is specific to asthma, or perhaps more likely, if asthmatics are 
simply more sensitive to the bronchoconstrictor effects than non-asthmatics, in keeping 
with other inhaled bronchoconstrictors. The main obstacle to such a study is the high 
cost of ET-1 (partly due to the inefficiencies of nébulisation), and the protocol would be
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identical to that of the studies presented here. Although we found that all the asthmatic 
subjects experienced a fall in lung function within the dose range used, this study was of 
necessity performed in a small number of patients, and it would also be of interest to 
extend the study to include larger numbers of asthmatics encompassing a range of 
asthma severity, and also subjects with borderline bronchial hyperreactivity to other 
agents such as histamine or methacholine, to establish the dose range for ET-1 as a 
bronchoconstrictor and the range of responses in asthmatic and non-asthmatic subjects. 
The effect of asthma treatment on ET-1-induced bronchoconstriction could also be 
examined. The duration of bronchoconstriction induced by ET-1 was prolonged at 
around 60-90 minutes, but this was only formally examined in 2 asthmatic subjects, and 
larger numbers would be needed to confirm this. Although none of our asthmatic 
subjects reported symptoms suggestive of a late-phase response, we did not examine for 
this, and in combination with a study examining the duration of bronchoconstrictor 
activity it would be possible to test for such a response. As mentioned above, we did not 
distinguish between atopic and non-atopic asthma in our bronchoconstrictor studies, and 
this would also be possible, as would further examination of potential interactions 
between ET-1 and other airway mediators. The study examining interactions between 
ET-1 and Ang II could be extended to a more severe group of asthmatics, and although 
it would not be possible to perform such a study in acute severe asthma, it would be 
possible to compare responses before and after reduction of inhaled corticosteroid 
therapy to a level at which symptoms become apparent. In addition, it would be 
interesting to explore the bronchoconstrictor action of ET-1 in other lung diseases, in 
particular COPD and CF, since we have observed elevated levels of ET-1 in sputum in 
these conditions. Bronchial hyperreactivity in the presence of increased release of ET-1 
might suggest a role for ET-1 in the pathophysiology of these conditions, with prospects 
for pharmacological modification of the effects of ET-1 in COPD and CF.
Examination of airway responses to inhaled ET-1 could be extended by increasing the 
number of mediators studied, and by extending the assessment to include other time
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points, in particular to assess whether ET-1-induced bronchoconstriction is associated 
with a late-phase response, and similarly, it would be of value to extend follow up after 
allergen challenge to measure ET-1 at a later time point, to assess any role that ET-1 
might have in the late-phase allergic response, and to compare the results with animal 
data (103, 289). The limitations of the study examining sputum ET-1 in acute severe 
asthma would suggest that this could be re-examined, with attempts made to obtain 
samples as early in the exacerbation as possible, and ideally prior to the administration 
of oral corticosteroids. While there are practical difficulties with this, the question will 
remain unanswered until these factors are controlled for.
It is not deal' whether the effect of smoking on ET-1 levels is an acute effect only, or a 
more chronic upregulation of ET-1 production. It would be possible to perform a study 
in smokers comparing induced sputum following a short period of abstinence from 
smoking, with a samples obtained after acute cigarette smoking, and in the light of the 
data from vascular studies indicating that short-term smoking enhances ET-1-induced 
vasoconstriction (310), it would be of interest also to examine the impact of smoking on 
bronchial reactivity to ET-1 in asthmatic and non-asthmatic smokers. Similarly, it would 
be interesting to compare sputum ET-1 in COPD patients treated with inhaled steroids 
with those taking only inhaled bronchodilators, current and ex-smokers with COPD, 
and to compare COPD patients with and without respiratory failure, since circulating 
ET-1 is increased by hypoxaemia (325).
The finding of elevated sputum ET-1 in CF is a novel, but isolated finding, which will 
require confirmation in larger and better characterised groups of CF patients, ideally 
representing a range of severity of the disease, to see if there is a relationship between 
sputum ET-1 and disease severity or prognosis. Any relationship between ET-1 and the 
presence or absence of active infection should be sought, and in view of its prognostic 
significance, it would be of interest to relate sputum ET-1 levels to colonisation with the 
organism Burkholderiacepacia, which is a common but adverse finding in CF.
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One of the most significant areas for future research into the role of ET-1 in airway 
diseases is the development of ET receptor antagonists and converting enzyme 
inhibitors. Although clinical trials have been initiated in other diseases, we have had no 
success in obtaining these compounds to assess their potential role in the treatment of 
airway diseases. Drugs which modify the production or action of ET-1 may have 
bronchodilator activity, even in non-asthmatics if ET-1 is involved in the maintenance of 
basal bronchial tone, and in asthma since airway concentrations of ET-1 may be 
sufficient to provoke bronchoconstriction either because of increased production or 
heightened bronchial reactivity to ET-1. A placebo-controlled study comparing lung 
function measurements before and after administration of the drug would be easy to 
perform, perhaps using body plethysmography as the most accurate method of 
assessing airway tone. ET receptor antagonists and enzyme inhibitors may also have the 
ability to inhibit bronchoconstriction in asthma, which could be studied using a non­
specific bronchoconstrictor such as methacholine, ET-1 given by inhalation as presented 
above, and also using allergen challenge to assess any contribution of ET-1 to allergen 
induced bronchoconstriction or hyperresponsiveness, as seen in animal models (263). 
Using sputum induction or bronchoscopic techniques, it would also be possible to use 
this model to assess the ability of these drugs to influence airway inflammation in 
response to allergen challenge, to compare with animal work in this area (103), and 
following from this, further exploration of potential suppression of asthmatic airway 
inflammation could be assessed using sputum induction. Any effects on airway 
remodelling would require longer studies to assess, although there is animal work to 
support this potential (74), and it may be that there is a greater role for drug development 
in the area of remodelling than bronchodilation for example, since currently available 
bronchodilators are not only cheap, but also veiy effective. Drugs could be administered 
either orally, or ideally by inhalation or nébulisation, although some pilot work would 
be required to ensure no loss of activity by the inhaled route. The choice of drug is also 
of interest, since although in vitro work suggests that ETp receptors may primarily
190
mediate bronchoconstriction (68), there is animal evidence that blockade of both ETa 
andETs receptors is necessary to completely abolish ET-1-induced bronchoconstriction 
(89). By contrast, other actions of ET-1 such as proliferation of airway smooth muscle 
(69) and proinflammatory activity appear to be predominantly ETa dependent (108, 
109).
The potential for the use of ET-1 antagonists or enzyme inhibitors in other conditions 
such as COPD or CF remains to be established, although the pulmonary vascular 
activity of ET-1 in COPD has been the source of much interest, and clinical studies have 
been initiated with an orally available ET -1 receptor antagonist in hypoxaemic COPD.
In summary, the results of this thesis provide evidence for a putative role for ET-1 in the 
pathophysiology of asthma, with initial evidence of a potential role in the processes 
affecting the airways in cigarette smoking, COPD and CF. We believe that our results 
support further studies in order to increase our understanding of the role of ET-1 in the 
airway, and speculate that in the future, specific pharmacological tai'geting of ET-1 may 
form the basis of a novel approach to therapy in asthma and in other conditions affecting 
the airway.
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Appendix 8.1
Relationship between FEVl (% predicted) and sputum ET-1 
in stable COPD (Spearman rank correlation - not significant)
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Appendix 8.2
Sputum ET-1 in acute exacerbation and in convalescence, 
comparing ex- and current cigarette smokers - no 
significant differences between groups
